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Cystic fibrosis (CF) is the most common fatal inherited single gene defect in
Caucasian populations. CF lung disease is characterised by infection, inflammation
and progressive lung destruction. Lung inflammation is measurable in CF patients
even with early disease. Gene therapy offers a theoretical cure for CF lung disease,
with large clinical trials now being planned. There is not only a clear need for the
development of new therapies in CF but also the means to measure the success of
these therapies. One possible approach is to measure biomarkers of airway
inflammation non-invasively (in sputum or serum). In this thesis I have employed a
number of techniques to measure potential biomarkers in sputum and blood in both
cross sectional and serial samples following treatment.
Sputum was collected from patients with CF and a number of control groups
including Asthma, Bronchiectasis, COPD and healthy controls. SELDI-TOF mass
spectrometry was utilised to identify candidate protein biomarkers in sputum.
Candidate biomarkers were then identified and compared to established biomarkers
by ELISA in sputum. Emission spectroscopy was used to measure metal ions as
non-protein biomarkers in sputum. SELDI TOF, ELISA and optical spectroscopy
were used to measure biomarkers in CF sputum before and after exacerbation
treatment. Calprotectin was also measured in serum before and after exacerbation.
SELDI TOF identified calprotectin as a marker of CF lung disease, which highly
discriminated CF from control. This could also be measured by ELISA and
compared favourably to other inflammatory markers such as Interleukin-8 (IL-8).
Emission spectroscopy identified sputum zinc and iron as discriminatory markers of
CF. Sputum calprotectin and zinc levels changed significantly following treatment of
CF exacerbation. Serum calprotectin also changed significantly and could predict
future outcome in these patients.
In this thesis I demonstrate the discover}' and application of novel biomarkers of CF
lung inflammation. I describe calprotectin (sputum and serum) as useful in the
monitoring of exacerbation therapy, with similar findings being displayed for sputum
zinc. Further work is now required to fully validate these findings for translation into
clinically useful tools.
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1. Introduction
1.1 Background and Historical Perspective
Cystic Fibrosis is the most common fatal single gene disorder in Caucasian
populations causing defects in the expression of the Cystic Fibrosis Transmembrane
Regulator (CFTR), a chloride channel essential for the normal function of epithelial
cells(l, 2). Defects in CFTR predispose the lung to bacterial infection and
colonisation, repeated cycles of infection impacting on respiratory function. The
median predicted survival of a patient born with CF in the United states in 2006 is
36.9 years (3), suggesting a vast improvement in patient care in recent years. In spite
of survival improving over the past 4 decades progress has reached a plateau, and
therefore CF patients are still more likely to die at a younger age than non-CF
subjects. Respiratory decline is the cause of death 85% of cases (4), although other
organs such as the pancreas and liver are often involved.
/
The term Cystic Fibrosis, although now widely used, is a relatively modern term,
although descriptions of the disease are not new. German folklore from the middle
ages dictates, "woe to that child which when kissed on the forehead tastes salty. He
is bewitched and soon must die "(5). The first description "Cystic Fibrosis" as a
clinical syndrome was made in 1938 by the American Pathologist Dorothy Andersen
and described the particular (cystic) pancreatic pathology found in a group of
neonates with high mortality(6). In 1949, it was first described as an autosomal
recessive disease, but it was not until the mid 1980s that further advances were made
into the understanding of the pathophysiology of CF with the characteristic
electrophysiology related to the impermiability of sweat ducts to chloride being
described(7). This was followed by similar abnormalities in chloride transport also
being observed in respiratory epithelium(8-l 1). It was not until 1989 however that
the CFTR gene was finally identified and located to chromosome 7(12). Prior to this,
several candidate genes and their products were proposed as the cause of CF
including Calgranulin A (CF antigen)(13). Gene therapy was suggested as a
potential curative treatment soon after the discovery of CFTR with the first such
studies being published in the early 1990s(14, 15), although since these studies
translation of gene therapy into a practical clinical treatment has been slower than
initially anticipated.
1.2 The Basic Genetics of CF
CFTR is a large gene of around 250 kilobases located on the long arm of
chromosome 7. In excess of 1000 candidate mutations have been identified and
reported, the most common mutation being deletion of phenylalanine at position 508
(F508del), which occurs in 70% of northern European Caucasian CF patients. Other
common mutations occur at frequencies of 1-3% and include R553X, G452X and
1717(G-A)(16). Although genotype aids in the diagnosis of the patient, the
prediction of phenotype is less reliable, particularly in reference to pulmonary
disease(17). Indeed the development of the pulmonary complications of CF is
widely variable and as such it is not uncommon for patients to be diagnosed with CF
in adulthood(18), particularly if associated with less common mutations.
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1.2.1 Molecular Classification of CF Genetic Mutations
In order to understand the pathophysiology of CF, mutations in CFTR have been
classified in terms of the molecular dysfunction of the chloride channel including
failure of production, processing or transport of the protein to the apical membrane
of epithelial cells. Five main types of mutation have been described.
1. Class I mutations. These are due to premature stop mutations in the CFTR
sequence resulting in termination of translation and protein synthesis.
Examples include G542X. These mutations are rare and account for only 7%
of CF subjects(19).
2. Class II mutations. These lead to the production of defective CFTR that
cannot be properly trafficked to the apical cell membrane(20), such as
F508del which affects up to 70% of CF patients.
3. Class III mutations. These lead to the production of dysfunctional CFTR
which is trafficked to the cell membrane but is not properly regulated(21).
Common mutations include G551D accounting for around 3% of CF patients.
4. Class IV mutations. These lead to CFTR that has abnormal ion conductance
and thus is dysfunctional(22). Common mutations include R117H.
5. Class V mutations. These mutations include splice mutations leading to the
complete or partial production of the CFTR protein and reduced protein
synthesis(23). Examples include A445E.
Although this classification is useful as a guide to the molecular defect the prediction
of clinical phenotype is less easy and therefore clinical classifications of CF
mutations have also been used to describe CFTR function.
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1.2.2 Clinical Classification of CF Mutations
CF genetic mutations have been classified as severe or mild with respect to exocrine
pancreatic function. Patients homozygous for the F508del mutation frequently
display severe pancreatic insufficiency(24). Those homozygous for the F508del
mutations have higher chloride levels on sweat testing suggesting greater chloride
channel dysfunction, and male homozygous F508del patients would be expected to
be infertile due to obstructive azoospermia(25). The relationship of genotype to lung
function is less clear, and even those with F508del mutations display a wide range of
disease from mild to severe. Furthermore genotype does not predict chloride
transport as measured by nasal potential difference(26), a common measurement
used in clinical trials of new treatments, and thus suggests a subtly different effect of
F508del mutations in the sweat gland and respiratory mucosa.
The reason for the apparent mismatch between CF genotype and severity of lung
disease is presently unclear although other genes, so called "modifiers", may be
involved. For example, polymorphisms of the transfonning growth factor beta gene
may be associated with increased severity of lung disease(27) and conversely
mutations in the enhancer region of the alpha one antitrypsin gene may lead to better
prognosis in lung disease(28). Therefore although a monogenic disease by
definition, the clinical syndrome of CF depends on the complicated interplay of a
number of genes, which ultimately, may interact to characterise the disease for any
given individual.
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1.3 The Cell Biology of CF
1.3.1 CFTR
CFTR shares homology with a family of proteins known as ATP-binding cassette
(ABC) transporters(12), which function as pumps that export macromolecules from
the cell interior to exterior utilising ATP(29). CFTR has 5 proposed domains
including 2 transmembrane domains spanning the lipid bilayer: two nucleotide
binding domains (NBD) and a cytoplasmic regulatory domain(12). An adapted
illustration of this is displayed in figure 1(30). CFTR is found in epithelial cells
lining the lung, gut, pancreas and liver among other organs. The dysfunction,
presence ofmutant, or absence of this protein channel leads to the clinical syndrome
of CF.
As well as having function as a chloride channel CFTR also has a key role in the
regulation of other ion channels. CFTR has also been implicated as a bicarbonate














Figure 1.1 Proposed Structure of Cystic Fibrosis Transmembrane Conductance
Regulator (CFTR) protein
CFTR is a chloride channel situated at the apical membrane of epithelial cells. CF
mutations lead to abnormal protein function or expression and as such abnormalities
in chloride transport. The site of the common F508del mutation is demonstrated in
the Nucleotide Binding Domain(30).
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1.3.2 Normal Function of CFTR
The activity of CFTR as a chloride transporter was demonstrated by showing
defective chloride transport in CF airway epithelial cells, characterised by an
inability to respond to cyclic adenosine monophosphate dependent protein kinase,
which is an inducer of chloride transport in normal cells(l 1, 31, 32). Conversely if
CFTR is expressed in cells that do not normally display endogenous CFTR, such as
xenopus oocytes, then chloride conductance can be induced via the cAMP-dependant
protein kinase pathway(33-35). Furthermore, expression of wild type CFTR in CF
epithelial cells leads to the restoration of chloride transport(36, 37). Thus normal
activity of CFTR is central to regular chloride transport. Confirmation of CFTR as a
chloride channel and not just a regulator of chloride transport was demonstrated by
altering chloride permeability in cells following site directed mutagenesis ofCFTR to
create mutants, and then the incorporation of CFTR into the lipid bilayers of these
cells to form chloride channels and allow chloride transport similar to wild type
epithelial cells(38, 39).
The regulation ofCFTR (opening and closing) is proposed to occur through cycles of
phosphorylation and dephosphorylation in conjunction with ATP hydrolysis(40-43).
The activation of cAMP dependant protein kinases cause phosphorylation ofmultiple
serine residues in the regulatory domain with subsequent hydrolysis of ATP at the
nuclear binding domain causing the channel to open and allow the free flow of
chloride ions.
As well as functioning as a chloride channel CFTR may also act as a regulator of
other ion channels such as the amiloride sensitive epithelial sodium channel (ENaC),
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suggested by abnormally elevated sodium absorption in CF airway cells compared to
control(44), which is again corrected by transfecting CFTR in similar cells(45).
Furthermore co-expression of CFTR and ENaC in constitutively non-expressing cell
lines leads to lower basal sodium currents suggesting direct inhibition of ENaC by
CFTR(46). This inhibition is thought to be secondary to effects on channel function
rather than channel number(47, 48). The loss of regulation of ENaC in CF can
therefore explain the findings of low chloride secretion and increased sodium
absorption thought to be important in CF lung disease (see later). This relationship
was further confirmed with an overexpressing ENaC transgenic mouse which has
been shown to develop a lung phenotype similar to that seen in CF(49) suggesting
that the interaction of CFTR with ENaC has a major pathogenic role in CF lung
disease.
CFTR may also have effects on other ion channels such as the outwardly-rectifying
chloride channel(50); calcium dependant chloride secretion(51); bicarbonate
transport via chloride coupled bicarbonate exchanger(52) and potassium transport via
the renal potassium channel ROMK2(53), although the significance of these
interactions is unclear.
A further possible function of CFTR is as a receptor for P. aeruginosa, by which
epithelial cells can bind and internalise bacteria as a mechanism of clearance(54, 55).
CF epithelial cell lines are less able to internalise P. aeruginosa than wild type cells
and this has been suggested by some researchers as a crucial defect in CF
pathogenesis, allowing the colonisation of the lung with bacteria and subsequent
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inflammation and damage (although it should be considered that the majority of
established early infections in CF are with gram positive organisms(3)). The binding
of P. aeruginosa is proposed to take place between the outer core bacterial
lipopolysaccharide and the first extracellular domain of CFTR. Recently it has been
suggested that the binding of P. aeruginosa to CFTR initiates an inflammatory
response that is crucial to the removal of bacteria(56). The interaction of P.
aeruginosa with CFTR may therefore be implicated in the pathogenesis of lung
disease, although evidence from animal models of CF and clinical samples will be
required to confirm this.
1.4 Multi-System Problems in CF
CF can affect any organ system in the body that has an epithelial lining. Thus the
skin (in particular the sweat glands), reproductive tract, bowel, pancreas and the liver
may be affected(l, 2) as well as the lung.
1.4.1 Skin
In the skin CF leads to the secretion of salt rich sweat with the dysfunction of CFTR
not allowing normal chloride ion resorption, thus leading to the accumulation of high
levels of salt in the sweat glands (57-60). This defect has been exploited clinically as
the sweat test, a commonly used to diagnostic test for CF. Furthermore CF can lead
to salt depletion and dehydration in small children(61), a phenomenon first observed
during a heat wave in New York in the 1950s(62).
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1.4.2 Gastrointestinal Disease
The majority of patients with CF suffer from pancreatic disease(2), indeed the
nomenclature cystic fibrosis is based on the pathological findings in the pancreas of
patients at post mortem(6). In the pancreas CFTR normally exchanges chloride ions
in exocrine secretions for bicarbonate to neutralise and inactivate pancreatic
enzymes. In the absence of CFTR, pancreatic enzymes are constantly activated with
the end result auto digestion and destruction of the pancreas. This is further
compounded by protein hypersecretion in the pancreas, protein plugging, and
relative luminal dehydration causing ductal blockage(63). Low levels of bicarbonate
in secretions also impair gastric acid neutralisation in the duodenum, leading to the
failure of digestive enzymes and malabsorption. As well as developing exocrine
pancreatic insufficiency, the chronic inflammation of the pancreas may lead to islet
of Langerhan atrophy and consequently insulin dependant diabetes mellitus(64),
which is seen in many adult CF patients.
Intestinal disease may also be a complicating feature of CF. Meconium ileus
(obstruction of the small bowel by thick mucus) is observed in 10 -20% of new-borns
with CF(65). In older patients distal intestinal obstruction syndrome due to
thickened mucous and incomplete digestion of food is experienced by up to 20% of
patients. A finding replicated by many mouse models of CF which have severe
gastrointestinal pathology(66).
Hepatobiliary disease is a further potential complication of CF below the diaphragm.
Dysfunctional secretion of chloride and bicarbonate into the biliary tract leads to
concentrated and acidic bile, but interestingly the majority of bile duct disease is
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intra-hepatic rather than effecting the common bile duct and gall bladder(67), and
thus complications include cirrhosis and portal hypertension. In a recent case series
from a large UK CF centre 154 patients with abnonnal liver function and CF were
followed or 5 years(68), and although 29 of these patients developed portal
hypertension only 1 patient developed liver failure requiring transplant.
1.4.3 Problems with Fertility
Infertility is seen in almost all male patients due to obstructive azoospermia with
congenital bilateral absence of the Vas Deferens (CBAVD) being common. Fertility
is maintained in many females (69), and if affected this is most likely secondary to
abnormalities in the menstrual cycle caused by chronic ill health and poor nutrition
related to underlying respiratory disease rather than CF mutations per se.
Interestingly CBAVD as well as being seen in virtually all male CF subjects is also
recorded in the general population, with CFTR function of at least 10% thought to be
necessary for normal embryological development of the Vas Deferens. Indeed
CBAVD in non-CF patients is associated with a higher incidence of carrying a CF
mutation(25), than the general population. In spite of this, advances in fertility
treatment have allowed adults with CF (even males) to have children.
1.5 CF Lung Disease
Decreased CFTR function is most significant in terms of mortality and morbidity in
the lung, with 85% CF deaths being due to the complications of pulmonary
disease(4). Many of the present therapies for CF are thus focussed at attempting to
correct or treat the pulmonary complications of CF.
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1.5.1 The Development of CF Lung Disease
The lungs of most CF patients are histologically normal at birth aside minor
morphological changes in the sub-mucosal glands(70-72), but during life there is a
gradual progression of disease throughout the respiratory tract leading to small
airway damage but mostly sparing the alveolar space(73), possibly reflecting the low
levels of CFTR in that area. In spite of the absence of frank histological changes at
birth, some studies have demonstrated the presence of increased levels of airways
inflammation with both interleukin-8 and neutrophil elastase being found in
increased levels in children with CF at 6 months of age(74). This is consistent with
the measurement of raised inflammatory mediators when CFTR is knocked out in
rats in-utero(75), and the increased levels of neutrophil proteins described in some
mouse models of CF(76). The reason why dysfunction of CFTR leads to
inflammatory lung disease are poorly understood. However it is widely accepted that
the basic defect in CF leads to changes in the airways surface liquid (ASL), the fluid
in the airway that bathes the cilia facilitating normal mucociliary clearance, and thus
the removal of harmful stimuli such as bacteria and inflammatory proteins is
impaired.
The ASL is a thin film of fluid (~30 pi) covering the airway surface in which foreign
inhaled matter is trapped and then moved by beating cilia towards the larynx for
disposal by expectoration or swallowing. Decreased mucociliary clearance is well
described in CF, although measurement is impaired by variability in the variety of
techniques used(77). As well as allowing free flow from the lung the ASL contains a
number of molecules that are central to the innate immune response to bacterial
infection in the lung. Antimicrobial proteins such as lactoferrin, secretory leukocyte
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protease inhibitor (SLPI), surfactant proteins A and D, peroxidises, cathelicidins and
beta defensins among many molecules are present in ASL. Therefore any alteration
in the physical properties ofASL may lead to both abnormal clearance from the lung
as well as innate immune dysfunction. The effects of CFTR dysfunction on ASL
have thus led to a number of different hypotheses.
1.5.2 High Salt vs. Low Volume Hypothesis
Two main hypotheses have been developed to explain the effects of CFTR
dysfunction on ASL: the high salt hypothesis and the low volume hypothesis. The
high salt hypothesis suggests that normal ASL is hypotonic with a low salt
concentration, and this environment is essential for the ability of innate immune
molecules, in particular beta defensins to kill bacteria(78, 79). This hypothesis
assumes that, as with the CF sweat gland, reduced chloride resorption by epithelial
cells leads to decreased sodium absorption and thus higher than normal salt levels in
ASL. This was supported by the apparent measurement of increased levels of
sodium chloride in CF ASL(80). This is not a consistent finding in all studies(81),
and has led to other explanations for the effects of CFTR dysfunction on the airway,
most prominently as the low volume hypothesis(82).
The low volume hypothesis suggests that ASL has salt concentrations similar to
plasma levels (i.e. normal) and that with CFTR dysfunction the activity ofENaC, the
inducible sodium channel, is increased leading to over absorption of sodium and thus
water from the airways surface, causing dehydration and a loss of ASL volume
which interferes with normal mucociliary clearance(83). This hypothesis relies on
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there also being chloride reabsorption via paracellular pathways and calcium-
activated chloride channels. As well as decreasing mucociliary clearance, airways
dehydration increases the viscosity of mucus, thus creating a more favourable
environment for bacterial colonisation and infection.
Several studies have since demonstrated no difference in ASL tonicity between CF
and non-CF in man and mouse ASL thus supporting the low volume hypothesis(81,
84-86). Furthermore a transgenic mouse over-expressing ENaC develops a
pulmonary disease phenotype similar to that of CF due to depletion of the airways
surface liquid volume(49), thus underlining the potential role for ENaC and airways
dehydration in CF lung disease.
The overriding evidence for the detrimental effects of CFTR dysfunction in the
development of CF lung disease is that with a decrease in airways surface liquid
there is impairment of mucociliary clearance increasing the susceptibility to infection
and the damaging effects of lung inflammation. This suggests an alternative function
for CFTR in the airway and the sweat gland. In particular with under absorption of
chloride in the sweat gland due to CFTR dysfunction; but removal of ENaC

















Figure 1.2. The Low Volume Hypothesis.
A. Normal airway surface liquid properties allow efficient mucociliary clearance of
bacteria (and inflammatory cells/material) from the small airways to the trachea,
which is then cleared, by coughing and expectorating or swallowing. B. The
increased absorption of sodium and water from the airway leads to depletion of the
ASL, therefore decreasing mucociliary clearance and allowing bacterial colonisation,





Inflammation may be detected in the CF airway even in the absence of proven
infection(74). The inflammatory response to infection is more pronounced in CF
with a more intense and longer lasting inflammatory response being observed
following infection with lower respiratory pathogens(87). It is commonly held that
in CF infection leads to chronic inflammation and consequently lung damage
creating a vicious cycle of lung infection, inflammation and damage(88). However
lung inflammation has been detected in some studies prior to infection(74, 89) and
therefore this area remains controversial. Nevertheless, regardless of the temporal
association the CF lung is prone to respiratory infection and inflammation leading to
damage as a consequence. A further aspect of CF lung inflammation is the
dysregulation of inflammatory cytokines, with increased levels of pro-inflammatory
mediators such as interleukin (IL)-8 and decreased levels of anti-inflammatory
cytokines such as IL-10 being observed in the CF airway compared to control
populations. Thus the interplay between infection and inflammation may be further
confounded by dysregulation of the normal inflammatory response.
The major effector cell in the (central) CF airway is the neutrophil, which is able to
secrete proteoloytic enzymes such as cathepsin G and neutrophil elastase (NE).
Increased NE activity is readily measureable in the CF airway and these and other
proteases may overwhelm the natural anti-protease system in the lung, contributing
to destruction of lung tissue (52) and cleaving opsonins, thus decreasing effective
bacterial phagocytosis and increasing IL8 production. Neutrophils are normally
cleared from sites of acute inflammation by apoptosis and phagocytosis(90), however
in the CF airway a greater number of secondary necrotic neutrophils are present
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suggesting a decrease in clearance of apoptotic cells(91). Furthermore neutrophil
elastase may delay the clearance of apoptotic cells by cleaving phosphatidylserine
receptors on macrophages decreasing the recognition and phagacytosis of apoptotic
neutrophils(92). Secondary necrosis of neutrophils may then lead to the release of
pro-inflammatory mediators, further driving inflammation in the CF lung and as such
the products of secondary7 necrosis may provide a suitable substrate to discover
biomarkers of disease. Other forms of neutrophil cell death such as the recently
described phenomenon of neutrophil extracellular trap (NET) formation may also be
important in the release of neutrophil products such as neutrophil elastase and



































Figure 1.3 Targets for Treatment of inflammation in Cystic Fibrosis
This figure demonstrates a number of potential targets for the treatment of Cystic
Fibrosis including gene therapy to correct the CF gene mutation, potentiation of low
level CFTR dysfunction or even modulating the inflammation seen as a consequence
to CF mutations. Further strategies also include the modulation of inflammatory
cells such as neutrophils and lymphocytes in the CF lung and monoclonal antibodies
to block the activity of key cytokines (adapted from workshop of targets for
inflammatory treatment)(93).
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1.5.4 Lung infection in CF
Chronic lung infection is a hallmark of established CF lung disease with
Staphlococcus aureus, Haemophilus influenzae and Pseudomonas aeruginosa being
the most common pathogens, with a prevalence of 52%, 17% and 55% respectively
in the CF Foundation annual registry report of 2006 (3). In infants with CF the most
common organisms cultured are S. aureus and H. influenzae. Following initial
colonisation the airway is likely to be more prone to further infection with organisms
such as P. aeruginosa. Whether this is a direct priming effect of the early infection
or the result of early lung damage following infection is unclear at present.
Intermittent P. aeruginosa colonisation followed by permanent infection is often
observed, suggesting that even in patients with CF that the initial clearance of this
organism may be possible. However in CF P. aeruginosa which is normally present
as a motile non-mucoid phenotype, can transform into a non-motile mucoid
phenotype at this time, allowing permanent infection of the lung. The presence of
mucoid phenotype P. aeruginosa in CF is associated with deterioration in lung
function(94, 95), and therefore patients with non-mucoid forms of P. aeruginosa
have better lung function than those infected with mucoid strains(96). Once
established in the lung P. aeruginosa becomes increasingly difficult to treat due to its
ability to mutate, form alginate and develop biofilms(97), thus rendering it less
susceptible to penetration by antibiotics. As CF lung disease progresses other
organisms such as Burkolderia cepacia complex and Stenotrophomonas maltophilia
are also implicated as pathogens as a consequence of the increased susceptibility of
the damaged lung to infection thus further complicating the lung environment in CF
patients. Indeed by adulthood many patients are chronically infected with multiple
pathogens, making treatment with antibiotic therapy increasingly difficult.
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Respiratory Infections vs. Age
Figure 1.4. CF Lung Infection By Pathogen
CF lung disease is characterised by infection. The most common organisms are
demonstrated in this figure and include Staphylococcus aureus, Haemophilus
influenza and Pseudomonas aeruginosa. The incidence of P. aeruginosa infection
increases with age and becomes the dominant pathogen by adulthood. This figure is
adapted from the CF Foundation Patient Registry 2006 report(3).
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1.5.5 CF Lung Disease Exacerbation
As well as having chronic bacterial colonisation patients with CF also experience
recurrent episodes of increasing pulmonary symptoms termed exacerbations which
are accompanied by a decrease in lung function(98). The aetiology of these episodes
is unclear but the acquisition of new pathogenic organisms(99) or an increase in
density of colonising organisms(lOO) have both been suggested as possible
aetiological factors. Viruses such as respiratory syncitial virus (RSV) have been
implicated as important initiating factors of pulmonary exacerbation in children(lOl)
Certainly, treatment of exacerbations with antibiotic therapy decreases the bacterial
density of respiratory secretions(102, 103). And both the treatment of bacterial
colonisation with nebulised anti-pseudomonal treatment(104) and nebulised therapy
to decrease the viscosity of respiratory secretions(105) decrease the need for
exacerbation treatment as well as improving lung function. Exacerbations represent
a complicated imbalance of multiple factors including bacterial burden, host defence
in combination with physical factors such as increases in mucus viscosity.
Nevertheless exacerbation represents an important part of the pathophysiology of
established CF lung disease, and may also allow the study of a changing state of
inflammation and infection in CF patients.
1.6 Present Therapy for Management of CF lung Disease
Mortality and morbidity in CF lung disease have improved steadily over the past 30
years, and as such a once universally fatal disease of childhood can now be managed
effectively to allow patients to live into adulthood. Nevertheless the predicted
median survival of around 36 years will only improve significantly if therapy is
focused on the correction of the underlying molecular defect in CF rather than it's
consequences. The present treatment strategies, which aim to control the
consequences of CF lung disease such as infection and inflammation, are
summarised below.
1.6.1 Aerosolised Antibiotics
In view of the highly pathogenic nature of P. aeruginosa infection, aerosolised
antibiotics have been advocated for the early eradication of PA infection as well as
the suppression of chronic infection. Studies using nebulised tobramycin have
demonstrated significant improvements in lung function when compared to placebo
and standard therapy (104, 106, 107), with fewer exacerbations and less time spent in
hospital, and also improvements quality of life (104). This is further supported by
Cochrane review(108). Therefore aerosolised anti-pseudomonal antibiotics have
been recommended for all patients 6 years or older with persistent PA infection with
moderate to severe lung disease(109).
1.6.2 Nebulised Recombinant DNAse
Cystic fibrosis sputum contains large amounts of cellular debris including DNA,
which increases the viscosity of mucus due to electrostatic interactions. The use of
DNAse as a strategy for decreasing the viscosity of CF secretions was first described
in the 1960s when bovine DNAse was utilised, these trials were however limited due
to the immunogenicity of the bovine product. More recently recombinant DNAse
(dornase alfa) was developed as a strategy to degrade DNA, decreasing the viscosity
ofmucus and thus facilitating mucociliary clearance. Several multi-centre trials have
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assessed the long-term efficacy ofDNAse on lung function in patients with moderate
to severe disease(105, 110). Furthermore Fuchs and colleagues demonstrated an
improvement in incidence and length of pulmonary exacerbation in DNAse treated
patients(105), and its use is supported by Cochrane review(lll). It has also been
demonstrated that in mild disease nebulised DNAse also reduces number of
exacerbations and maintains lung function(l 12). As such the use of DNAse is
recommended in the treatment of moderate to severe patients over 6 years and may
even be indicated in the treatment milder lung disease(109).
1.6.3 Hypertonic Saline
Another strategy to increase mucociliary clearance in CF is by osmotically hydrating
the airways surface liquid by the use of hypertonic saline (HS)(113). FIS both
improves lung function(l 14) and decreases the number of pulmonary
exacerbations( 115), which is remarkable for such a simple therapy. Furthermore HS
is well tolerated by patients with few adverse events being recorded in published
studies, leading to the study of further osmotic agents in the airway (116). Therefore
the use of HS may be indicated all patients over six years to improve lung function
and exacerbation frequency(109).
1.6.4 Anti-Inflammatory Medications
As excessive airways inflammation is a hallmark of CF lung disease, treatment with
various anti-inflammatory agents have long been proposed as possible management
strategies. Inhaled corticosteroids (ICS) however, the mainstay of treatment in
asthma (an allergic inflammatory disease), have recently been demonstrated
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ineffective in CF in a study that followed ICS withdrawal in a large number of
patients(l 17). A large multi-centre trial earned out in a children demonstrated an
improvement in lung function in subjects taking oral corticosteroids^ 18), however a
Cochrane review suggested that the side effects related to long term oral
corticosteroid outweigh any benefit in lung function improvement^ 19). As such
corticosteroid therapy is not recommended in CF unless it is used to treat
concomitant allergic airways disease(109).
Treatment with non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen
have proved a successful strategy in terms of slowing the decline in lung function in
CF over a 4 year period in patients with mild lung disease(120), although the
mechanism of anti-inflammatory activity in the CF airway is not well described. In
view of these findings high dose ibuprofen is recommended as treatment to slow the
loss of lung function in patients with CF over 6 years old with mild disease (FEVi
>60% predicted)(109). This treatment must however be used with caution due to the
potential side effects of NSAID treatment such as gastro-duodenal ulceration and
renal impairment. Other anti-inflammatory drugs such as leukotriene receptor
antagonists and sodium cromoglycate are not presently recommended in CF due to a
lack of demonstrated treatment effect(109).
1.6.5 Macrolide Therapy
In view of the positive benefits of macrolide antibiotic treatment in the lung
condition diffuse Japanese pan-bronchiolitis (121) (a disease characterised by P.
aerugenosa colonisation), macrolides were suggested as a possible treatment agent in
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CF with its proposed anti-microbial and anti-inflammatory activity. Several studies
using the macrolide azithromycin have demonstrated a significant improvement in
lung function(122-124) in CF patients. In those patients chronically infected with P.
aeruginosa there was a significant decrease in exacerbation frequency(122) and
therefore long term azithromycin treatment is recommended in all CF patient six
years and older with persistent P. aerugenosa colonisation(109).
1.6.6 Treatment of CF Lung Exacerbation
No unifying diagnostic criteria have been developed for the diagnosis and treatment
of CF exacerbation and indeed differences in criteria exist between those treating
adults and children(125). In spite of no new organism being cultured at the time of
exacerbation in most subjects antibiotic therapy remains the mainstay of
treatment! 126). In general, combinations of antibiotics rather than monotherapy are
used due to the concern of bacterial resistance to antibiotics developing! 127),
although this is not supported by a recent Cochrane review! 128). Combination
antibiotic therapy is usually in the form of two antibiotics with differing modes of
activity. Interestingly a recent study demonstrated no benefit in testing the
synergistic combination of antibiotics in the laboratory compared to physician best
choice in terms of patient outcome(129). Although antibiotics form the mainstay of
therapy, physiotherapy and nutritional support are also of importance! 126), and there




Lung transplant offers the only theoretical "cure" for CF lung disease although this is
not without limitations. Strict criteria exist for lung transplantation and not all
patients will ultimately meet these(130). Furthermore there is an on-going lack of
donor organs and as such many patients who are eligible for lung transplant will die
before donor organs become available. Although offering a "cure" for CF lung
disease, lung transplant does not treat any of the other complications of CF and the
donor organ has a limited lifespan with the ten year survival following transplant
being around 50%(131). Further to these problems, transplantation requires
immunosupression with drugs that as well as suppressing the immune system can
lead to host damage such as renal failure and malignancy. Nevertheless lung
transplantation offers a viable life changing treatment for patients with end stage CF
lung disease.
1.7 Treatment of The Basic Defect in CF
Treatments for CF lung disease are available but these slow the progression of lung
disease rather than halting the progression of disease altogether. In order to alter the
course of disease definitively, treatments that correct the basic defect in CF are
required. These broadly fall into three categories: gene correction therapy; ion
channel potentiators and inhibitors (both to CFTR and ENaC); and treatments that
process faulty CFTR to active protein.
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1.7.1 Gene Therapy for Cystic Fibrosis Lung Disease
Following the sequencing of the CFTR gene in 1989, gene therapy was suggested as
a possible curative treatment for CF due to its monogenic nature. Moreover,
heterozygotes have a normal phenotype in spite of having only 50% of CFTR
expression suggesting that full replacement of the gene would not be necessary for
disease modification. Furthermore it has been demonstrated that only 5%
transfection efficiency of CFTR is required to correct the chloride transport
abnormality in CF epithelium(132), and therefore only partial correction will be
required to alter the disease process in the CF lung. The first trials of gene therapy
for CF took place in the early 1990s(14, 15) and now over 30 clinical trials of CF
gene therapy, mainly as proof of principle, have been published(133), the efficiency
of gene transfer being poor in most cases (although as noted above, inefficient gene
transfer may be adequate for disease modification). A wide range of viral and non-
viral vectors have been used for gene transfer, although viral administration may be
impaired by a host immune response following repeat administration(134). As gene
expression following viral vector administration is generally short lived this requires
repeat dosing, which is likely to lead to diminished transduction efficiency(135).
Successful viral gene therapy for CF may depend on the use of more sophisticated
viral vector technology to attain longer gene expression. Recent strategies have
included an HIV based vector in an Ebola virus derived envelope resulting in
efficient and sustained gene transfer to epithelial cel!s(136).
In view of the present limitations to viral gene therapy for CF, non-viral vectors have
also been used to effect successful gene transfer to the CF respiratory epithelium in
the nasal cavity with effective gene expression (137-139), these studies were carried
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out by a number of groups based in the UK and ultimately led to the formation of the
UK Cystic Fibrosis Gene Therapy Consortium. Non-viral vectors have the potential
to be less immunogenic and as such be more amenable to repeat dosing regimens
(133). Studies to date have used cationic lipids complexed with DNA to transfect
respiratory epithelium in the nasal cavity and demonstrated transgene expression
following treatment. Alton et al also demonstrated an ability to transfect respiratory
epithelium in the lung in the same patients with a correction in chloride transport,
although this was accompanied by systemic side effects including flu like
symptoms(137), although the side effects of therapy may have been related to the
plasmid DNA rather than the lipid vector. In view of the potential treatment benefit
of correcting the underlying physiological defect in CF with gene therapy the UK CF
gene therapy consortium is embarking on the first lung multi-dose CF gene therapy
trial using a non-viral vector in the near future following recent success in
administration of such products to a large animal model(140).
1.7.2 Ion Channel Modulators
An alternative approach to CF treatment is to either increase chloride transport by
non-CFTR channels or block the over activity ofENaC which has been demonstrated
to have a potential role in disease pathogenesis. Amiloride has been utilised as an
ENaC blocker but has a short half-life, which has led to newer longer acting sodium
channel blockers such as PS552 being developed(141). Combined activation of
calcium activated chloride channels and inhibition of epithelial sodium channels may
be achieved by stimulating ATP-activated purigenic receptors (P2Y2 receptor
pathway) with synthetic nucleotides(142) and although further clinical studies are
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required early clinical trial evidence shows such agents to be well tolerated as well as
having potential benefit on lung function(143).
1.7.3 CFTR Mutation Corrector Therapy
Several approaches have been suggested to correct the faulty gene products of
several CF mutations. One such example is the use of high dose aminoglycoside to
correct mutations of class 1 CFTR mutations due to premature stop codons as has
been demonstrated in vivo in the nasal epithelium(144), although the practical
application of this intervention may be limited by the toxic nature of this class of
drug, and furthermore as the majority of patients have class II mutations the
generalisibility of these treatments is questionable. Toxicity may be less prominent
with a newly described compound PTC 124 (145, 146). This compound was
demonstrated to improve chloride transport in the nasal epithelium in patients with
class 1 mutations, although the results from this trial were not consistent when the
patients received repeat dosing of the compound(147). Further research has also
focused on the potential correction of class 2 mutations using the compound Sodium-
4-phenylbutyrate (PBA), which acts by stopping the degradation mutant CFTR(148).
This area remains a focus of on going research and may ultimately compliment other
treatment approaches tailoring therapy specifically to a patient's genotype as well as
phenotype.
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1.8 Measuring Outcome in Trials of CF Therapy
Defining the success of any (new) therapy in CF is difficult. CF is a relatively
uncommon disease, and as such the appropriate powering of clinical trials can be
difficult, particularly if looking at the effects of treatment on long-term outcomes
such as mortality, which may lead to potentially successful therapies being rejected
inappropriately. Therefore, surrogate markers of the success of therapy are required
to allow smaller numbers of patients to be utilised in studies whilst allowing them to
be powered appropriately. As CF lung disease is characterised by excessive airways
inflammation, one would expect any new treatment of CF lung disease, if it is to be
successful, to have a beneficial effect on lung inflammation, and as such the
measurement of inflammatory mediators may offer potential surrogates. This should
be true for any new therapy whether it be gene correction therapy, a new antibiotic or
a new agent to increase mucociliary transport. Unfortunately at present there is no
universally accepted measurement of inflammation in CF and therefore the majority
of studies use lung function as their primary outcome measurement as a marker of
disease severity.
1.8.1 Lung Function as an Outcome Measurement in CF Therapy
The measurement of airways physiology by spirometry is well described in many
respiratory diseases. FEVi (forced expiratory volume in 1 second) and FVC (forced
vital capacity) are simple to measure and easy to perform in the clinic. FEVi can
predict outcome in patients when used to classify the severity of lung disease in
clinical studies(149). Furthermore an FEVi of less than 30% predicted is associated
with a two year mortality of greater than 50% in CF(150). Section 1.6 concentrated
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on the main therapeutic options in CF lung disease treatment. Treatments such as
DNAse, aerosolised antibiotics, hypertonic saline and NSAIDs were all assessed by
there ability to either improve FEVi(104, 105, 107, 110, 115) or decrease the rate of
decline of FEV](120) in their given populations. This is hardly surprising as FEVi
represents the best predictor of mortality in CF(151, 152). The rate of decline in
FEVi over time may be more reflective of the overall effects of therapy on lung
disease than absolute changes in lung function in the short term but this strategy
requires large numbers of patients and longer follow up to assess(153). New
developments in lung function measurement such as inert gas washout may improve
the sensitivity of lung function measurements as outcomes in CF therapy trials(154).
However, the development of surrogate markers of inflammation may offer more
insight into the underlying disease process whilst allowing the measurement of an
outcome that is directly related to the treatment being given, and allow smaller
numbers of patients to be used when assessing new therapies.
1.8.2 Biomarkers of Lung Disease in CF
A biomarker is a "characteristic that is objectively measured and evaluated as an
indicator of a normal biological process, pathogenic process or pharmacological
response to a therapeutic intervention"^ 55). Biomarkers should measure biological
activity and can either be used as an endpoint test of efficacy or to discover new
modes of biological activity. Functional biomarkers have been used in previous
studies of CF therapy, such as nasal potential difference in CF gene therapy
trials(137-139). However a growing area of research is the use of biomarkers of
inflammation in CF airways disease to assess outcomes in future CF trials.
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Inflammatory biomarkers have been sought directly from lung fluid in studies
examining bronchoalveolar lavage fluid (BALF) and sputum as well as blood.
Indeed lung secretions from CF patients contain large amounts of inflammatory
mediators, neutrophils and neutrophil products. High concentrations of tumour
necrosis factor (TNF)-a, interleukin (IL)ip, IL-6, and IL-8 are readily
measurable(156).
1.8.3 Exhaled Breath Condensate
This technique involves the collection of exhaled air from the respiratory tract, which
is then condensed to a liquid by cooling. It is proposed that this exhaled breath may
contain micro droplets of fluid from the airways lining and thus allow a truly non¬
invasive means of measuring the airways fluid. Physical characteristics of exhaled
breath such as pH(157) and levels of nitrite(158) can differentiate CF patients from
controls. However, previous work performed by the UK CF Gene Therapy
Consortium demonstrated insufficient levels of proteins in exhaled breath to allow
detailed proteomic analysis (personal communication, Gordon MacGregor).
1.8.4 Bronchoalveolar Lavage
Bronchoalveolar lavage (BAL) involves the washing of segments of the lung during
a bronchoscopy, an invasive procedure, and usually requires sedation or (in children)
a general anaesthetic. Many of the early studies of CF lung inflammation utilised
this technique(74, 87-89, 159-164) and indeed therapeutic response to interventions
may be measured in this way(165-172). There are now accepted standard operating
procedures for performing BAL in CF patients to investigate new treatments used by
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the Cystic Fibrosis Foundation in the united states(173). Moreover, previous work
performed by the UK CF gene therapy consortium and others has demonstrated the
usefulness of BALF in the discovery of novel biomarkers in CF (174, 175). Less
invasive approaches, such as sputum sampling, have been developed as a non¬
invasive alternative and may be more appropriate in groups of patients where
repeated measurements of inflammation, such as in clinical trials, are required.
1.8.5 Sputum
Expectoration of sputum has been used for many years to monitor CF lung disease,
as an appropriate sample for microbial culture. Spontaneous expectoration of
sputum requires patients to have sufficient lung disease such that they have regular
sputum production, therefore this means of sampling airways fluid may be less suited
to children and those with less severe airways disease. Sputum induction with
hypertonic saline has therefore been developed and has proved useful in a number of
respiratory diseases, in particular asthma(176-180) where chronic sputum production
is not a common feature. Indeed several studies have now been performed to
demonstrate normal values of biomarkers in sputum for control populations(181,
182). Early studies focussed on the cellular component of induced sputum and have
been particularly effective in airways diseases such as asthma. However the fluid
phase of sputum has also been utilised to investigate protein biomarkers in sputum
with great success(173, 183). The fluid phase of sputum has been employed in
biomarker studies of the inflamed CF lung (99, 102, 184-199), and may also be used
as an accurate measure of infection(200-202). Moreover, as well as identifying
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pathogens by conventional means sputum can be utilised for molecular testing of
pathogens and bacterial proteins(203, 204).
Several studies have now demonstrated relationships between sputum biomarkers
and clinical outcome measurements such as lung function. Scott Sagel and
colleagues have demonstrated significant correlations between FEVi and sputum
neutrophil counts with IL-8, neutrophil elastase and matrix metalloproteinase levels
in CF sputum from children (198, 199), a finding that has been replicated in adult
populations (205). Recently a large retrospective study of 250 subject across
multiple CF centres has demonstrated significant negative correlations between FEV i
and spontaneously expectorated sputum markers including IL-8 and neutrophil
elastase (193). Several studies have also demonstrated changing levels of sputum
biomarkers such as IL-8 following treatment of CF exacerbation (102, 103).
Therefore sputum biomarkers may possibly be used in conjunction with other
outcome measures in the future to assess the effectiveness of new treatments in CF.
Flowever, further studies will be required to assess the reproducibility of these
biomarkers in CF before they can be fully integrated as useful clinical tests, although
early data remains promising(194). Table 1.1 demonstrates many of the presently
measurable biomarkers in sputum.
Some methodological concerns with sputum as an appropriate source of biomarker
relate to its processing. Sputum is most commonly liquefied with dithiothreitol
(DTT) a reducing agent that breaks down disulphide bonds in mucins. This can
interfere with some immunoassays designed to measure biomarkers and in order to
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minimise variability from these sources, standardised guidelines have been published
by the European Respiratory Society on the processing of sputum and measuring of
inflammatory markers therein(206, 207).
Thus the measurement of biomarkers in sputum may lead to the development of
clinically useful tests for the study of new therapies in CF and compliment present
clinical measurements. It is likely that sputum contains many so far undiscovered
markers of inflammation and as such provides an excellent medium for the discovery
of new biomarkers. furthermore these biomarkers may also allow further insights
into the complicated pathophysiology of CF lung disease and provide information
regarding the mechanisms of disease.
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Biomarker Class Examples
Inflammatory Cells Neutrophil counts, macrophage characteristics
Cytokines IL-lp, IL-6, IL-8, IL-10, IL-17, IL-23, TNF-a, TGF-P
Proteases Elastase, matrix metalloproteinases, Cathepsin G
Anti-Proteases a-1 antitrypsin, SLPI, elafin
Neutrophil Products Myeloperoxidase, DNA
Anti-microbial Proteins Lysosyme, lactoferrin, secretory component of IgA
Anti-microbial Peptides Defensins, cathelicidin LL37
Markers of Tissue Injury Elastin and collagen degradation products
Table 1.1 Possible Biomarkers in Sputum
This table demonstrates the abundance of potential biomarkers in CF sputum. These
range from cytokines to natural defence proteins. In spite of a great number of target
molecules being described few have made the transition into mainstream clinical
assays. Table adapted from Sagel et al(l73).
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1.9 Discovery ofNew Biomarkers in CF
So far in this introduction I have reviewed some of the evidence relating to the
pathogenesis, treatment and further the monitoring of CF lung disease. Although
there is merit in using presently described markers of inflammation in the study of
CF lung disease (and its treatment), it is likely that other as yet unknown biomarkers
are present in clinical samples that will aid the study and understanding of the
disease process. 1 will therefore concentrate on alternative methods of protein
biomarker discovery in this section with particular reference to mass spectrometry.
1.9.1 Proteomics
The proteome is the entire compliment of proteins expressed by a genome, cell,
tissue or organism. Proteomics is the study of the proteome including the basic
chemistry of proteins; their function and role; the measurement of protein levels in-
vivo and in-vitro; the discovery of new protein markers; and the interaction of
proteins in complicated biological systems and as such employs a range of scientific
and analytical techniques.
1.9.2 Proteomics in CF Lung Disease
The majority of studies investigating protein biomarkers in CF have focussed on the
application of specific immunoassays to measure the level of known proteins. The
discovery of new markers ofCF has been attempted utilising a number of body fluids
including serum, sputum and BALF, utilising proteomics techniques such as
polyacrylamide gel electrophoresis and mass spectrometry.
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Sloan et al observed protein biomarkers in CF sputum that appeared to change with
disease severity during CF exacerbations using 2 dimensional polyacrylamide gel
electrophoresis (2DPAGE), and observed of increased levels of myeloperoxidase, as
well as increased levels of immunoglobulin breakdown products were described in
this group of CF patients(208). Furthermore McMorran et al have now demonstrated
increased levels of specific neutrophil proteins in BALF from children with CF(175),
a finding replicated by the UK CF gene therapy consortium in a separate cohort of
patients (174). Therefore proteomics offers a new approach for the discovery of




Mass spectrometry is the separation of proteins in a sample by molecular weight.
The sample is first ionised (i.e. converted to gaseous phase) by laser or by
electrospray (fine spraying of sample through a small diameter needle) and then
enters a flight tube, where separation by molecular weight takes place. The weight
of individual molecules is calculated from the speed of travel along the tube.
All mass spectrometers consist of three essential components: an ion source, a mass
analyser and a detector. The sample is ionised in the ion source and these ions are
then separated in the mass analyser (in most cases a flight tube, but other methods
include quadropole magnets) based on their mass-to-charge (m/z) ratios and then
detected by the detector (normally an electromagnetic plate that the ions collide
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with). This allows the production of a mass spectrum, which represents a plot of ion
abundance vs. m/z. In laser ionised mass spectrometry the ion source, mass analyser
and detector are situated inside a high-vacuum chamber and as such are expensive to
maintain. Electrospray ionisation (ESI) and matrix-assisted laser
desorption/ionisation (MALDI) represent the most common ionisation methods used
in mass spectrometry and produce intact protonated molecular ions of proteins and
peptides i.e. the proteins being studied are generally not degraded before detection.
Matrix (or energy absorbing molecules) is used to absorb the energy of the laser
source and allow ionisation of the sample in MALDI TOF. Surface enhanced laser
desorption/ionisation (SELDI) is a modification of MALDI TOF and will be
described in the following sections.
1.10.2 MALDI TOF Mass Spectrometry
As briefly described above MALDI TOF is a form of mass spectrometry utilising a
UV (laser) absorbing organic acid as matrix, and a UV laser source to desorb and
ionise the proteins. The matrix is added in to the analyte molecules in excess (a
saturated solution) so that the analyte and matrix co-crystalize thus increasing the
surface area for interaction with the laser. This technique was first described in 1988
by Karas and Hillenkamp(209). The matrix has a number of important roles: firstly
the large excess of matrix separates the analyte molecules from each other reducing
intramolecular interactions; secondly the matrix absorbs large amounts of energy
from the incoming photons produced by the laser causing the matrix-analyte mix on
the chip surface to explode sending these molecules into the gas phase; and thirdly
the matrix donates protons to the proteins in the analyte during the gas phase
(ionisation), thus giving the proteins energy to separate in the flight tube.
After the ions are formed by MALDI the protonated molecules are accelerated out of
the source under the influence of a strong electric field. Once in the flight tube the
ions all have the same kinetic energy thus the arrival time of a given ion at the linear
1 2
detector will vary depending on its mass. The equation E = A mv is central to
mass spectrometry. E is the kinetic energy of an ion, m mass and v is velocity. Ions
of the same charge are accelerated to the same energy and therefore their velocity
(and therefore time of flight) will be inversely proportional to the square root of their
molecular mass, and therefore heavier ions travel slower than lighter ones. Time of
flight (TOF) mass spectrometers can be either linear and reflector type instruments.
Reflector instruments use an ion mirror. The ion mirror (not a physical mirror) uses
high voltage to stop ions in the flight tube and then reaccelerate them towards the
detector allowing better resolution. Reflector-type instruments allow better
resolution of peptides and allow the monoisotopic mass of peptides and proteins to
be calculated, whereas linear TOF measures the average mass of the combined
isotopes of the peptide or protein. Surface enhanced laser desorption time of flight
(SELDI TOF) is a modification of a linear MALDI TOF instrument with the addition
of on-chip chromatography.
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1.10.3 SELDI TOF Mass Spectrometry
SELDI TOF MS is a combination of affinity capture technologies with mass
spectrometry and is based on the initial work of Hutchens and Yip(210), and in
particular the development of Surface Enhanced Affinity Capture (SEAC). In
contrast to MALDI where the chip surface merely acts to present a sample to laser
desorption, surface enhanced technology utilises a chip surface that plays an active
role in extraction, fractionation, clean up or amplification of the sample. Importantly
the surface enhanced affinity capture element of SELDI TOF MS takes place prior to
the actual mass spectrometry. Samples are processed on the chip surfaces with a
number of buffers and washing steps prior to subsequent MS. This technology was
commercialised as the Ciphergen ProteinChip (Ciphergen Biosystems, Freemont,
California) in 1997. Protein chips are pre-coated stainless steel slides, with the
coating determining the surface properties. Each Protein Chip slide has 8 individual
spots for the application of a sample and are disposable following single use. SELDI
TOF MS then uses a linear time of flight instrument to calculate the average
molecular weight (see above) of the proteins in the sample, and as such the mass
accuracy of SELDI TOF MS instruments is not as good as true MALDI TOF
instruments. SELDI TOF MS provides semi-quantitative data on the protein profile
of a given sample and thus comparisons between disease groups and controls can be
used. The SELDI TOF MS data may either be analysed in terms of individual
significantly different peaks or using the whole protein profile to demonstrate
differences between groups. Figure 1.4 is a graphical representation of SELDI TOF
MS technology.
53
SELDI TOF MS technology has been utilised by many groups to discover
biomarkers by comparing samples from disease groups to control groups. The
primary focus of much of this research has been to determine diagnostic biomarkers
in a wide range of diseases such as rheumatoid arthritis (211), HIV infection (212),
prostate cancer (213), ovarian cancer (214, 215), motor neurone disease(216),
ischaemic heart disease(217), and infectious diseases (218, 219). These studies
utilised a diverse range of body fluids such as serum, urine and CSF and joint fluid.
These studies vary in the number of subjects used and the type of analysis performed.
Initial evidence suggested that SELDI TOF MS had the potential to become an
important diagnostic platform for use in the diagnosis of complicated diseases. This
work however, has not been without controversy.
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Molecular Mass (Da)
Figure 1.5 SELDITOF Mass Spectrometry
A. Crude sample is added to a protein chip array and processed prior to the addition
of matrix. B. Sample and matrix are ionised by laser and the resultant ions fly along
the vacuum filled flight tube and time of flight is calculated. Thus a representative
spectrograph of the constituent proteins is generated. Adapted from Abramovitz et
al(220).
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1.10.4 Controversies with SELDI TOF MS
A major study utilising SELDI TOF MS published in the Lancet in 2002 led to much
controversy(214). In this (Lancet) study sera from patients with ovarian cancer were
compared with that of healthy controls using SELDI TOF MS. It was suggested that
the resultant data could be used to differentiate cases of ovarian cancer from normal
control subjects, and serve as a diagnostic screening test for ovarian cancer, which
could be useful in the early diagnosis of disease (in a disease characterised by
frequent presentation at an advanced stage). The data analysis however was based
on the differential clustering of peptides less than 1 OOODa in weight, a mass range in
which one would expect significant experimental noise. Further problems with the
study included non-uniform sample processing prior to mass spectrometry as well as
inconsistencies in the mass spectral data processing and analysing. The interpretation
of the data in this particular study also relied on the examination of mass spectral
patterns rather than identifying individual proteins, an approach which has now been
widely criticised in the literature. Indeed further independent analysis of data sets
from this study by other researchers led to completely different conclusions being
drawn (221). In particular, Baggerly et al demonstrated that inconsistent data
processing alters the ultimate outcome of these sorts of studies. It has now been
suggested that the identification of key biomarkers following initial proteomic
studies may provide a more viable route to clinical application(222), and furthermore
may allow the function of such markers to be investigated. Therefore utilising
SELDI TOF MS as a screening tool to identify individual biomarkers for
identification may be a more valid approach than attempting to use biomarker
patterns per se as a clinical test. SELDI TOF MS has been applied to a small
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number of patients with COPD demonstrating a protein profile in BAL(223), and
also in pulmonary sarcoidosis(224). The UK CF gene therapy consortium has
demonstrated differential protein expression in BALF in CF, findings that have been
replicated by an independent group(174, 175). There is as of yet a lack of published
data utilising SELDI TOF to profile sputum in CF, although the complimentary
proteomic approaches of two-dimensional electrophoresis(208), shotgun protein
sequencing(225), and affinity immunoproteomics(196) have been applied to sputum
in an effort to discover new biomarkers and been successful in this aim.
1.10.5 A Rational Approach with SELDI TOF MS
In view of the obvious problems with data analysis ofmass spectral data 1 have used
SELDI TOF MS as a screening platform for the selection of biomarkers prior to their
confirmation with traditional proteomic techniques and then validation in further
studies. In this way SELDI TOF MS is used as a non-biased, high throughput,
screening tool to discover new biomarkers rather than being utilised as a primary
assay that employs bioinformatics to differentiate between disease groups.
Furthermore as CF is a disease with established diagnostic tests and algorithms the
aim of this thesis was to discover biomarkers that may be related to the disease
process and ultimately may be used to monitor the response to new therapies. Thus
SELDI TOF MS analysis may be seen only as the first step in biomarker discovery
and validation, which needs to be followed by biomarker identification and
confirmation of biomarker expression by other techniques.
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1.10.6 Protein Identification
When a clinical sample is assayed by platforms such as SELDI TOF MS, the initial
analysis will reveal the molecular weight and abundance proteins and peptides in a
sample but not provide the identification of significant protein peaks and thus protein
identification by other methods is necessary. For example, initial analysis may
reveal highly expressed proteins at 10, 12 and 14 kDa, but will give no information
as to what these proteins are - this will require further proteomic analysis. Following
the selection of a peak of interest this protein must then be purified by, for example,
gel electrophoresis and chromatography and then subjected to trypsin digestion and
identification with peptide mass fingerprinting or MSMS. Peptide mass
fingerprinting is the process by which the trypsin digested fragments of a protein are
subjected to mass spectrometry and the resultant masses are searched against
databases of known peptide fragments and thus a theoretical sequence of a digested
protein can be used to predict the parent molecule, with these databases being based
on theoretical digestions of known proteins by the identified trypsin cleavage sites.
Thus a database searching for protein by mass fingerprinting will give a list of
potential matches and the best fit is determined by scoring systems such as the
Molecular Weight Score (MOWSE), with some databases giving a statistical
probability of the likelihood of a match(226). Formal identification of a protein is
completed when the identity is confirmed by antibody techniques such as western
blot and ELISA, or by amino acid sequencing of a protein by MSMS (for further
details please refer to chapter 4). Following protein identification, immunoassays
may then be employed to measure protein biomarkers quantitatively and thus applied
clinically to diseases such as CF.
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1.11 Other Methods of Biomarkers Discovery
As well as containing proteins, sputum in CF is likely to contain non-organic
materials such as metal ions. Increased levels of total iron and iron binding proteins
have been reported in the sputum of patients with cystic fibrosis (CF) and chronic
obstructive pulmonary disease (COPD) in cross-sectional studies, possibly reflecting
the level of lung inflammation in these patients(227-230). The measurement of
metal ions in body fluids is a specialised technique but can be performed by
inductively coupled plasma optical emission spectrometry. This will be covered in
chapter 6 of this thesis.
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1.12 Hypothesis
CF sputum contains biomarkers of disease that have yet to be discovered and
utilised. I propose that by using a proteomics approach (and other approaches as
appropriate) I will be able to discover biomarkers of CF lung disease and compare
these to healthy control populations and patients with other lung diseases and
furthermore that these may be investigated and further validated in CF exacerbation.
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2.0 Materials and Methods
2.1 Reagents Used
All chemicals were purchased from Sigma (UK) unless otherwise stated.
Hypertonic Saline 3, 4 and 5% (HS)













2.2 Subject Selection for Studies
All subjects gave informed consent prior to participation in studies related to this
thesis. The South East Scotland Research Ethics Service (SESRES) approved all
studies.
2.2.1 Healthy Volunteers
Healthy Volunteers were recruited from university and hospital staff on the Western
General Hospital campus in Edinburgh. Any volunteers with a history of respiratory
disease, for example asthma or COPD, were excluded from further participation in
studies.
2.2.2 Cystic Fibrosis Patients
All Cystic fibrosis patients were attending the Scottish National Adult Cystic
Fibrosis Clinic at the Western General Hospital, Edinburgh unless otheiwise
indicated. Patients attending this clinic had a formal diagnosis of cystic fibrosis by
clinical and genetic parameters. As such the population of CF patients used in the
following studies represent an adult population with minimum age being 16 years.
2.2.3 Asthmatic Patients
Asthmatic patients were recruited from the adult asthma clinic at the Western
General Hospital, Edinburgh unless otherwise indicated. Diagnosis had been
previously confirmed on clinical grounds meeting British Thoracic Society criteria




COPD patients were recruited from the adult respiratory clinic at the Western
General Hospital, Edinburgh unless otherwise indicated. Diagnosis had been
previously confirmed on clinical grounds and parameters supported British Thoracic
Society criteria (232).
2.2.5 Bronchiectasis Patients
Patients with bronchiectasis were recruited from the adult respiratory clinic at the
Western General Hospital, Edinburgh unless otherwise indicated. All patients had a
diagnosis of Bronchiectasis confirmed by Computed Tomography (CT) scan of
chest.
2.2.6 Cystic Fibrosis Patients Undergoing Exacerbation
Patients with CF confirmed as above were recruited at the time of exacerbation on
attendance to the Scottish National Adult Cystic Fibrosis Clinic at the Western
General Hospital when they required antibiotics. The definition of exacerbation was:
the clinical need for antibiotic therapy above normal treatment. The clinical need for
antibiotic therapy was based on the parameters of a decrease in FEVi, increase in




Forced Expired Volume in 1 second (FEVi) was measured according to ERS/ATS
guidelines(233) using a Vitalograph spirometer (Vitalograph, Buckingham, UK) that
was calibrated twice weekly. FEVi was recorded as % predicted.
2.4 Sputum Collection
2.4.1 Procedure
Some CF patients were able to expectorate freely without the need for induction, and
if this was the case spontaneous samples were collected. In some CF patients both
spontaneous and induced samples were collected. Sputum induction was carried out
with hypertonic saline (HS) following a strict protocol. Prior to sputum induction
subjects were pre-treated with 400 meg of salbutamol, a bronchodilator to avoid
bronchoconstriction secondary to hypertonic airways challenge. FEVi was measured
as above and if it fell by greater than 20% during the collection then the procedure
was abandoned and further bronchodilator given.
Subjects inhaled nebulised hypertonic saline solution at successive concentrations of
3, 4 and 5 % similar to a method previously described (176, 177). Saline was
nebulised through a Liberty ultrasonic nebuliser (Clement Clarke, Essex, UK). Each
concentration of saline was inhaled for 5 minutes. Spirometry was performed
following each inhalation step and the procedure abandoned if there was a drop in
FEVi greater than 20 %. After each inhalation period the patient was asked to blow
their nose into a clean handkerchief and rinse their mouth with water. Patients were
then asked to cough and expectorate sputum. This process was repeated for each
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successive concentration of HS. The success rate of sputum induction varied
between disease groups but was generally above 70%.
2.4.2 Sample Collection/Transportation
Sputum was collected into polypropylene tubes and transported on ice for further
sample preparation. All sputum was transferred to a clean laboratory for preparation.
2.4.3 Sputum Preparation
Sputum was prepared as a modification of previously described techniques(176, 177)
and processed within 2 hours of expectoration from the patient. All reagents and
sample tubes were pre-chilled to 4°C. The collected sample was transferred to a
sterile Petri dish and mucus plugs were separated from saliva using forceps. Plugs
were then transferred to a fresh Petri dish and the gathered together by moving the
mass of plugs in circular movements around the dish until a solid mass was formed
expelling any remaining saliva.
The mucus plugs as above were transferred to a pre-weighed polypropylene tube and
the weight calculated on a standard laboratory balance. 4x weight in volume of 0.1%
DTT (i.e. 4mls/lg of plugs) was added to the selected mucus plugs. This mixture
was then mixed with a lml pastette and then vortexed for 15 seconds. The sample
was then mixed on a rotator at 4°C for 15 minutes. Following rotation a further 4x
weight in volume of DPBS was added to the sample and it was vortexed for 15s.
The diluted sample was then filtered through pre wet (with DPBS) 48pm pore nylon
gauze set in a polypropylene funnel into a chilled 15ml polypropylene tube.
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The above sample was then centrifuged at 1200 rpm for 10 minutes at 4°C. The
supernatant was removed for storage at -80°C in polypropylene cryovials (Nunc,
Thermo Fisher Scientific, Denmark) until further analysis.
2.4.4 Preparation of Cellular Phase
The cell pellet from above was resuspended in DPBS in a ratio of 1 ml to 0.5mm
depth of pellet. Resupended cells were spun on to glass microscope slides at 400
rpm for 5 minutes. Slides were air dried, fixed with methanol and stained by May-
Grunwald-Giemsa using MGG Quick Stain (Bio-Optica, Milan, Italy).
2.5 Collection and Preparation of Serum Samples
Venous blood was collected by venepuncture of the forearm. Blood was collected
into serum tubes with pre-added clotting activator (monovette serum collection tubes,
Sarstedt AG and Co, Germany). The tube was then mixed by inverting 5 times.
Blood was left to clot at room temperature for 45 minutes. Tubes were then
centrifuged at 1800g for 15 minutes at room temperature. Separated serum was
removed into polypropylene cryovials (Nunc, Thermo Fisher Scientific, Denmark)
and stored at -80 °C until further analysis.
2.6 Protein Assay of Sputum Samples
A protein assay of sputum samples to be used in mass spectrometiy experiments (see
below) was performed. Total protein content of sputum samples was determined by
a Pierce reducing agent compatible BCA (bicinchoninic acid) protein assay (Thermo
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Fisher Scientific, Denmark). Samples were compared against a standard curve in
0.05% DTT diluent (the final concentration ofDTT in prepared sputum samples) at a
range of 62.5 - 2000pg/ml. 20pl of each sample or standard were added to
polypropylene tubes with 20 pi of assay reconstitution buffer. Tubes were sealed
with parafilm and incubated at 37°C for 15 minutes. Following this 1 ml of kit
working reagent was added to each tube and incubated at 37°C for a further 30
minutes. 200 pi of each sample were transferred to a microplate and read in a plate
reader at wavelength of 540nm and the protein concentration calculated from the
standard curve.
2.7 Surface Enhanced Laser Desorption Time of Flight Mass
Spectrometry
2.7.1 Protein Chips Used
For the SELD1 TOF MS experiments in this thesis four types of ProteinChip were
utilised: A normal phase protein array (NP20) with no specific binding properties; a
weak cation exchange (CM 10) at varying pH; a strong anion exchange (Q10) at
varying pH; and an immobilised metal affinity surface (IMAC) activated with nickel.
CM 10 and Q10 experiments were performed using a 96 well bioprocessor
(Ciphergen, USA), a means of attaching wells on top of the spot surface allowing
larger volumes of sample to be used, whilst processing up to 12 chips at one time.
IMAC Experiments were not carried out in the bioprocessor, as metal reagents are
known to bind to the bioprocessor reservoir wells and not the chip surface (personal
communication Nathan Flarris, Ciphergen, UK). NP20 experiments were carried out
on-chip allowing smaller volumes of samples to be utilised with no pre-activation of
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the surface being required. All experiments were performed at room temperature
unless otherwise indicated.
2.7.2 CM10/ QIO Chip Protocols
CM 10 and Q10 ProteinChips were placed in the bioprocessor. Chromatographic
spots on the chip surface were equilibrated by adding buffer: 200 pi of either 100
mM ammonium acetate/0.1% triton (pH 4/6) or 100 mM tris HC1/0.1% triton (pH
8/10) to each well. The bioprocessor was shaken at 600 rpm for 5 minutes and then
emptied. This process was repeated. The bioprocessor was emptied and 20 pi of
sample (sputum fluid phase) was added to a well with 230 pi of the appropriate
buffer/0.1%triton. The plate was sealed with adhesive plate sealer and shaken at 600
rpm for 2 hours. Following this the bioprocessor was emptied and 2 washes of 5
minutes were performed with the appropriate buffer that was used to equilibrate the
chip in 0.1% triton on the shaker. Following this 3 washes with buffer alone minus
triton were performed. A final wash of 280 pi deionised water was then performed
without shaking. Following this the bioprocessor was opened and chips were
removed and allowed to air dry. 0.8 ul of sinapinnic acid matrix (in 50%
acetonitrile/0.5% trifluoroacetic acid) was then added to each spot and allowed to air
dry. This process was repeated. Chips were then read on a Protein Biology System
2 (PBS II) mass spectrometer (Ciphergen, Freemont, CA, USA).
2.7.3 IMAC Nickel Chip Protocol
1 Oul of 1 OOmM nickel sulphate was added to each spot on an IMAC ProteinChip and
incubated in a humidified chamber for 15 minutes. Each spot was then washed with
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10 ul UPH2O. A further lOul of lOOmM nickel sulphate was added and incubated as
above or a further 15 minutes. Spots were washed again with water and excess
moisture removed from the chip using fine tissue paper. 6ul of 0.5M sodium
chloride/0. l%Triton was then added to each spot. 2ul of sample (sputum
supernatant) was then added to each spot. Chips were then incubated for 2 hours in a
humidified chamber. Following this spots were washed twice with lOul 0.5M
sodium chloride in PBS/0.l%Triton and then twice with 0.5M sodium chloride in
PBS with no triton. A final wash was performed with deionised water. Excess
moisture was removed from spots and chips were allowed to air dry. 0.8 pi of
sinapinnic acid matrix (in 50% acetonitrile/0.5% trifluoroacetic acid) was then added
to each spot and allowed to air dry. This process was repeated. Chips were then read
on a PBS II mass spectrometer.
2.7.4 NP 20 Chip Protocol
NP 20 chips required no pre-activation. 2 pi of sample were added to spots and
allowed to air dry. Spots were washed twice with 10 pi deionised water and allowed
to air diy. 0.8 pi of sinapinnic acid matrix (in 50% acetonitrile/0.5% trifluoroacetic
acid) was then added to each spot and allowed to air dry. This process was repeated.
Chips were then read on a PBS II mass spectrometer.
2.7.5 SELDI TOF Mass Spectrometry
All SELDI TOF mass spectrometry was performed on a Protein Biology System 2
(PBS II) mass spectrometer (Ciphergen, Freemont, CA, USA) situated in the
Molecular Medicine centre Laboratories of Edinburgh University. When performing
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analysis on sputum samples a standardised protocol was used to read all chips
(regardless of surface properties) to enable direct comparisons to be made within and
between groups. The mass spectrometer was calibrated regularly with known protein
and peptide standards.
Chips were placed in the mass spectrometer and read automatically with the
following settings unless otherwise stated. Laser intensity of 205 with deflector set
at 4000 Da and a focus mass of 7500 Da with optimisation of the instrument from
3000 to 25000 Da. Chips were read in the mass range 0-50000 Da unless otherwise
indicated. Chips were read at 12 individual areas on each spot with 8 laser shots at
each spot being recorded, allowing an average of 96 shots for each spot to produce
mass spectra. Prior to reading each area was given two warming shots at higher laser
intensity, to initiate ionisation, which were not included in the average spectra. Data
were exported from the mass spectrometer to a dedicated PC and analysed in
platform specific software (Ciphergen ProteinChip and Ciphergen Express,
Ciphergen, Freemont, CA, USA).
When undertaking individual experiments such as protein identification a manual
chip reading protocol was used. This allowed the alteration of laser intensity,
detector sensitivity, focus mass and deflector settings. Individual settings will be
described in the text when applicable. During manual reading, data were collected
from at least 10 areas on a spot surface and averaged to form spectra following each
experiment.
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2.7.6 Mass Spectral Data Processing
Prior to comparisons of spectra the data were processed using Ciphergen ProteinChip
software and Ciphergen Express software. Data were processed in the following
fashion consistent with previously published data(174). Baseline correction was
performed to enhance the contrast of peaks to baseline using a fitting width of 4
times the expected width. Noise was automatically measured from 4 to 50 kDa and
spectra corrected for average noise. Data were then normalised for total ion current
to account for spot to spot variability in the matrix crystallisation and efficiency of
ionisation. The total ion current for an individual spectrum was divided by the
average total ion current over all spectra and thus each spectrum was awarded a
normalisation coefficient. A normalisation coefficient of 1 reflected individual AUC
the same as average, <1 suggests a greater AUC than average, and >1 a smaller AUC
than average. Thus spectra with high normalisation coefficients were individually
scrutinised and, if they reflected poor quality (inconsistent or noisy signal) or absent
spectra, were excluded from analysis consistent with previously published
work(174). Finally peaks were detected using a peak detection wizard, which
automatically detected peaks by signal to noise ratio. Peaks with a signal to noise
ratio >3 were selected to perform analysis within and between groups.
2.7.7 Mass Spectral Data Analysis
Data analysis of SELDI TOF MS data was performed using the platfonn specific
software Ciphergen Express. Following uniform processing steps as above data were
subjected to a cluster wizard. This automatically clustered peaks across all spectra of
a similar molecular weight (within 0.3%) allowing the comparison of biomarkers
between spectra and ultimately between groups. Clusters of peaks were compared
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between groups by signal intensity of the peaks. Statistical analysis between groups
was performed using Mann Whitney testing. Following initial data analysis p values
were corrected for multiple comparisons using the Bonferoni correction. Data were
also subjected to principal component analysis to demonstrate differences between
disease groups when complete protein profiles were compared using an automated
algorithm on Ciphergen Express, as a means of distinguishing between groups by
comparison of the overall mass spectral data.
2.8 One Dimension Polyacrlyamide Gel Electrophoresis (1D PAGE)
All ID PAGE was performed in the Novex (Invitrogen, Paisley, UK) gel
electrophoresis system. Precast 18 % tricene/glycine gels (Invitrogen, Paisley, UK)
were used unless otherwise stated. MultiMark (Invitrogen, Paisley, UK) markers
were used. Sputum samples w7ere prepared linl with running buffer to a final
volume of no more than 20 pi and heated at 85°C for 2 minutes. Samples were then
added to gels and run at 125 volts for 90 to 120 minutes until the running buffer was
seen to approach the lower edge of the gel. Gels were fixed in 50% methanol/10%
acetic acid in UPFFO for 10 minutes and then stained with coomassie or subjected to
blotting.
2.9 Western Blotting
All Western Blotting was performed in the Novex Blotting Module (Invitrogen,
Paisley, UK). Gels were blotted to PVDF in Tris-Glycine transfer buffer with 20%
methanol at 25 volts for 1 hour. Positive blotting was confirmed by staining
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membranes with Ponceau S in 7% TCA. Membranes were then incubated overnight
in 5% Skimmed Milk/0.2% tween in PBS at 4°C. The following day primary
antibody (usually 1 in 1000) in PBS/0.2% tween was added to membranes and
incubated at room temperature for 1 hour. Membranes were then washed once for 15
minutes and then 3 times for 5 minutes in PBS/0.2% tween. Secondary antibody was
then added and incubated for 30 minutes at room temperature. Washes as above
were then performed. ECL plus detection reagent (Amersham Biosciences, UK) was
used as per manufacturer's instructions and the membranes exposed to xray film for
30 s, 1 minute, 5 minutes and 10 minutes.
2.10 Protein Identification
Protein identification was performed on sputum samples following purification on
either ID PAGE or a combination of pre-fractionation and I D PAGE.
2.10.1 Protein Pre-Fractionation Using Reverse Chromatography Beads
Fractionation was carried out using HyperD ceramic reverse phase chromatography
beads (Pall, New York, USA). Beads were first equilibrated in 50% acetonitrile
overnight. The following day 30 pi of bead suspension is added to 4 epindorf tubes
and washed twice with 1ml 10% acetonitrile/0.5% TFA in deionised water for 5
minutes. Samples to be fractionated were adjusted to contain 10% acetonitrile and
0.5% TFA i.e. 900 pi of sample with 100 pi acetonitrile and 5 pi TFA. Tubes
containing the beads were centrifuged and the supernatant discarded. 250pl of
sample was added to each tube and the beads/sample mixed on a rotating mixer for
30 mins at room temperature. Following this the samples were centrifuged at
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300rpm for 2 mins and the supernatant removed. The supernatant representing the
unbound fraction, was dried in a Speed Vac (Eppindorf, Hamburg, Germany).
Following this, beads from all 4 tubes were pooled and 500ul of 10%
acetonitrile/0.1% TFA in deionised water is added. The sample was mixed for 5
minutes and centrifuged at 300 rpm for 2 mins. The resulting supernatant was
removed and dried Speed Vac. Following this 500 pi of 20% acetonitrile/0.1% TFA
was added to the beads, mixed for 5 minutes then centrifuged and the supernatant
removed and dried as above and so on. This process was repeated with increasing
concentrations of buffer at from 30-70% acetonitrile/0.1% TFA. At each stage 20pl
of supernatant was saved for SELDI TOF MS analysis allowing the protein profile in
each sample to be recorded. Once samples were dried in the Speed Vac they were
stored at -20°C prior to further analysis. Desiccated samples were reconstituted for
SDS PAGE using 20 pi sample running buffer. If samples were acidic following
reconstitution ammonium bicarbonate was added to achieve neutral pH.
2.10.2 SDS PAGE For Protein Identification
SDS PAGE was performed as in section 2.8 for both pre-fractionated samples and
non-fractionated samples. Following staining bands of interest were excised with a
clean scalpel blade and subjected to passive elution and in-solution digestion, or in
gel digestion with trypsin. Passive elution prior to in solution digestion allows the
visualisation of protein profiles on SELDI TOF MS from an excised band, allowing
the appropriate proteins to be selected for trypsin digestion, whilst however yielding
a lower concentration of protein for trypsin digestion.
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2.10.3 Passive Elution From Coomassie Stained Gels
Individual gel bands were first de-stained by excising as above, cutting into smaller
pieces and placing in tube with 200ul of 50% methanol/10% acetic acid. This was
mixed on a rotating mixer for 30 minutes. Following this the supernatant was
removed and a further volume of methanol/acetic acid was added. This step was
repeated until the gel pieces were clear of stain. Once clear, 100 pi of acetonitrile
was added and the sample mixed for 5 minutes, or until the gel pieces turned white.
Following the removal of supernatant the gel pieces were dried in a Speed Vac
(Eppindorf, Hamburg, Germany). 70 pi of 50% formic acid/25% acetonitril/15%
isopropanol/10% H2O was added and the sample was vortexed for 2 hours. The
resulting elute was then used for SELDI TOF MS or subjected to in-solution trypsin
digest.
2.10.4 In Solution Trypsin Digest
Passive elution material was dried as above and then reconstituted in saturated
ammonium bicarbonate solution diluted 1 in 25 and again dried as before. Following
this 20 pi of 10 ng/ml of proteomics grade trypsin in 25 mM ammonium
bicarbonate/10% acetonitrile was added. The sample was vortexed and then
incubated at 37°C for 2 hrs. The resulting digest was then subjected to SELDI TOF
MS.
2.10.5 In Gel Trypsin Digest
Gel bands were first excised and diced as above. The diced gel pieces were de-
stained by incubating at room temperature in 100 pi ofwater for 10 min and washing
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with 50 pi of acetonitrile 50% for 15 min twice at room temperature. Pieces were
then washed in 50 pi of ammonium bicarbonate 100 mM for 15 min at RT and
finally in 50pl of ammonium bicarbonate lOOmM and 50pl of acetonitrile for 15 min
at RT. The solution was discarded and the gel pieces completely dried as before.
The sample was then reduced and alkylated (to prevent disulphide bonds forming
between cysteine residues in peptides). 40 pi of 10 mM DTT in ammonium
bicarbonate lOOmM was added to the dried samples and incubated at 56°C for 45
min. This solution was discarded and 40pl of 55mM iodoacetamide/lOOmM
ammonium bicarbonate was added and incubated in the dark for 30 min. This
solution was then discarded and the pellet washed with 40 pi ammonium bicarbonate
lOOmM twice for 5 minutes and then 40 pi acetonitrile for 5 minutes. The solution
was discarded and the gel pieces dried completely as before.
Trypsin 0.01 pg/ml in 50mM ammonium bicarbonate was added to cover the gel
pieces and incubated at 4°C for 45 min. Excess solution was then removed and 40 pi
of 50mM ammonium bicarbonate was added and incubated overnight at 37°C. After
digestion, the samples were centrifuged at 300rpm for 10 minutes and the
supernatant removed and kept at 4°C. The gel pieces were then washed as follows
and the supernatants added to the original supernatant. The extraction and washing
steps involved: (i) 20 pi 25 mM ammonium bicarbonate for 15 min, (ii) 20 pi 25 mM
ammonium bicarbonate and 20 pi acetonitrile for 15 min, (iii) 20 pi 5% formic acid
for 15 min twice, (iv) 20 pi 5% Formic acid and 20 pi acetonitrile for 15 min twice.
DTT was added to the pooled supernatants to give a final concentration of 1 mM
DTT. The solution was dried as before in a speed vac.
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2.10.6 SELDI TOF MS For Protein Identification
Peptide mass fingerprinting was performed on the (PBS II) mass spectrometer
(Ciphergen, Freemont, CA, USA). All protein identification work was performed on
normal phase (NP20) ProteinChips. 1 pi of digested protein (from in solution digest)
was added to each spot and allowed to air dry. 0.8 pi of Alpha-cyano-4-hydroxy
Cinnamic Acid (CHCA) in 50% acetonitrile/0.5% trifluoroacetic acid was added to
each spot twice as matrix. Chips were read with a manual protocol as in section
2.7.4. Mass spectral data were then exported for online database searching (see
below).
2.10.7 MALDI TOF MS for Protein Identification
For in-gel protein digestions, peptide mass fingerprinting was performed on MALDI
TOF using a Voyager DE STR mass spectrometer (Applied Biosystems CA, USA)
situated in the Department of Chemistry', University of Edinburgh. 1 pi of in gel
digest material was spotted onto a stainless steel MALDI plate (similar to a
ProteinChip but containing 100 spots). 1 pi of a saturated solution of CHCA in 50%
acetonitrile and 0.5% trifluoroacetic acid was then added to each spot. Spots were
then read manually. Spectral data were then exported to Data Explorer software
(Applied Biosystems CA, USA) for processing. Processing involved internal
calibration to trypsin fragments and removal of isotopic data from spectra, to leave
monoisotopic peaks. Mass spectral data was then extracted for online database
searching.
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2.10.8 Tandem Quadropole Time of Flight Analysis
Tandem Q-TOF analysis was performed to confirm identification of some proteins
using a Q-star tandem MS instrument (Applied Biosystems CA, USA) with SELDI
chip interface. This allowed ProteinChips to present samples for Q-TOF and
collision induced dissociation (C1D). The quadropole performs separation of
peptides by charge using a magnet, allowing individual peptides to be selected and
separated from other peptides. The selected peptides are then released into a
collision chamber where under the influence of an electric field they collide and are
separated into individual amino acid constituents. All O-TOF work was carried out
by Nathan Harris, an employee of Ciphergen. at their UK training laboratory.
2.10.9 Peptide Mass Finger Printing (PMF) Using Online Data Bases
Mass spectral data of digested proteins was subjected to online searching. MASCOT
(Matrix Science, Boston, USA) and MS FIT (University of California, San
Francisco, USA) databases were employed for PMF data generated by SELDI TOF,
MALDI TOF and Q TOF. Both databases rank possible protein identification from
peptide mass fingerprint data in terms of a probability score(226) (Molecular Weight
Search [MOWSE]) and confirmation can only be made either with secondary
antibody mediated techniques or further mass spectrometry such as Q-TOF to
provide the amino acid sequence of individual peptide fragments.
2.11 Immunoassays of Biomarkers
Immunoassay of specific protein biomarkers was carried out with Enzyme-linked
immunosorbent assay (ELISA). Biomarkers for ELISA were either informed by
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SELDI TOF data or selected from previously described biomarkers of CF in the
literature. All assays were double antibody sandwich assays performed in a
microtitre plate. When available, commercial assays were employed but only if
compatible with reducing agents due to our processed sputum samples containing
0.05% DTT. Therefore all standard curves for commercial assays were performed
with the addition of DTT to standard curve diluent allowing a more accurate
determination of protein levels in our samples. A number of immunoassays were
also employed in serum. Details of individual assays are given below.
2.11.1 Calprotectin ELISA
An in-house calprotectin ELISA was used, which has an intra-assay coefficient of
variation of 5.6% (Personal communication Mags Imrie, Edinburgh). Calprotectin
mono- and polyclonal antibodies and calprotectin protein standard were kind gifts of
Erling Sundrehagen, Oslo, Norway. Microtitre plates (Corning, Lowell, MA, USA)
were coated with 100 pi mouse anti-calprotectin monoclonal (mouse anti-human)
antibody overnight at 4°C at a concentration of 40pg/ml diluted in coating buffer
(KPL Gaithersburg, MA, USA). Plates were then blocked with 1% BSA for 1 hour
at 37°C and the plate washed with 0.05% tween x3. 100 pi of sample was added to
the plate in dilutions of 1/5000, 1/10000 and 1/50000 for sputum (0.05% DTT in
PBS diluent); 1/500, 1/2500 and 1/5000 for serum (50% fetal calf serum in PBS
diluent). Purified calprotectin standard was also added to the plate in the appropriate
diluent for the assay being undertaken (i.e. DTT for sputum, FCS for serum) with a
top standard of 100 ng/ml and limit of detection of 1.56 ng/ml. Samples were
incubated at RT for 2 hrs and the plate washed x3 as before. Anti-calprotectin
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(chicken anti-human) polyclonal antibody at 1 in 1000 was added and incubated for 2
hours and washed as before. 100 pi donkey anti-chicken antibody conjugated to
horseradish peroxidase (Jackson ImmunoResearch, Sulfolk, UK) was added at a
concentration of 1 in 250, incubated for 2 hrs and washed x3 as before. 100 pi
substrate to horseradish peroxidase (KPL Gaithersburg, MA, USA) was then added
and plates were incubated for 20 minutes and then read on a microplate reader at 450
nm. Concentrations of calprotectin were then calculated from the standard curve.
2.11.2 Commercial ELISA Kits
Commercial ELISA kits were employed to measure Interleukin-8 (Biosource, UK);
Myeloperoxidase (Assay Designs, Michigan, USA); Vascular Endothelial Growth
Factor (Quantikine, R and D Systems, Oxford, UK); Clara cell secretory protein
(Biovendor, Poland). Kits were performed as per manufacturers instructions but with
the addition of 0.05% DTT to the provided sample buffer thus equilibrating standard
curve to the DTT levels present in native sputum samples.
2.12 Measurement of Trace Elements in Sputum
Trace element assay was performed by the staff of the Scottish National Trace
Element Reference Laboratory. Glasgow. UK under the guidance of Dr Andrew
Duncan. A four-point calibration was used (0, 100, 500, 1000 pg/L Cu, Fe, Zn, Mn
in 1% nitric acid). Sputum samples were centrifuged at 800g for 5 minutes and 200
pL of sample was then diluted with 2 ml internal standard solution (100 p/L yttrium
in 1% nitric acid) and mixed by inversion. Internal accuracy was assessed by use of
two aqueous certified reference materials TMDA 62 and TMDA 64 (Promochem
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Ltd, UK). Trace element levels were measured by inductively coupled plasma
optical emission spectrometry using a VISTA AX (Varian Limited, UK).
2.13 Statistical Analysis
Analysis of SELDI TOF data is covered in section 2.7, with platform specific
software being utilised as stated in the text, and further analysis carried out on
GraphPad Prism 4 (GraphPad, La Jolla, CA, USA). Statistical analysis of ELISA,
trace metal and clinical data were performed on GraphPad Prism 4. Local statistical
advice was sought from a biostatistician. Appropriate statistical testing was chosen
following Kolmogorov Smirnof testing to assess normality of distribution. Normally
distributed cross sectional data between two groups was assessed with Student t test,
non-normally distributed data utilised Mann Whitney testing. The Bonferoni
correction was applied to cross-sectional mass-spectral data to allow for multiple
comparisons. For paired data, if normally distributed a paired Student t test was
used, if not non-normally distributed data a Wilcoxon matched pairs test was used.
Data from the trace metal assays was analysed using Kruskal Wallace followed by
Dumi's test following statistical advice to allow the comparison of each trace
element between all groups of diseases. For all data, p<0.05 was considered
significant. Further statistical method is described in the appropriate chapters.
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3.0 Development of SELDI TOF MS as a Screening Tool in
Sputum
3.1 Background
3.1.1 SELDI TOF MS and ProteinChip Technology
A more in depth description of mass spectrometry based techniques is given in the
introduction. This chapter will deal with the use of SELDI TOF MS to screen
specifically for biomarkers of respiratory disease. SELDI TOF MS has previously
been demonstrated as a useful research tool in a variety of body fluids, in particular
serum(213-215, 217-219). The technology has also been exploited for the
investigation of respiratory tract such as analysis of bronchoalveolar lavage
fluid(223, 224). This chapter covers early work during which chip surfaces were
selected for future experiments and the variability of the technique and its
reproducibility in terms of sputum biomarker measurement assessed.
ProteinChip technology allows a wide array of surface chemistries to be employed in
biomarker experiments. Different surface chemistries may compliment as well as
contrast each other; however a pragmatic approach may also be required when
selecting a subset of the many chemistries available, particularly in terms of
generating manageable data sets and addressing financial constraints.
3.1.2 Selection of Appropriate ProteinChip Surface Chemistry
As intimated there are several available ProteinChip surfaces available. Previous
work utilising ProteinChip technology in bronchoalveolar lavage fluid(l 74) has
demonstrated the usefulness of anionic exchange surfaces (Q10), cationic exchange
(CM10) surfaces and metal affinity (IMAC) surfaces in the discovery of biomarkers
from this similar body fluid. Indeed based on previous work in this research group I
chose IMAC Nickel as the metal affinity surface for future experiments in sputum.
Anionic and cationic exchange could be used at a number of different pH binding
conditions prior to the addition of a sample. ProteinChip technology utilises
disposable chip arrays and as such can be expensive. Therefore on pragmatic
grounds decided to use a limited number of chip surfaces. This pragmatism takes
account of economic concerns as well as addressing the concern of multiple
comparisons leading to type 1 error.
3.1.3 Comparison of Induced and Spontaneous Sputum in CF
As many patients with CF expectorate sputum spontaneously due to their underlying
respiratory disease I wished to assess whether spontaneous and induced sputum from
CF patients taken contemporaneously were comparable, as many CF patients are able
to spontaneously expectorate and thus this form of sampling may ultimately be more
relevant to CF.
3.1.4 Studies of Reproducibilty
The reproducibility of SELDI TOF MS has previously been investigated in serum
with a quoted intra assay variation of 15.6 % (variability spot to spot on a
ProteinChip) and an inter assay variation of 24.4% (variability between spots on
different ProteinChips)(218). In urine with the intra assay coefficient of variation
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ranges from 8-30 %(234). In saliva intra- and inter- assay coefficients of variation
were 18% and 31% respectively(235). Such data take no account of biological
variability and are simply an assessment of the accuracy of the experimental
procedure. Therefore the reproducibility of SELDI TOF MS measurements in
sputum was assessed prior to biomarker discovery experiments.
3.1.5 Aims of Chapter
The main aim of this chapter is to select the most appropriate ProteinChip surface
chemistries for further experiments. This chapter will also assess the reproducibility
and repeatability of SELDI TOF MS measurement in sputum. This chapter also
assesses the similarites in spontaneous and induced sputum protein profiles.
Furthermore the inter- and intra- assay variability of SELDI TOF MS will be
investigated. Biological variation in sputum samples from CF patients will also be
measured to investigate the effect of time of day on sputum protein profiles.
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3.2 Methods
3.2.1 Selection of Appropriate ProteinChip Surfaces
3 separate pH gradients were performed for ion exchange surfaces and nickel
sulphate activation surface for IMAC ProteinChips was utilised as this had
previously been demonstrated useful in BAL fluid(174). Pools of sputum from
patients with CF and healthy controls were used to assess differences between chip
surfaces. Surfaces were selected quantitatelively by the largest number of peaks
differentiating CF from control with a signal to noise value of 10 or more to ensure
genuine peaks were selected and qualitatively based on the appearance of spectra.
Pooled sample from each group (n=at least 5 subjects) was incubated on the CM10
Protein chip at pH of 4 and 6; the Q10 ProteinChip at pH 6 and 8; and the IMAC
ProteinChip activated with Nickel. For full experimental methods please refer to the
methods chapter. Chips were read automatically and data was processed and
clustered as described in the methods section. To determine the effectiveness of each
surface, the total number of clusters across all groups was determined. Spectra were
also assessed qualitatively. ProteinChip binding characteristics were ultimately
chosen by their ability to separate CF from control samples as well as taking into
account the binding characteristics of each chip surface.
3.2.2 Comparison of Induced and Spontaneous Sputum
During sample collection from 16 CF patients we asked them to firstly provide a
spontaneous followed by sputum induction as described in the methods section.
Spontaneous and induced sputum sampled were then spotted onto adjacent spots on
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CM10 ProteinChips activated at pH4 and then read as before and subjected to cross
correlation to assess the variability between the two sampling techniques.
3.2.3 Reproducibility
All reproducibility experiments were earned out using CM10 weak cation exchange
ProteinChips activated at pH 4. To assess intra-assay variability sample from a
single subject with CF was spotted onto eight adjacent spots on a CM10 ProteinChip
activated at pH4. The chip was read automatically and protein peaks clustered.
Peaks with a signal to noise ratio of greater than 10 were selected and the coefficient
of variation for each cluster was calculated on GraphPad Prism (GraphPad, CA,
USA). An average intra-assay coefficient of variation was then calculated. To
assess inter-assay variability sample from a single CF subject was spotted onto six
individual spots on six separate ProteinChips. Chips were read and clustered as
above and coefficients of variation calculated for individual clusters of peaks. To
further assess intra-assay variability samples from 4 CF patient and 4 healthy
controls were run on adjacent spots on ProteinChips. The resultant data was
clustered and cross correlation between each individual performed. In order to assess
the effects of crude biological variability on SELDI TOF MS, 4 CF patients donated
paired spontaneous sputum samples from am and pm on the same day. Samples




IMAC Nickel was chosen as an appropriate chip surface based on previous data form
BALF fluid studies in CF(174). In pooled experiments pH4 CM10 demonstrated 107
clustered peaks vs. control compared to 92 with pH6 and thus I selected CM10 pH4
for further experiments. pFI 6 Q10 revealed 80 clustered peaks compared to control
vs. 75 with pH 8. In view of the similar number of peaks we chose pH8 for further
experiments in order to look at proteins in the more basic range compared to the
acidic range used in the CM10 analysis. These selection are broadly in keeping with
the most successful surfaces for differentiating CF from control in BALF fluidfl 74).
3.3.2 Induced Vs. Spontaneous Sputum in CF
Induced and spontaneous samples were taken contemporaneously in 16 CF patients.
Cross correlation of signal intensities for 19 peaks with a signal to noise ratio of >10
(to ensure we were comparing abundant peaks) revealed Spearman r values ranging
from 0.55 to 0.97 all at p<0.05. The majority of subjects demonstrated a Spearman r
>0.8 suggesting that induced and spontaneous sputum samples in CF are similar.
Data are demonstrated in figure 3.1.
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Figure 3.1 Spontaneous and Induced Sputum Samples Represent Similar Protein
Profiles in Cystic Fibrosis.
Spontaneous and induced samples of sputum were obtained from patients with CF.
Spontaneous sputum was expectorated immediately prior to sputum induction.
Samples were subjected to SELDI TOF MS using a CM10 pH 4 cation exchange
surface. Peaks with a signal to noise ratio of greater than 10 were selected and the
intensity of signal for each peak in the spontaneous sample was plotted against the
intensity from the induced sample. Spearman r ranged from 0.55 to 0.97 and all
correlations were statistically significant.
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3.3.3 Intra- and Inter-Assay Coefficient of Variation
Intra-assay variation was measured by spotting the same CF sputum sample onto 8
adjacent spots on a CM 10 ProteinChip. Overlaid mass spectra demonstrating intra-
assay variability are demonstrated in figure 3.2. The intra-assay coefficient of
variation ranged from 11.5 to 44% with an average CV of 22.4%, which is similar to
previously published data in other body fluids. Inter-assay variation over six
measurements on different ProteinChips for the same sample demonstrated
coefficient of variation ranging from 6 to 43% with an average CV of 16.2%.
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Figure 3.2 Intra-assay reproducibility of SELDI TOF MS in CF sputum
A sample from the same subject with CF was applied to eight adjacent spots on a
CM10 ProteinChip (labelled 1-8). Peaks with a signal to noise ratio of greater than
10 in the mass range of 5 to 50 kDa were selected and compared. The top panel
displays the overlaid spectra for each spot from 5000-17500 Da. The lower panel
demonstrates spectra in the 10000-12000 Da range. Spectra were qualitatively
similar and average coefficient of variation across the spectra was 22.4%.
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3.3.4 Cross Correlation of Individual Subjects to Assess Inter-Assay Variation
4 CF and 4 control subjects had sputum assessed on two separate chip surfaces in
duplicate. For all correlations spearman r was greater than 0.9 suggesting highly
reproducible spectra on SELDI TOF in the 5 to 50 kDa mass range. Cross
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Figure 3.3 Cross Correlation of SELDITOF MS in Control Sputum Samples.
Sputum samples from 4 separate control samples were run in duplicate on two
separate ProteinChips. Peaks with a signal to noise ratio of greater than 10 were
selected and the intensity of signal for each peak on one chip was plotted against the
intensity from the other chip. Correlation was calculated with Spearman rank






































































Figure 3.4. Cross correlation of SELDITOF MS in CF sputum samples.
Sputum samples from 4 separate CF patients were run in duplicate on two separate
ProteinChips. Peaks with a signal to noise ratio of greater than 10 were selected and
the intensity of signal for each peak on one chip was plotted against the intensity
from the other chip. In all cases spearman r was >0.95 with high statistical
significance.
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3.3.5 Within Patient Diurnal Variability of Spontaneous Sputum
Independent sampling of spontaneous sputum from individual patients in the
morning and afternoon of the same day demonstrate that the spectra are qualitatively
similar and cross correlation analysis demonstrates statistically significant
similarities. Figure 3.5 demonstrates cross correlations of spectral data for 4
individual patients.
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Figure 3.5 Cross Correlation of Morning and Afternoon CF Sputum Samples.
Sputum samples were collected from 4 subjects with CF in the morning and
afternoon of the same day and subjected to analysis on adjacent spots of a CM10
ProteinChip. Peaks of signal to noise greater than 10 in the mass range of 5-50 kDa
were selected. Correlation was assessed by Spearman rank testing. Significant
correlations were demonstrated for all subjects. Spearman r ranged from 0.597 to




This chapter deals with experiments undertaken to assess the performance and
reproducibility of the SELDI TOF MS platform in the assessment of sputum
samples. No previous literature existed on the application of SELDI TOF MS to
sputum samples in CF prior to work performed in this thesis. I have demonstrated
the criteria and rationale for the chip selections which will be utilised in further
chapters as well as addressing issues of reproducibility and sample selection i.e can
spontaneously expectorated as well as induced sputum be utilised.
3.4.2 Chip Selection
I selected a limited number of chip surfaces for our experiments utilising SELDI
TOF MS to investigate the presence of sputum biomarkers. The reasons for this are
threefold. Firstly using all of the available surface chemistry and activation
combinations of ProteinChips would be very expensive. Secondly prior knowledge
of the surface chemistries used in the ProteinChip arrays allows us to predict
optimum performance with specific activation characteristics, for example using a
very basic pH with a cationic exchange would lead to fewer proteins being bound as
the majority of proteins are anionic at a basic pH. Thirdly using a greater number of
chip surfaces with similar binding characteristics would lead to duplication of peak
information over a number of surfaces and potentially lead to over-interpretation of
any changes between CF and control groups.
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Thus the pragmatic selection of three chip surfaces allows us to use a limited number
of ProteinChip arrays whilst maximising the coverage of potential biomarkers.
When using a cationic exchange the selection of a low pH favours the binding of
more proteins as at an acidic pH most proteins would be expected to have a net
positive charge and thus be attracted to the cationic exchange. The reverse is true for
the anioinc exchange and thus a higher pH of activation should bind more proteins.
Thus CM10 ProteinChips at pH 4 demonstrating the largest number of clustering
proteins is reassuring. Q10 pH 8 although demonstrating slightly fewer proteins than
pH6 was selected in view of the chemical reasons listed above, although obviously
the Q10 surface at pH6 could have been chosen for the further experiments. In terms
of the most appropriate metal affinity surface we selected IMAC Nickel based its
previous application in CF BALF fluid(174).
Clearly the use of all available chip surfaces and activation conditions would allow a
greater coverage of the complete proteome in the proteome. This may simply
increase type 1 error, i.e. by measuring biomarkers over many surfaces we may find
a difference between groups purely by chance. Conversely if a large number of
surfaces were used any real difference may be excluded due to correcting for
multiple comparisons representing type 2 error. The majority of biomarkers were
found in the 5-20 kDa range, which limits the SELDI platform to the resolution of
small proteins and peptides. This has led some investigators to describe SELDI TOF
MS as a peptidomics rather than truly a proteomics approach, and thus one should
view further data in this thesis as complimentary to other proteomic techniques rather
than as a replacement for them.
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3.4.3 Spontaneous and Induced Sputum in CF Patients
Following the selection of appropriate chip surfaces for the further experiments I
wished to assess whether it was necessary to use induced sputum from CF subjects if
spontaneous sputum was available. Many CF patients expectorate sputum
spontaneously. I have demonstrated that induced and spontaneous sputum from CF
patients have very similar protein profiles on SELDI TOF MS. Thus I would suggest
that spontaneous sputum collection is a valid a method for sampling sputum from CF
if the patient produces spontaneous sputum. These findings are consistent with
previously published work demonstrating similarities in biomarker levels when
measured in sputum by ELISA in Asthma(180). In patients with less severe lung
disease sputum induction may be necessary but in older patients who readily
expectorate sputum, induction should not be required.
3.4.4 Variability
I assessed the variability of ProteinChip technology when used to (repeatedly)
determine sputum protein profiles. Intra- and inter-assay coefficients of variation
were similar to those published for body fluids including serum(218). I also assessed
intra-assay variability in a number of individual CF patients and controls and
demonstrated significant cross-correlation. This suggests that SELDI TOF MS is a
reproducible assay for biomarker discovery in sputum. However, biological
variability in the CF population may lead to difficulties in the interpretation of
possible difference in the CF patients from controls. Of particular concern was
whether the time of day at which a sputum sample was taken could affect the protein
profile present in the sputum sample, the rationale being that samples expectorated in
the morning may be physiologically "older" as they result from the accumulation of
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mucous and debris overnight which is expectorated in the morning, and therefore that
samples collected later in the day would reflect "fresher" sputum. There are
statistically significant correlations of clustered proteins when comparing samples
from the same patients collected in the morning and the afternoon of the same day.
This suggests that regardless of whether a sample is taken in the morning or
afternoon it is likely to yield similar information in terms of protein expression. This
finding is reassuring, in the context that spontaneous and induced sputum from CF
patients demonstrate very similar protein profiles. Sputum sampling from CF
patients can therefore be optimised to have little effect on patient lifestyle e.g. a
spontaneous samples being collected in either morning or afternoon, and assessment
of biomarkers by this means is likely to be readily translatable in to clinical practice.
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3.5 Conclusions
In this chapter I have demonstrated selection of 3 ProteinChip surfaces with distinct
binding characteristics for use in further experiments. I have also demonstrated that
SELDI TOF MS may be employed to assay protein profiles in sputum with similar
reproducibility to that published for serum. Furthermore I have demonstrated that
spontaneous and induced sputum in CF patients have very similar protein expression
profiles when measured by SELDI TOF MS and thus in spontaneous sputum
producers sputum induction is not required. I have also demonstrated, albeit in a
modest number of patients, that the time of day at which sputum is sampled has little
effect on sputum profile.
4.0 Examination of the Sputum fluid Phase with SELDI TOF
Mass Spectrometry
4.11ntroduction
4.1.1 Non-Invasive Markers of Airways Inflammation
The assessment of new therapies in respiratory disease requires realistic endpoints,
particularly when considering less common diseases such as cystic fibrosis, where
smaller numbers of patients will be available for the study of any new therapy.
Assessment of lung inflammation using biomarkers offers the possibility to study the
effects of drug therapy directly on the target organ. Traditionally direct assessment
of the airway has involved invasive procedures such as bronchoscopy with
endobronchial biopsy and bronchoalveolar lavage (BAL), which precludes sampling
from a wide range of patients at repeated time points on ethical and safety grounds.
Thus investigators have tested other means of assessing airways inflammation such
as analysis of exhaled nitric oxide(236-242) and exhaled breath condensate
measurements(157, 158, 243-249). Indeed in CF, exhaled breath condensate
pH(157) and nitrite( 158) have been demonstrated a promising surrogate markers of
inflammation which change with disease severity. Measurement of exhaled nitric
oxide in CF is less useful however(158). A further way in which to investigate
airways inflammation is the collection of sputum, either by induction or spontaneous
expectoration.
4.1.2 Assesment of Airways Inflammation Using Sputum
Sputum is the end product of lung secretions as they work their way from the
peripheral to central airway, and as such is a mixture of cellular material, proteins
and inorganic substances. Approximately 200 mis of sputum can be expectorated by
the average CF patient in a 24 hour period(229). Several studies have demonstrated
that the cellular content of sputum is mainly derived from the central airways(250,
251). In many patients sputum may be expectorated spontaneously, however the
advent of sputum induction with hypertonic saline allows the collection of adequate
sputum samples from a range of patient groups and control populations(179).
Induced sputum cell counts and biochemical mediator concentrations have been
validated in healthy adult populations(181, 182, 252). The majority of studies on
induced sputum have concentrated on the cellular properties of sputum with
particular reference to airways diseases such as COPD and Asthma(253), and sputum
has long been used in the investigation of lung cancer. The clinical impact of sputum
cytology in Asthma was best demonstrated by Green et al (176) who showed that
tailoring therapy to sputum eosinophil counts reduced the number of exacerbations
from which patients suffered.
4.1.3 Protein Biomarkers in Sputum
The fluid phase of sputum contains a mixture of substances related to inflammation
such as pro-inflammatory cytokines. Protein biomarkers have been described in the
fluid phase of CF sputum (102, 183, 194, 195, 197-199, 208, 254-259), among other
diseases. These approaches mainly rely on immunoassays to detect differences in
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(known) protein profiles and are as such prejudiced to proteins in a sample already
known to be biomarkers.
An alternative approach is to attempt biomarker discovery i.e. looking for proteins in
a sample without prejudice of which proteins should be present in a sample. This
approach may utilise a number of techniques such as gel electrophoresis, mass
spectrometry or multiplex protein arrays. For example sputum biomarkers of Cystic
Fibrosis were investigated by 2D PAGE revealing myeloperoxidase, cleaved o.\-
antitrypsin degraded IgG and interleukin-8 as biomarkers (208). SELDI TOF MS
offers a further approach in proteomic biomarker discovery and has been utilised to
measure protein biomarkers in CF BALF (174, 175). A full description of SELDI
TOF MS can be found in the introduction of this thesis.
4.1.4 Aims of Chapter
The aim of this chapter was to utilise SELDI TOF MS to discover sputum
biomarkers of lung disease in CF compared to control and other respirator}' disease
populations. I hypothesised that SELDI-TOF MS analysis of sputum from patients
with CF, bronchiectasis, asthma. COPD and healthy adult controls would allow the
discovery of novel biomarkers of CF lung disease unltimately allowing the





The South East Scotland Research Ethics Service granted ethical approval and all
participants gave written consent. Sputum was obtained from 28 patients with CF, 19
with bronchiectasis, 24 with asthma, 24 with COPD, and 20 healthy controls.
Patients were recruited as per criteria outlined in chapter 3.
4.2.2 Sputum Induction and Processing
Sputum induction was performed as described in chapter 2 and all samples were
processed within 2 hrs of collection.
4.2.3 SELDI-TOF Mass Spectrometry
Three chromatographic chip surfaces were used to cover a wide range of protein
characteristics: a weak cation exchange at pH4 (CM 10), an anion exchange at pH8
(Q10) and an immobilised metal affinity surface activated with nickel (IMAC Nickel
[IMACNi]). Sputum samples were adjusted to contain lmg/ml protein following a
standard colorometric protein assay. 20 pL of sample were added to CM10 and Q10
surfaces in a bioprocessor unit (Ciphergen, Freemont, CA, USA) and 2 pL of sample
was added to preactivated IMACNi surface for on spot incubation (more
reproducible for IMACNi surfaces). All chips were treated with SPA matrix (2x0.8
pL/spot) and allowed to air dry. Samples were analysed on the Protein Biology
System 2 SELDI-TOF mass spectrometer (Ciphergen, Freemont, CA, USA). Chips
were read with a laser intensity of 205 with deflector set at 4000 Da and a focus mass
of 7500 Da from 0 to 50,000 Da. A full description of SELDI TOF MS methods is
given in chapter 2.
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4.2.4 Data Analysis
Data were processed as outlined in the materials and methods chapter. Protein peaks
were automatically clustered to identify biomarkers of similar molecular weight.
Mann Whitney rank testing was performed to demonstrate statistical differences in
clusters between disease groups. Values of P<0.05 were taken to be significant
following correction for multiple comparisons with Bonferoni. Bonferoni correction
was applied to the data following initial analysis and based on the number of peaks
compared in a given analysis thus decreasing the possibility of a significant
difference arising by chance. Therefore, following each experiment the crude p
value was multiplied by the number of comparisons made and the corrected p value
recorded. Principal component analysis (PCA) was performed using Ciphergen
Express Software by an automated clustering algorithm using a correlation matrix
allowed the entire data set to be simplified and graphed. PCA was used to display
differences between groups but not for further analysis. Correlations with clinical
data were performed using Spearman rank on GraphPad Prism 4 (GraphPad, Ca,
USA).
4.2.5 Protein Identification
Highly abundant significantly different (between CF and control) protein peaks were
selected for protein identification experiments. Pooled sputum from at least 5
subjects from either CF or control was used for identification. Protein identification
work was performed as outlined in the materials and methods chapter. Commercial
antibodies to calgranulin A (AbCam, Oxford, UK) and clara cell secretory protein




Sputum was obtained from 28 patients with CF, 19 with bronchiectasis, 24 with
asthma, 24 with COPD, and 20 healthy controls. Patients were recruited as per
criteria outlined in chapter 3. The demographics and sputum neutrophil counts of
these subjects are displayed in Table 4.1.
Group Age Years Sex FEV, % pred Sputum
Neutrophil %
Asthma 47.8(2.9) 15F/8M 82.3(4.4) 50.6(5.0)
COPD 65.2(1.2) 10F/14M 57.7(4.1) 79.1(2.7)
Bronchiectasis 61.8(3.5) 15F/3M 71.7(11.6) 83.2(5.6)
CF 28.8(1.7) 8F/19M 59.2(3.9) 91.6(2.0)
Control 36.4(2.1) 11F/9M 101.4(3.1) 54.2(5.3)
Table 4.1 Subject Characteristics for SELDI TOF MS Sputum Study
Demographic, lung function, and sputum neutrophil data of the patients studied.
Mean (SEM) are given.
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4.3.2 Raw Mass Spectral Data
Individual spectra were produced for each subject and examined qualitatively. In
terms of abundance and peak intensity the CF and bronchiectasis groups had the best
quality spectra. An example of spectral data from 5 individual subjects is
demonstrated in figure 4.1. Figure 4.2 demonstrates the abundance of peaks
demonstrated in a subject with CF by showing the spectra at different levels of
magnification. The majority of the differential peaks were found in the mass range
of 4 to 20 kDa.
4.3.3 Differentiation of CF and Other Disease Groups from Control Population
Clustering and univariate analyses determined a large number of proteins present in
relative proportions that differentiated between disease groups and healthy controls.
Following correction for multiple comparisons with bonferoni, the number of
differential proteins for each disease groups vs. control reaching pre-defined
statistical significance (p<0.05 corrected) was as follows:
Cationic exchange (CM10): 28 CF from control, 29 bronchiectasis from control, 2
asthma from control, 2 COPD from control.
Anionic exchange (Q10): 28 CF from control, 34 Bronchiectasis from control, 13
asthma from control and 14 COPD from control.
Metal affinity surface (IMAC Ni): 46 CF from control, 48 bronchiectasis from
control, 1 asthma from control and 5 COPD from control.
The total number of clustering peaks for each chip surface and disease group are
demonstrated in table 4.2.
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5CC0 7500 10OCO 12500 15000
Figure 4.1 Mass Spectra from Individual Subjects
CF, Bronchiectasis, COPD, Asthma and control spectra are shown. Sputum samples
were processed and then applied to IMAC Ni ProteinChips. SELDI TOF MS was
performed and individual spectra for each subject generated. Protein profiles are
demonstrated for the mass range 5-20 kDa, clear differences in peak profiles are
visible between subjects.
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Figure 4.2 Magnified Spectra Display Abundance of Peaks
Spectra from an individual with CF on the CM10 pH4 (cationic exchange) surface
shown at different magnifications demonstrating the abundance of peaks in an
individual sample. Panel A demonstrates the entire spectrum (3000-50000 Da); each
label (most of which cannot be discerned individually at this magnification)
represents a peak with signal to noise ratio of >3. Panel B demonstrates some
magnification to cover the spectrum from 5000 to 20000 Da and again most of the
individual labels cannot be seen clearly at this magnification. Panel C demonstrates















Asthma 47 13 2
Bronchiecatsis 43 39 29
Cystic Fibrosis 44 36 28













Asthma 47 26 13
Bronchiectasis 45 39 34
Cystic Fibrosis 38 35 28
COPD 46 25 14
C
IMAC Nickel Number of Number of *Number
Clustering Differentiating P<0.05
Peaks Peaks p<0.05 Corrected
Asthma 35 9 1
Bronchiectasis 49 40 48
Cystic Fibrosis 55 51 46
COPD 45 25 5
Table 4.2 No of Protein Peaks Differentiating Disease Groups From Control
A, B and C represent the number of protein peaks differentiating disease groups from
control subjects over the cation exchange, anion exchange and IMAC nickel surface
respectively. *P values were corrected with Bonferoni. Number of clustering peaks
refers to the number of peaks compared between each group and control. The
majority of differentiating peaks were in the CF and bronchiectasis groups.
4.3.4 Differentiation between Groups Using Principal Component Analysis
Principal component analysis was performed by an automated algorithm on
Ciphergen Express Software (Ciphergen, Freemont, Ca, USA). This allows one to
then perform 3 dimensional principal component plots demonstrating that CF and
Bronchiectasis group together separately from asthma, controls and COPD on all 3
surfaces. This is demonstrated in figure 4.3 for three chip surfaces covering the
complete data set.
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Figure 4.3 Principal Component Analysis ofAll Subjects Across 3 Chip Surfaces.
Each plot represents the results of analysis from a full experiment and includes all
subjects utilised in the study. A: IMAC Nickel, B: CM10, C: Q10. Each Coloured
dot represents an individual subject. Green dots are CF, blue bronchiectasis,
turquoise control, red asthma and yellow COPD. Principal components were
calculated by an automated correlation matrix. On all surfaces CF and
Bronchiectasis patients co-segregate from other groups, most impressively so on the
IMACNi(A).
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4.3.5 Recognition of the Most Statistically Significant Biomarkers CF Patients Vs.
Controls by Statistical Ranking
By ranking all biomarkers over the 3 chip surfaces a list of the most differential
peaks on SELDI TOF is generated. This ranking relies on the statistical significance
of the biomarkers rather than the abundance. The 3 most significant markers for CF
vs. control were 10531, 10576 and 12244 Da respectively on the IMAC ni surface.
A similar peak (to 10576) on the CM 10 surface was seen at 10582 Da and represents
the same protein. This has now been identified as Calgranulin A.
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Molecular Surface P value Direction of
Weight Da Change in CF
10576* IMAC Ni 0.0000004 Increased
10531 IMAC Ni 0.0000004 Increased
12244 IMAC Ni 0.0000004 Increased
10786.55 IMAC Ni 0.0000006 Increased
12893.18 IMAC Ni 0.0000006 Increased
10582.34* CM 10 0.0000006 Increased
12681.95* IMAC Ni 0.0000007 Increased
12697.67* CM 10 0.0000008 Increased
13372.49 CM 10 0.0000010 Increased
24003.81 IMAC Ni 0.0000011 Increased
7933.153 CM 10 0.0000012 Decreased
7948.071 CM 10 0.0000012 Decreased
10173.6 IMAC Ni 0.0000012 Increased
13173.33 CM 10 0.0000015 Increased
4923.537 IMAC Ni 0.0000016 Decreased
15485.36 IMAC Ni 0.0000016 Decreased
34583.18 IMAC Ni 0.0000016 Increased
8844.436 Q 10 0.0000018 Increased
11046.58 CM 10 0.0000020 Increased
11736.38 CM 10 0.0000020 Decreased
Table 4.3 Markers Differentiating CF from Control
The top twenty sputum markers ranked by statistical significance for CF vs. control
are given indicating the chip surface on which they were identified and their
molecular weights. Proteins with (*) are the same peak with a similar molecular
weight appearing on 2 surfaces and represent the same protein, based on known
identification and known protein properties.
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4.3.6 The Most Significant Biomarker Differentiating CF From Other Groups
Biomarker 10576 Da on the Nickel surface also differentiated CF from control,
asthma and COPD but not from bronchiectasis. This biomarker was identified as
calgranulin A following the identification steps described in material and methods
and the relative expression on SELDI TOF MS is demonstrated in figure 4.4. The
differential presence of calgranulin A was confirmed with western blotting in pooled
sputum samples from CF and control patients (figure 4.4). A peak at 10832 was also
identified as calgranulin A by mass finger printing following purification on SDS
PAGE (see later sections). The relative expression of calgranulin A 10832 across all
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Figure 4.4 Calgranulin A (1 0576Da) Differentiates CF and Bronchiectasis From Other
Groups
A. Biomarker at 10576 Da (calgranulin A) on IMAC Ni Surface Differentiates CF
and bronchiectasis from control and other disease groups (p<0.001). Bars represent
median.
B. This confirmed by western blot in pooled samples of each group (lanes are
labelled as Bl= blank; A= asthma; Br= bronchiectasis; CF= cystic fibrosis; Con=
control; CO= COPD). When blotted in sputum calgranulin A runs as doublet with
predominance of lower molecular weight isoform. Blot representative of three
separate experiments. (Western blot utilised mouse anti-human monoclonal antibody
at 1/1000 concentration and rabbit anti-mouse conjugated secondary antibody at
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Figure 4.5 Native Molecular Weight Calgranulin A is Increased in all Disease Groups
Biomarker 10832 (Calgranulin A) on IMAC Ni surface is elevated in all disease
groups vs. control (CF and Bronchiectasis p<0.001; Asthma and COPD p<0.01).
There is no differentiation between disease groups as with 10576 Calgranulin A.
Bars represent median.
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4.3.7 Down Regulated Protein Biomarkers
The majority of differential biomarkers identified in the CF and bronchiectatic
groups were up regulated when compared to the control samples. A limited number
were however down regulated. The most significantly decreased protein in CF was
at 7.9 kDa on the weak cation exchange and was later identified as clara cell
secretory protein, this identification being confirmed by western blot. The relative




































Figure 4.6 Clara Cell Secretory Protein is Decreased in CF
Clara cell secretory protein (CCSP), M.W. 7.9kDa, was in lower abundance for all
disease groups compared to controls (CF and bronchiectasis vs. control p<0.0001;
asthma and COPD vs. control p<0.01), on CM10 surface. Bars represent median. B.
This confirmed by western blot in pooled samples of each group (lanes are labelled
as Bl= blank; A= asthma; Br= bronchiectasis; CF= cystic fibrosis; Con= control;
CO= COPD). CCSP runs as doublet with 7.5 kDa protein and 15kDa dimer (Blot
utilised rabbit ant-human polyclonal antibody to CCSP at 1/1000 and pig anti-rabbit
conjugated antibody 1/1000, 5 minute exposure). There is strong staining in control
and COPD and weaker staining in bronchiectasis and asthma. Blot representative of
two separate experiments.
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4.3.8 Proteins Differentiating Between Disease Groups
CF and bronchiectasis demonstrated similar biomarker profiles to each other, albeit
the abundance of protein in the CF group was greater. Only 5 proteins differentiated
CF from bronchiectasis at p<0.05 following correction for multiple comparisons.
Two of these proteins were observed on the IMACNi surface and 3 on Q10. These
results are summarised in table 4.3.3. Further analysis revealed a number of peaks
differentiating CF from the disease groups ofAsthma and COPD. 29 and 30 proteins
differentiated CF from asthma and COPD respectively on the IMAC Nickel surface
at p<0.05; 27 and 24 on the CM10 surface; and 16 and 14 on the Q10 surface. The
20 most significant proteins in for each disease group on each surface are listed in
table 4.3.4. Only 1 peak differentiated between asthma and COPD over the three
surfaces and this is displayed in figure 4.7.
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Molecular Surface p value Direction of
Weight Change in CF
17410.19 Q 10 0.0120 Increased
5146.118 IMAC Ni 0.0139 Increased
5421.827 IMAC Ni 0.0288 Decreased
14241.45 Q 10 0.0352 Increased
6924.865 Q 10 0.0387 Decreased
Table 4.4 Proteins Differentiating CF and Bronchiectasis
Only 5 protein peaks are found to differentiate CF from bronchiectasis following
correction for multiple comparisons. The most statistically significant differential
protein was discovered on the anionic exchange at a molecular weight of 17410 Da.
This protein remains unidentified.
124
A
Molecular Surface P value Direction of
Weight Da Change in CF
10532 IMAC Nickel 0.0000004 Increased
10576 IMAC Nickel 0.0000009 Increased
15857 CM 10 0.0000020 Increased
10583 CM 10 0.0000030 Increased
6396 CM 10 0.0000038 Increased
7947 CM 10 0.0000043 Decreased
21139 IMAC Nickel 0.0000056 Increased
5295 IMAC Nickel 0.0000063 Increased
12893 IMAC Nickel 0.0000063 Increased
21380 IMAC Nickel 0.0000063 Increased
4923 IMAC Nickel 0.0000086 Decreased
6509 CM 10 0.0000112 Decreased
10174 IMAC Nickel 0.0000131 Increased
23251 IMAC Nickel 0.0000145 Increased
4883 CM 10 0.0000159 Decreased
14665 IMAC Nickel 0.0000161 Decreased
14872 IMAC Nickel 0.0000178 Increased
7337 IMAC Nickel 0.0000198 Increased
11723 IMAC Nickel 0.0000242 Increased
4867 CM 10 0.0000284 Decreased
B
Molecular Surface P value Direction of
Weight Da Change in CF
10532 IMAC Nickel 0.0000006 Increased
4923 IMAC Nickel 0.0000019 Increased
10576 IMAC Nickel 0.0000019 Increased
10584 CM 10 0.0000036 Increased
21139 IMAC Nickel 0.0000043 Increased
10981 Q 10 0.0000057 Increased
11052 Q 10 0.0000064 Increased
10174 IMAC Nickel 0.0000072 Increased
21381 IMAC Nickel 0.0000080 Increased
4843 IMAC Nickel 0.0000121 Increased
10167 Q 10 0.0000129 Increased
10574 Q 10 0.0000129 Increased
23251 IMAC Nickel 0.0000199 Increased
5374 IMAC Nickel 0.0000219 Increased
6397 CM 10 0.0000239 Increased
15485 IMAC Nickel 0.0000242 Increased
15397 Q 10 0.0000317 Increased
11139 Q 10 0.0000396 Increased
4707 IMAC Nickel 0.0000435 Increased
5295 IMAC Nickel 0.0000478 Increased
Table 4.5 Protein Peaks Differentiating CF from Asthma and COPD
The twenty most differential peaks for CF vs. Asthma (A) and COPD (B). Peaks are
ranked by statistical significance. There protein peaks differentiating CF from both



















Figure 4.7 29kDa Protein Differentiates Asthma from COPD on SELDITOF MS
One protein peak separated asthma from COPD patients with SELDI TOF MS
(.P<0.05). This protein had a molecular weight of 29 kDa, and was detected on the
IMAC Ni surface. This biomarker has remained unidentified.
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4.3.9 Correlation of Calgranulin A and B with FEViand Sputum Neutrophil
Identification of key biomarkers is covered in the following sections. I wished to
assess the relationship of our top identified biomarkers with other markers of disease
activity and airways inflammation in the CF patients in order to assess the clinical
relevance of these markers so as to understand their potential usefulness for
development into future assays. Calgranulin A and Calgranulin B demonstrated no
significant correlation with FEVi% predicted and differential sputum neutrophil
count. Clara cell secretory protein demonstrated a positive correlation with FEVi%
predicted (Spearman rank 0.43, p<0.05) but no relationship to differential neutrophil
count.
4.3.10 Proteins Identified From Disease Groups
This chapter has focussed on the development ofmarkers of CF lung disease. Thus
an attempt was made to identify biomarkers with relevance to CF lung disease. The
proteins listed in table 4 were identified from pooled samples of sputum from the CF
and control groups and were confirmed by antibody-based techniques where
possible. As a number of the differential protein peaks were in the sub 7 kDa range,
these have proved difficult to identify due to the technical problems of resolving
peptides in this mass range on polyacrylamide gel. Figure 4.8 demonstrates the
identification of calgranulin A and B from sputum with pre-fractionation, resolution
on gel, passive elution, trypsin digestion and peptide mass fingerprinting using the
SELDI TOF MS platform. Data is also demonstrated for confirmatory MS/MS in
figure 4.9. Figure 4.10 demonstrates the identification clara cell secretory protein
(CCSP, uteroglobin) using MSMS (Q-TOF), as peptide mass fingerprinting was
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inconclusive for this protein. A further number of proteins were identified from
MSMS (Q-TOF) without prior mass fingerprinting and these are listed in table 4.3.3.
The positive identifications of calgranulin A and clara cell secretory protein were
confirmed with western blotting using specific commercial antibodies and are
demonstrated previously in the results section. Quantitative immunosassays for these
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Figure 4.8. Identification of Calgranulins A and B by Peptide Mass Fingerprinting on
SELDITOF MS platform.
A: Pooled CF sputum sample was purified reverse phase chromatography and elution
with 50% acetonitrile. This was applied to an NP20 ProteinChip and demonstrates
dominant peaks in the 10-13 kDa on SELDI TOF MS. The lower molecular weight
peaks labelled in green indicate doubly pronated (double charged) protein. B: This
eluted sample was run on 18% tris/glycine gel, stained with coomassie and the bands
cut as shown. C: Passive elution of protein from the cut gel bands demonstrates the
further purification of peaks around 10576 Da and 13200 Da. D: Passive elution
from band 1 was digested with trypsin and applied to an NP20 ProteinChip. The
resultant peptides were subjected to a Mascot search (Matrix Science Inc, MA, USA)
and demonstrated a highly significant hit for calgranulin A with probability based
Molecular Weight Score (MOWSE) of 72 (score of >64 indicates significant
identification at p<0.05). Sequence coverage of 61% by fragments is demonstrated
in bold red. E: Trypsin digest of passive elution from band 2 processed as in D,
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Figure 4.9 Confirmation of Calgranulin A and B with MS/MS (Q-TOF)
Proteins were purified as in figure 4.8. Samples were subjected to MSMS (Q-TOF)
Individual peptides were selected from trypsin digests spotted on NP20 ProteinChips
(seen in figure 4.8, D and E) by a quadropole and subjected to collision-induced
dissociation followed by TOF MS. A: Peptide at 1272 Da was dissociated and
sequenced as calgranulin A with significant MOWSE score of 42 (p<0.05). B:
Peptide at 1806 Da was selected and following dissociation was sequenced as
calgranulin B with significant MOWSE score of 38 (p<0.05). Experiments were
performed on Applied Biosystems QSTAR tandem MSMS (Q-TOF), with
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Figure 4.10 The Identification of Clara Cell Secretory Protein
A. Reverse phase chromatography and gel electrophoresis was performed as in figure
4.8. Panel A demonstrates the original spectrum from a control subject, the reverse
phase purification and the eluted protein from gel band leading to a successively
purified protein sample. B. Following purification the protein at 7900 Da was
digested with trypsin and mass spectrometry performed on the resultant peptide
fragments. Peptide mass fingerprinting did not return a positive identification and
therefore Q-TOF analysis was performed on peptide fragment at 1166.3 Da from and
amino acid sequence derived with good peptide coverage for clara cell secretory
protein (CCSP, uteroglobin) with a MOWSE score of 32 (p<0.05). CCSP was
further confirmed in sputum samples of control subjects by western blotting (see























10834 P05109 10832, 10576 yes yes yes Increased
Calgranulin
B
12960 P06702 12960, 13200 yes yes yes Increased
Calgranulin
C








8188 P02814 8119 no yes no Decreased
Lysosyme C 16537 P61626 14600 yes yes no No
Change




15117 P69905 15080 no yes no No
Change
Table 4.6 Protein identifications confirmed from present study.
Predicted molecular weight and accession number are displayed for identified
proteins. Proteins were identified by trypsin digest and peptide mass fingerprinting
(PMF) and well as tandem (Q-TOF) MS/MS. When available, antibodies were
employed to confirm protein identification by Western Blot. Molecular weight refers
to the theoretical molecular weight of each protein as derived from sequence.
Corresponding SELDI peak refers to the protein peak seen on SELD1 TOF MS
analysis of sputum fluid phase (differences in molecular weight may represent post
translational modifications). Direction of change in CF represents direction of
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Peptide Fragments cover 60% of the protein sequence for Calgranulin A. Proving that lower molecular weight peak is


















Peptide Fragments cover 67% of the protein sequence for Calgranulin A. Proving that higher molecular weight
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Peptide Fragments cover 89% of the protein sequence for Calgranulin B. Mowse score for this mass fingerprint is
124,000 indicating high certainty of identification.
Figure 4.11 Further Characterisation of Calgranulin A and B
A: the appearance of peaks in an individual sample previously identified as
Calgranulin A and B on CM 10 pH4 surface. B: a simulated gel view of SELDI TOF
MS spectra from A showing the close proximity of two bands around 10.6 kDa and
10.8 kDa as well as further bands at 12-13 kDa. C: Pooled sputum samples from CF
patients were resolved by 18% tris-glycine PAGE demonstrating a similar pattern to
the simulated gel. Gel bands were cut as shown and half of the material used for
passive elution, the other half subjected to in gel trypsin digestion. D: Passive
elution demonstrates bands 1 and 2 being of different molecular weights at
approximately 10.6 and 10.9 kDa. Band 3 is a mixture of molecular weights of 12.7
and 13.2 kda. Panels E, F and G demonstrate the peptide mass fingerprints on
MALDI TOF and sequence coverage of fragments following trypsin digest and show
that both the peak at 10.6 and 10.9 kDa represent calgranulin A and that the higher
molecular weight band, a mixture of 12.7 and 13.2 kDa material, is Calgranulin B.
Database searches were performed on MS FIT (University of California, San
Francisco, USA), a free online peptide search engine. The MOWSE score from MS
FIT gives is calculated differently than Mascot with a score of greater than 10000




The use of SELDI-TOF mass spectrometry has allowed us to generate sputum mass
spectral profiles for several diseases and then compare these between groups. There
are large numbers of potential protein biomarkers that differentiate CF from healthy
subjects and other disease groups. Several of these candidate biomarkers have been
identified, including calgranulin A and B and clara cell secretory protein, which were
among the top twenty most statistically significant proteins to differentiate CF from
control subjects and also differentiated CF from Asthma and COPD (when using
Calgranulin A 10576 marker). Thus I have demonstrated the potential of SELDI TOF
MS to screen sputum samples for biomarkers and then identified these markers for
further characterisation and functional testing by other assays as discussed in further
chapters.
4.4.2 SELDI TOF MS as A Screening Tool in Sputum
I chose to use SELDI TOF MS as our primary method for biomarker discovery in
this study. SELDI TOF MS provides a rapid high throughput method of proteomics,
and has been successfully utilised in a range of diseases and body fluids to identify
biomarkers or signature protein profiles(211-219). The application of SELDI TOF to
respiratory secretions has been limited so far to studies of bronchoalveolar fluid(223,
224) with two further studies concentrating on CF(174, 175), although other
proteomics based biomarker discovery methods have been utilised in CF sputum
with success(196, 208, 225). By choosing a mass spectrometry based strategy I
aimed to remove any pre-selection bias from the study. A major draw back of using
140
a mass spectrometry based technology is that it effectively limits the range of
proteins that may be discovered as the resolution of mass spectrometry is probably
best in the mass range of 1000 to 50000 Da, and thus potentially misses important
higher molecular weight proteins. Indeed in sputum I demonstrated that the majority
of peaks discovered using the above experimental protocols lay in the 4 to 20 kDa
range, consistent with a previous study in CF BAL(174). Nevertheless I have
demonstrated large numbers of differential peaks in this mass range and have
demonstrated the identification of biologically significant proteins in sputum.
SELDI-TOF MS has been used as a high throughput screening platform for
biomarker discovery rather than a primary diagnostic platform. This avoids many of
the criticisms levelled at the interpretation of multivariate bioinformatics data in
some previous SELDI TOF MS studies. Separation of patient and control groups is
possible using principal component analysis of our mass spectral data, but the
identification of key biomarkers is more likely to yield assays that ultimately have
greater application in the clinic, a view shared by others in the field (222). As mass
spectrometry is a specialised technique it is much more likely that a biomarker will
be accepted as a clinical test if it is readily measurable, for example by ELISA.
4.4.3 Sputum as an Appropriate Body Fluid
I utilised the fluid phase of sputum as a non-invasive means of assessing the airways.
Previous work has demonstrated a correlation of induced sputum with bronchial
washings but not BAL (251), and therefore suggests that it reflects the
pathophysiology of more central airways(250, 251). Induced sputum has previously
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been demonstrated useful sampling method in CF lung disease(102, 183, 194, 195,
197-199, 208, 250, 251, 255, 257-260). Proteomic assessment of sputum is a valid
means of assessing airways disease, the caveat being that it may be underestimate the
presence of biomarkers derived from the distal airway, however this may be highly
relevant to CF where disease is prominent in the bronchial rather than alveolar space.
Sputum also offers a non-invasive means of airways sampling in comparison to the
methods needed to sample lower airways fluid such as BAL.
A further consideration in this data set is the absence of paired serum samples in the
disease and control groups. Serum sampling would have enabled an assessment of
whether significant biomarkers were a result of local production and/or release in the
lung or due leak of systemically produced/released proteins into the airway. Future
proteomic studies of sputum should consider this. Nevertheless I have demonstrated
the presence of biologically relevant proteins in the sputum of CF patients compared
to control subjects and other inflammatory lung diseases. The potential clinical and
functional relevance of these markers will be considered in future chapters.
4.4.4 Differentiating Protein Peaks
The largest numbers of differentiating protein peaks between disease and control
were found in CF and bronchiectasis. This may suggest greater numbers of
inflammatory and disease related proteins in these groups or alternatively that the
samples obtained from these groups had greater abundance of protein. Sputum
samples obtained from CF and bronchiectatic subjects were of greater volume and
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better quality, subjectively. However, mucus plugs were used for analysis and
processed with equal ratios of buffer as previously described and recommended by a
recent ERS working group(207, 261). Moreover to ensure samples were comparable
when measured on SELDI TOF MS, supernatants were adjusted to a total protein
concentration of lmg/ml before applying to chip surfaces. Also, mass spectral data
were normalised to total ion current prior to data analysis, thus minimising effects of
possible variation in total protein binding to chip surfaces. These steps were
implemented in order to ensure that differences in protein profiles between groups
did not simply represent differences in the overall abundance of total protein in each
sample group. A lower limit cut-off of 4 kDa was selected for analysis of spectra to
select biomarkers. This cut off was chosen to reflect the mass deflector setting
employed in the experiments, as spectra below 4000 Da would have been less
reliable in terms of accuracy and contained more experimental noise. This may bias
the analysis to proteins of molecular weight greater than 4 kDa, whilst also
potentially ignoring biomarkers of below 4 kDa. Indeed all spectra contained peaks
around 3 kDa with the appearance of alpha defensins, which had to be excluded from
analysis due to the preset experimental criteria.
Alternatively, I may have overestimated true numbers of differentiating markers as
some proteins are detected on more than one chip surface. Also, a proportion of
some proteins may be doubly protonated or "double charged" due to interactions
between protein on the chip surface and matrix at the time of ionisation, some
proteins picking up 2 protons rather than 1. As the time of flight is related to both
MW and charge, such proteins will appear "twice", once with half the MW of the
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original protein as it flies twice as fast. Finally different peaks may represent
cleavage products of the same (higher molecular weight) proteins although this is
only discernable once identification of each peak is available.
Irrespective of the potential confounding factors, large numbers of potential
biomarkers are demonstrated. From these I have identified a modest number of
proteins, including the most differential up-regulated protein for CF vs. control,
calgranulin A (in 10576 Da form), and also the most differential down-regulated
protein for CF vs. control, clara cell secretory protein. Further proteins were also
identified during this process. The failure to identify a greater number of protein
peaks is disappointing and demonstrates the difficulties in protein identification
using the SELDI TOF MS platform. Indeed a number of the proteins were only
identified following the combination of SELDI TOF MS with tandem MSMS (Q-
TOF). Further strategies such as shotgun profiling may offer a more realistic
approach to identifying a larger number of proteins(225), although such methods are
still in developmental stages and will require further validation.
A further consideration whilst identifying possible candidate biomarkers in sputum
from cystic fibrosis is that proteins could be eukaryotic as well as prokaryotic. This
has not been borne out so far as all of the proteins identified are human in origin.
Indeed, to ensure I only identified human proteins that may be appropriate
biomarkers I only searched online repositories for human proteins when using
peptide mass fingerprinting data.
144
In spite of finding a large number of peaks differentiating CF and bronchiectasis
from control I was surprised not to have identified any of these as known biomarkers
of inflammation such as interleukin 8 or neutrophil elastase. SELDI TOF MS was
most efficient at demonstrating peaks in the 5-20 kDa range and this may in part
explain these findings as the predicted molecular weights of neutrophil elastase is
29.5 kDa(262). Alternatively, the chip surface chemistries and binding conditions
may simply have not favoured preferential selection of proteins such as interleukin-8
which has a predicted molecular weight of 8.9 kDa.
4.3.5 Calgranulin A and B: Calprotectin
In all disease groups 1 identified calgranulin A at higher levels than controls. In the
CF and bronchiectasis groups a protein at 10576 Da was also identified as
calgranulin A. This proved to be the most discriminating biomarker between CF and
all other groups and represents a cleavage product or post-translational modification
resulting in a mass shift of 256 Da. In spite of being able to identify both molecular
weights as calgranulin A I have been unable to identify the precise reason for this
mass shift but the truncated form may represent a loss of amino acids lysine and
glutamic acid from the C terminus, a finding recently reported in an alternative data
set from CF BAL fluid( 175), and supported by the peptide mass fingerprinting data
shown in figure 4.7.
Calgranulins have previously been described in the sera of subjects homo- and
heterozygous for CF mutations and referred to as CF antigen (263). Calgranulin A
may therefore be a sensitive marker of airways inflammation in CF. I also identified
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2 further protein peaks as calgranulin B. Calgranulin B showed a similar expression
to calgranulin A in terms of differentiating CF and other diseases from control, but
also CF from other diseases. Calgranulin A and B combine to form a heterodimer
commonly referred to as calprotectin. The likely source of calgranulin A and B is
the airway neutrophil, although it is also produced by macrophages and epithelial
cells. Previously known as the LI protein complex, calprotectin accounts for 40-
60% of the non-granular protein load in the neutrophil and has a multipotent role in
neutrophils including the transport of calcium intracellularly and the chelation of zinc
extracellularly(264), as well as being a potent anti-fungal protein. Furthermore its
release from neutrophils has been demonstrated during a novel form of cell death
described as NETosis where upon cell death a network of DNA strands and proteins
is released with a major protein constituent being calprotectin(265).
Surprisingly there was no con-elation between FEV] and levels of calgranulin A
suggesting that calgranulin levels are associated with lung inflammation but not lung
function. Furthermore I failed to demonstrate any significant correlation between
neutrophil% in sputum and calgranulin A as measured by SELDI TOF. This may in
part be explained by the finding that the majority of the CF patients had a profound
sputum neutrophilia and thus calgranulin levels may offer a better understanding of
levels of inflammation. Calprotectin (calgranulin A and B) has previously been
recognized as a biomarker in other inflammatory disorders, such as inflammatory
bowel disease and arthritis (103, 266, 267) thus suggesting further roles as a marker
of inflammation in a diverse group of diseases. Furthermore, recent experimental
evidence suggests that functional knock out of calprotectin in the lung in an
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experimental model of pneumonia decreases the level of inflammatory cell influx
into the lung thus further suggesting a pro-inflammatory role(268). Further data has
also proposed calgranulin A and B as pro-inflammatory mediators via the activation
of Toll Like Receptor 4 (TLR-4), which is a key receptor in the promotion of
inflammation(269). Thus the presence of calgranulin in the CF lung may be both a
marker of inflammation as well as a (potentially) potent mediator of inflammation.
4.4.6 Clara Cell Secretory Protein (CCSP)
A second abundant protein identified showed opposite effects to calgranulin A. Clara
cell secretory protein (CCSP) was reduced in all disease groups compared with
controls. CCSP is an anti-inflammatory protein mainly expressed in the epithelial
cells of the airways. Low serum levels have been reported in asthma(270), and low
nasal lavage levels have also been measured in allergic rhinitis(271). CCSP has a
number of possible activities including inhibition of phospholipase A2, chelation of
calcium and down regulation of IFN-y, IL-1 and TNF-a. My findings are consistent
with previous clinical studies demonstrating low levels of this protein during airways
inflammation, and raise the possibility that resolution of inflammatory processes
might be monitored by rising levels of CCSP or alternatively that low levels of CCSP
in CF may allow uncontrolled inflammatory stimulation in the lung by other
mediators as listed above.
4.4.7 Correlation of Calgranulin and CCSP with Lung Function and Sputum
Neutrophil
I demonstrated no correlation between lung function and sputum neutrophil counts
with calgranulin A and B. CCSP was correlated to lung function but not to
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neutrophil counts. The primary aim of this study was to differentiate between CF
and other control groups in terms of protein peak expression. I have effectively
demonstrated this, however any further interpretation as to the clinical significance
of these findings is difficult without longitudinal studies. Nevertheless many of the
proposed sputum biomarkers in publication have been suggested following cross
sectional studies(91, 183, 194, 197-199, 255, 256, 272). It is also important to
consider that the CF subjects taking part in this study were from an adult cohort and
as such had established lung disease as evidenced by their average FEVi% predicted
of 59%, further studies of proteomics in patients with milder disease are therefore




In conclusion I have demonstrated the utility of SELDI-TOF mass spectrometry as a
tool for biomarker discovery in induced sputum. I have positively identified proteins
of biological significance in the fluid phase of sputum. These proteins will be
assessed in the following chapters to assess their usefulness as clinical assays. I
demonstrated not only markers that differentiated CF from control but also CF from
asthma and COPD. In the process of the study I was also able to demonstrate
differences in protein profile between asthma and COPD with control but very few
differences between asthma and COPD, reflecting the similarities of these diseases at
a protein level particularly in our cohort of patients (particularly when we consider
that asthmatics attending a hospital clinic may have more severe disease and thus
have some phenotypic similarities to the COPD patients). Calgranulin A and B as
well as CCSP appear to be suitable candidate biomarkers for CF and will be
investigated in future chapters.
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5.0 Examination Specific Biomarkers in Cystic Fibrosis Using
Enzyme Linked Immunosorbent Assays
5.11ntroduction
5.1.1 Background
As demonstrated in the previous chapters sputum from CF subjects contains an
abundance of proteins, which have yet to be fully classified. Several studies have
been published utilising immunoassays to measure specific proteins in sputum and
have been summarised in chapter 1 of this thesis (table 1.2).
The measurement of protein biomarkers with enzyme linked immunosorbent assays
(ELISA) allows a truly quantitative test of protein level in sputum whereas mass
spectrometry is semi-quantitative (albeit with high sensitivity). The clinical
application of any biomarker will be limited by the expertise and equipment required
to make the measurement. For example spirometry is readily performed at the
bedside and requires relatively little training whereas techniques such as mass
spectrometry require sophisticated hardware and technical expertise. Translating the
findings from interesting observations with mass spectrometry to clinically useful
tests will therefore require the application of techniques that can be utilised across
many centres. ELISA is a well-established technique for measuring proteins in body
fluids and forms the basis of many standard clinical tests. Therefore I propose that
ELISA is a more clinically applicable means of measuring biomarkers discovered by




Calprotectin is the heterodimer of Calgranulin A and B. Chapter 4 demonstrates its
discovery in sputum using SELDI TOF mass spectrometry. On mass spectrometry
the most prominent differentiating peak between CF and control subjects is
Calgranulin A, part of the Calprotecin complex. Furthermore a peak identified as
Calgranulin B was also differential for CF vs. control. Calprotectin is a neutrophil
protein which accounts for 40 - 60 % of the non-granular neutrophil cytoplasmic
protein load(264). Calgranulin A has previously been described as CF antigen(13)
and was measured in the serum of CF patients and heterozygote carriers of CF
mutations. Calprotectin has also been previously described as neutrophil LI
complex, and is measurable in the serum of patients with a range of respiratory
conditions(273). More recently Calprotectin has been utilised as a clinical test in the
field of gastroenterology(274). Ulcerative colitis is a neutrophil mediated
inflammatory bowel disease and high levels of calprotectin have been described in
the stool of such patients.
Therefore based on the findings of Calgranulin A and B levels being increased in CF
sputum compared to control subjects I utilised an in-house ELISA to measure
calprotectin in sputum.
5.1.3 Sputum Clara Cell Secretory Protein (CCSP)
In chapter 4 CCSP when measured by mass spectrometry was demonstrated to
differentiate all lung diseases from control, in particular CF and bronchiectasis.
CCSP has been demonstrated to be lower in BALF fluid from subjects with CF and
lung inflammation(275). CCSP has been previously described as decreased in nasal
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lavage fluid from patients with allergic rhinitis and increased in the BALF of rats
following intravenous LPS administration(276). I therefore sought to reproduce the
findings of low levels of CCSP with SELDI TOF MS by utilising a commercially
available ELISA.
5.1.4 Sputum lnterleukin-8 and Myeloperoxidase
In order to effectively study the utility of the biomarkers discovered in chapter 4 we
wished to compare these with more established biomarkers of lung inflammation
namely Interleukin-8 (IL-8) and myeloperoxidase (MPO). IL8 has been widely
measured in studies of CF lung disease. Levels of IL8 in sputum correlate with the
severity of lung function as measured by FEV], and can be used to differentiate CF
patients from control patients(l 81, 183, 197, 199, 255, 259). Sputum measurement
of IL8 has also been demonstrated to change when patients suffering from CF lung
disease are treated with antibiotic therapy(102, 195). IL-8 may be produced by a
number of cells in the lung including epithelial cells and monocytes whereas the
majority of MPO production is from the neutrophil. MPO is found in the primary
azurophilic granules of neutrophils and as such may act as a comparitor to the non¬
granular calprotectin. Previous studies have demonstrated the presence of
myeloperoxidase in the sputum of patients with a range of respiratory diseases, and
in particular CF(189, 194, 208, 277). Furthermore sputum myeloperoxidase has been
demonstrated to correlate with lung function in CF(189).
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5.1.5 Sputum Vascular Endothelial Growth Factor (VEGF)
Vascular endothelial growth factor (VEGF) has been reported to be a marker of CF
airways disease, being increased in the serum of patients(278). The measurement of
VEGF allows a comparison of a novel biomarker described in the literature with
those discovered in chapter 4. The source of increased levels of VEGF was
postulated as being the (relatively) hypoxic lung tissue of CF patients, so I wished to
assess whether increased concentrations could be measured in CF sputum compared
to control.
5.1.6 Serum Calprotectin
In chapter 4 I concentrated on the measurement of biomarkers in sputum, however in
order to increase the possible clinical application of Calprotectin in CF I assessed
whether this was measurable in serum. To this end a collaborating group from the
University of Lisbon in Portugal provided us with clinical samples from CF patients
and control subjects to facilitate its measurement.
5.1.7 Aims of Chapter
In this chapter I aim to measure levels of novel biomarkers in sputum (and serum),
namely calprotectin and CCSP, and compare these to previously described sputum
biomarkers from the literature. 1 hypothesised that calprotectin and CCSP would be




For this section of the study I attempted to validate markers of CF lung disease
against a control population. Samples were obtained from CF patients and healthy
control subjects as in the previous chapter. Due to the sample limitation I was not
able to measure each biomarker in every sample. The number of samples used in
each experiment is noted in the results section. Patient samples for serum
calprotectin measurement were obtained from the university of Lisbon, Portugal and
represented samples from patients attending a local CF clinic with an appropriate
diagnosis of CF and control samples. No tandem serum samples had been collected
in this study to allow serum measurements in the same subjects as the sputum
samples and thus serum samples from this seprate cohort of CF patients were
utilised.
5.2.2 Sputum ELISA
An in-house ELISA was utilised to measure sputum calprotectin, please refer to
chapter 2 for full methods. IL-8, MPO, CCSP and VEGF were measured using
commercially available ELISA kits. For methods please refer to chapter 2.
5.2.3 Serum Calprotectin
Serum Calprotectin was measured by in-house ELISA. The same method was
utilised as per sputum aside the sample diluent. For all serum experiments 50% fetal
calf serum in DPBS was used as diluent for standards and serum.
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5.2.4 Data Analysis
Data analysis was performed on Prism4 (GraphPad, San Diego, USA). Data were
subjected to Mami Whitney testing and p <0.05 considered significant. Data were
also subjected to receiver operator characteristic (ROC) analysis, to assess the
sensitivity and specificity of each test at separating CF from control.
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5.3 Results
Data are presented as median (interquartile range) unless otherwise stated.
5.3.1 Subject Characteristics
Samples were obtained from 23 CF patients and 20 control subjects. Serum samples
were obtained from 26 CF patients and 28 control subjects. The basic demographics
are demonstrated in table 5.1. Unfortunately no lung function data was available for
the serum cohort.
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Disease n Male Age FEV, Sputum
n years % pred Neutrophil%
Controls Sputum 20 6 36.9 (2.5) 105.8(2.6) 55(4.3)
CF Sputum 23 14 26.3 (2.0) 59.1 (4.4) 92(2.0)
Control Serum 28 10 32(2.1) n/a n/a
CF Serum 26 15 27(1.3) n/a n/a
Table 5.1 Subject Characteristics For ELISA Biomarker Study




Sputum Calprotectin was higher in the CF group compared to control (1434 pg/ml
[409-2626] vs. 16.65 [8.6-28.6]). This was statistically significant (p<0.001). ROC
analysis reveals an area under the curve of 0.9932 (p<0.001), demonstrating sputum
calprotectin to have 100% sensitivity and 95% specificity at a cut off of >49pg/ml in
separating CF from control subjects, (figure 5.1).
5.3.3 Sputum Clara Cell Secretory Protein (CCSP)
Sputum CCSP was significantly lower in the CF group compared to control subjects
(1790 ng/ml [601-3279] vs.27.2 [9.2-112]). This was significant at pO.OOl. ROC
analysis reveals an area under the curve of 0.9561 (pO.OOl), demonstrating sputum
CCSP to have 95% specificity and 94% sensitivity with a cut off of <310ng/ml
separating CF from control (figure 5.2).
5.3.4 Sputum Interleukin 8 ELISA
Sputum IL-8 was increased in the CF patients when compared to control subjects
(23.56 pg/ml [10.2 - 44.0] vs. 0.4395 [0.31 - 0.55 pg/ml], pO.OOl). ROC analysis
reveals an area under the curve of 0.9929 (pO.OOl), demonstrating sputum IL-8 to
have sensitivity of 100% and specificity of 95% with a cut off of >1.6 pg/ml








































Figure 5.1 Sputum Calprotectin Differentiates CF From Control
Sputum samples were subjected to calprotectin ELISA. Panel A Sputum calprotectin
is higher in CF patients than in healthy controls (p<0.001) [n= 23 vs. 20]. Panel B
receiver operator curve analysis demonstrates the high sensitivity and specificity of
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Figure 5.2 Sputum Clara Cell Secretory Protein (CCSP) Differentiates CF From
Control
Sputum was subjected to ELISA for CCSP. Panel A Sputum CCSP is lower in CF
patients than in healthy controls (p<0.001) [n= 19 vs. 18]. Panel B receiver operator
curve analysis demonstrates the high sensitivity and specificity of sputum CCSP for







































Figure 5.3 Sputum IL-8 Differentiates CF from Control
Panel A Sputum IL-8 is higher in CF patients than in healthy controls at p<0.001 (n
= 21 vs. 20). Panel B receiver operator curve analysis demonstrates the high
sensitivity and specificity of sputum IL-8 in differentiating CF from control
(pO.OOl).
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5.3.5 Sputum MPO ELISA
Sputum MPO was increased in CF patients compared to control subjects (14.44
pg/ml vs. 0.115 pg/ml. p<0.001). ROC analysis reveals an area under the curve of
0.995 (p<0.001) suggesting 100% specificity and 95 % sensitivity for CF using a cut
off value of 0.5 pg/ml.
5.3.6 Sputum Vascular Endothelial Growth Factor
Sputum VEGF was lower in the CF group vs. controls at 133 pg/ml (87.4-171.9) vs.
448.5 (255.6-719.6) at p<0.001. ROC analysis reveals an area under the curve of
0.8975 (p<0.001). Using a cut off value of <173.6 pg/ml VEGF demonstrates 90%




































Figure 5.4 Sputum Myeloperoxidase Differentiates CF from Control.
Panel A Sputum MPO is higher in CF patients than in healthy controls at p<0.001
(n=20 vs. 19). Panel B receiver operator curve analysis demonstrates the high
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Figure 5.5 Sputum Vascular Endothelial Growth Factor (VEGF) Differentiates CF
from Control
Panel A Sputum VEGF is higher in CF patients than in healthy controls (n = 16
vs. 14). ). Panel B receiver operator curve analysis demonstrates the high sensitivity
and specificity of sputum VEGF in differentiating CF from control (p<0.001).
164
5.3.7 Correlation of Sputum Markers With Lung Function
No significant correlations were demonstrated between levels of sputum calprotectin,
interleukin 8 and myeloperoxidase with FEVi. There was a significant correlation of
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Figure 5.6 Correlations of Sputum Biomarkers With Lung Function in CF Subjects
A. demonstrates Calprotectin vs. FEVI (n=22), Spearman r=-0.33, (p=0.145). B.
demonstrates IL8 vs. FEVI (n=21), Spearman r=-0.15, (p=0.537). C. demonstrates
myeloperoxidase vs. FEVI (n=19), Spearman r=-0.35, (p=0.142). D. demonstrates
VEGF vs. FEVl(n=14), Spearman r=0.23, (p=0.436). E. demonstrates the only




Serum calprotectin was measured in serum samples obtained from Lisbon
University, Portugal. The CF and control groups were similar in terms of age.
Serum Calprotectin differentiated CF patients from control patients with high
statistical significance (9.40 pg/ml [3.5-16.7] vs. 1.72 [1.1-2.9], p<0.001). ROC
analysis revealed an area under the curve of 0.9025 (p<0.001). Using a cut off value
of >4.9 pg/ml, serum Calprotectin has 65% sensitivity and 94% specificity in
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Figure 5.7 Serum Calprotectin Differentiates CF from Control
Serum was obtained from CF patients and healthy adult controls. Panel A serum
calprotectin is higher in CF patients than control subjects (n=26 vs. 28). ). Panel B
receiver operator curve analysis demonstrates the high sensitivity and specificity of




This chapter demonstrates the application of specific immunoassays to measure
protein biomarkers in sputum. As such this chapter represents a natural extension of
the findings in previous where several candidate biomarkers were suggested by mass
spectrometry. Sputum calprotectin and sputum CCSP were chosen as these were the
most differential over- and under- expressed biomarkers in CF sputum. Ultimately
the use of immunoassays to assess biomarkers is cheaper and more widely
translatable into clinical practice than mass spectrometry, and allows quantification
of a given biomarker in a given sample. The use of Reciever Operator Characteristic
plots (ROC) allows one to directly compare how well these biomarkers separate a
group of control subjects from a group of patients with CF (in terms of area under the
curve) and also assess the sensitivity and specificity of this test, allowing the
demonstration of calprotectin and CCSP as excellent biomarkers with similar
discrimination properties as previously described sputum biomarkers markers.
Furthermore sputum calprotectin has a similar discriminating potential for CF lung
disease from control to that of faecal calprotectin in distinguishing inflammatory
bowel disease from irritable bowel syndrome, a clinical test which is now widely
accepted(267).
5.4.2 Sputum Calprotectin
As suggested in the previous chapter calprotectin may be a useful sputum biomarker
in CF. The likely source of calprotectin is the airway neutrophil, although it is also
produced by macrophages and epithelial cells. Using SELDI TOF MS I described
the abundance of calgranulin A and B in CF sputum samples. The heterodimeric
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form of these molecules is calprotectin and thus its measurement by ELISA seems
relevant. I used an established in-house assay for calprotectin using antibodies and
calprotectin standard provided as a gift by Earling Sunderhagen, Norway. These
results demonstrate that calprotectin is readily measurable in sputum samples from
CF patients and that it differentiates CF from control subjects with a high level of
sensitivity and specificity as well as high statistical significance. The results also
demonstrate that calprotectin is grossly abundant in the sputum of subjects, in some
cases reaching millimolar range. Furthermore calprotectin separates CF from control
subjects with a level of sensitivity and specificity similar to previously studied
markers of inflammation in CF sputum namely IL8, Myeloperoxidase and VEGF.
The potential significance of high levels of calprotectin in sputum is discussed in
chapter 4.
5.4.3 Sputum Clara Cell Secretory Protein
CCSP when measured by EFISA can differentiate CF and control patients and
furthermore that this correlates with lung function whereas other biomarkers
measured in this chapter do not. The correlation of CCSP with lung function in CF
patients represents a novel clinical observation and thus merits further investigation.
The potential significance of low levels of CCSP in CF sputum was also discussed in
chapter 4 and the results in this chapter highlight its potential role as a biomarker in
CF.
5.4.4 Sputum lnterleukin-8
In this study IL8 is elevated in CF sputum when compared to control values. This
has previously been described (193, 197, 199, 255, 259, 279, 280). Previous studies
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have demonstrated a relationship between the sputum IL-8 and the severity of lung
disease in individual subjects(193, 199). I did not demonstrate any relationship
between lung function sputum IL-8. Previous studies were performed however in
mainly paediatric populations, whereas the subjects in this study were adults with
worse lung function and as such an association with lung function (which is likely to
be grossly impaired) may be more difficult to demonstrate.
5.4.5 Sputum Myeloperoxidase
High levels of myeloperoxidase were measured in CF sputum compared to normal
controls. These data are in keeping with previous studies in which MPO has been
measured (189, 194, 208, 277). This may be predictable as MPO is a major
neutrophil protein and thus should be present in large amounts in CF sputum, which
contains a high level of neutrophils. As with IL-8 however, there was no correlation
with lung function, possibly for the reasons suggested above.
5.4.6 Sputum Vascular Endothelial Growth Factor (VEGF)
VEGF has previously been described as a potential serum biomarker in CF being
demonstrated to change informatively during infective exacerbations(278). The
source of VEGF was proposed as hypoxic lung tissue in that study, as previous in
vitro work suggests that VEGF is induced by hypoxia(281). In view of these
findings I measured VEGF levels in sputum as a potential biomarker in CF. Contrary
to the hypothesis that VEGF levels would be elevated in CF sputum. I demonstrated
that VEGF was present in lower levels in CF sputum than control subjects. This
finding, although surprising, may simply demonstrate the sampling limitations with
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sputum. The level of VEGF measured in the central airway lumen by sputum
collection may not reflect changes in the production of VEGF by the pulmonary
vascular endothelium. Alternatively the lower level of VEGF in CF sputum may
represent either a real decrease VEGF production in CF or a decreased ability to
detect this protein in CF sputum. Ultimately paired serum and sputum samples from
the same subjects would provide further information, however no serum was
collected in this part of the study. Paired measurement in serum and sputum of
biomarkers will be commented on in further chapters.
5.4.7 Serum Calprotectin
In this chapter I demonstrate that calprotectin may be measured in serum as in
sputum and differentiates CF from control subjects. Serum measurement of
calgranulin A has been previously described and led to the description of CF antigen
in serum samples from CF subjects(282). Therefore it is reassuring that calprotectin
is measureable by ELISA in CF patients, and also in keeping with the previous
measurement of calprotectin in the serum of patients with COPD (albeit under the
name ofLI protein)(273). As the serum and sputum data are derived from 2 separate
patient groups little can be derived from comparisons between the two, and the lack
of clinical data from the CF serum sample group would suggest interpretation of this
data with some caution. Flowever it does seem evident from the data that the levels
of calprotectin measured in the serum are far lower than those measured in sputum.
This would suggest that the majority of calprotectin measured in the lung is derived
locally from neutrophils and not due to lung leak of serum proteins. Ultimately the
measurement of calprotectin in serum may be a more clinically applicable test, as
serum samples are relatively easy to collect and need less processing than sputum.
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Longitudinal studies are required to assess the application of this assay and will be
the focus of chapter 7 in this thesis.
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5.5 Conclusions
I have demonstrated the measurement biomarkers discovered in chapter 4, namely
calprotectin and CCSP by immunoassay. Furthermore I have shown similar findings
to more established biomarkers in CF sputum. I have thus demonstrated in cross
sectional data that measurement of calprotectin and CCSP is at least as successful as
more established biomarkers in differentiating CF from control with comparable
levels of sensitivity and specificity when compared by Receiver Operator
Characteristic (ROC) analysis. There were no significant correlations between
sputum biomarkers and lung function apart from with CCSP. A potential disparity
between the measurement of biomarkers in serum and sputum is suggested in the
measurement of VEGF. Further work is required to investigate these findings, such
as further cross sectional and longitudinal studies utilising paired serum and sputum
samples from the same subjects.
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This thesis has concentrated so far on the discovery and validation of protein
biomarkers in sputum. As previously noted, sputum cytology has also been
employed in previous studies to guide therapy, and the previous chapters have
demonstrated the discovery of protein biomarkers in the fluid phase of sputum, but a
largely ignored constituent of sputum however is the inorganic content such as metal
ions. Trace metals such as zinc are readily measurable in body fluids such as serum
but have mainly been used as a markers nutritional status. Furthermore fluctuations
in serum levels of trace elements have been described in patients with respiratory
diseases, and in particular in CF(283). The presence of trace elements in the lung
lining fluid has been less well investigated although increased levels of sputum iron
have been described in CF and COPD(229, 230). Conversely a study investigating
exhaled breath iron levels in COPD demonstrated lower levels in disease than
control(284). Therefore the measurement of trace elements in sputum offers an
interesting proposition.
Increased levels of zinc, iron and copper have been reported in abscess fluid(285),
and zinc and calprotectin have been demonstrated to co-localise in staphylococcal
abscess in a murine model (286), which is of particular relevance to CF considering
the high levels of calprotectin measured in the CF airway in the previous chapters. A
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major proposed role of calprotectin is as a metal chelater and therefore the interaction
of zinc and calprotectin in the CF airway may be of pathophysiological significance.
6.1.2 Trace Metal Ions in Inflammation
Zinc is associated with states of acute and chronic inflammation. Long bone fracture
in rats, a classical model of acute inflammation, leads to the accumulation of radio-
labelled zinc at the site of induced fractures(287). Furthermore metal ions such as
zinc, manganese and copper are obligate co-factors for anti-inflammatory proteins
such as superoxide dismutases (SODs) and as such have a close relationship to
inflammation(288). Zinc in particular may have a multi-potent role in lung
inflammation(289). Metal ions are essential for the growth of pathogenic organisms
with the scavenging of free iron being an important component of antimicrobial
defence mechanism against organisms such as pseudomonas aeruginosa(290).
Increased zinc levels in culture media may alter the sensitivity of pseudomonas to
antibiotics (254), and may also stimulate elastase production in these bacteria (291,
292) further suggesting important roles for zinc in the airways inflammation
associated with CF.
Metal ions such as zinc are present in tightly controlled pools in the body and zinc
may have multipotent effects in the airway with involvement in apoptotic and anti¬
oxidant pathways(289, 293), as well as being found in mast cell granules(294). In a
mouse model of allergic airways disease, decreased levels of labile (unbound) zinc
were recorded in airway epithelial cells(295), and dietary restriction of zinc in these
mice led to more significant airways inflammation. Moreover, restriction of zinc in
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wild-type rats leads to lung damage with findings characteristic of oxidative
stress(296). Interestingly the majority of absorbed dietary zinc is incorporated into
metalloenzymes and zinc finger transcription factors(297), thus underscoring zinc's
role as an essential micronutrient. Unbound (unincorporated) or labile zinc is
available to regulate processes such as cell growth and signalling(298), with labile
zinc being demonstrated in airway epithelial cells using specific flurophores(299).
Labile zinc co-localises with copper/zinc dismutase, as well as pro-caspase-3 further
signifying a role in inflammation and modulation of apoptosis(300, 301). Thus the
homeostasis of zinc levels in the airway may be important with elevated levels of
zinc and deficiency thereof both having potential effects on inflammation.
The majority of iron in the human body is bound to haemoglobin, myoglobin and
cytochromes with more labile stores of iron being bound to iron binding proteins
such as transferrin, lactoferrin and ferritin(302). In spite of this tight physiological
control, increased levels of total iron and iron binding proteins have been reported in
the sputum of patients with cystic fibrosis (CF) and chronic obstructive pulmonary
disease (COPD) in cross-sectional studies, possibly reflecting the level of lung
inflammation in these patients(227-230)
6.1.3 Hypothesis
As reported in chapters 4 and 5 of this thesis CF sputum contains higher
concentrations than control subjects of calprotectin, an abundant neutrophil protein.
Calprotectin is anti-microbial via the chelation of zinc (303, 304) and is found to co-
localise with zinc in abscess fluid(286). I thus hypothesised that the sputum zinc
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levels would be higher in individuals with cystic fibrosis. As an extension of this
hypothesis I supposed that levels of a number of trace metals would also be elevated
in CF. Therefore I determined levels of iron, zinc, manganese and copper in the
sputum of healthy subjects and CF patients as well as subjects with the inflammatory
lung diseases asthma, COPD, and bronchiectasis. Furthermore in the CF group I
compared these findings to measurements of sputum protein biomarkers.
6.1.4 Aims of Chapter
The aim of this study was to determine sputum trace metal levels in a number of





CF and control samples were obtained from the same cohort of individuals utilised in
chapter 5 of this thesis, other disease subjects were obtained from the cohort of
individuals used in chapter 4. All patients provided informed consent and the study
was approved by South East Scotland Research Ethics Service.
6.2.2 Sputum Collection and Processing
Sputum was collected by induction or spontaneously and processed within 2 hours of
collection as described in the methods section.
6.2.3 Trace Element Assay
Trace element assay was performed in the Scottish National Trace Element
Reference Laboratory, Glasgow, EiK. A four-point calibration was used (0, 100,
500, 1000 pg/L Cu, Fe, Zn, Mn in 1% nitric acid). Sputum samples were centrifuged
at 800g for 5 minutes and 200 pL of sample was then diluted with 2 ml internal
standard solution (100 p/L yttrium in 1% nitric acid) and mixed by inversion.
Internal accuracy was assessed by use of two aqueous certified reference materials
TMDA 62 and TMDA 64 (Promochem Ltd, EIK). Trace element levels were
measured by inductively coupled plasma optical emission spectrometry using a
VISTA AX (Varian Limited, UK).
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6.2.4 Measurement of Sputum Interleukin 8, Myeloperoxidase and Calprotectin
Sputum measurements for the above biomarkers were obtained from the data set
used in chapter 5 and compared to the trace element levels in these patients.
6.2.5 Data Analysis
Data analysis was carried out on Prism4 software (GraphPad, Ca, USA) for
Windows. Kruskal-Wallis ANOVA and Dunn's multiple comparison test, p < 0.05
was considered statistically significant. Correlations between data were performed




23 patients with CF, 16 with bronchiectasis, 17 with asthma, 23 with COPD and 20
healthy controls were studied. All samples were collected at a time of clinical
stability. Patient characteristics are given in Table 6.1. Of the COPD group 10 were
current smokers, 9 ex smokers and 4 gave no information on current smoking status.
Of the CF patients 14 were colonised with Pseudomonas aeruginosa, the other
patients being colonised by a variety of organisms including Stenotrophomonas
maltophilia and Burkholderia cepacia complex.
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Disease n Male Age FEV, Neutrophil%
n years % pred
Controls 20 6 36.9 (2.5) 105.8 (2.6) 55(4.3)
Asthma 17 5 51.9(3.3) 80 (5.6) 60(6.1)
COPD 23 16 66.0(1.4) 55.0 (4.0) 81(2.6)
Cystic Fibrosis 23 14 26.3 (2.0) 59.1 (4.4) 92(2.0)
Bronchiectasis 16 1 62.3 (2.1) 70.4 (8.5) 84 (4.0)
Table 6.1 Subject Characteristics in Sputum Trace Metals Study
Characteristics for subjects utilised in this chapter. Data are displayed as mean
(SEM).
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6.3.2 Metal Elements as Contaminants of Experimental Procedure
In order to ensure that trace element levels were not simply a reflection of
contamination of samples during preparation, 2 sputum-free sham samples were
prepared using identical reagents and procedure (sham samples consisted of 500 pi
PBS that was submitted to the same preparation steps as sputum). Zinc, manganese
and iron were not detected, but copper was observed as a contaminant at 7.5 pg/L.
6.3.3 Assay Reproducibility
Pooled samples of at least 5 subjects in each group of control, CF and bronchiectasis
were assayed in duplicate for zinc levels with CVs of 14.7, 2.7 and 5.4 respectively
giving an average coefficient of variation of 7.6%.
6.3.4 Differential Expression of Sputum Zinc and Iron Levels
The absolute concentrations of all trace metals in sputum are displayed in Table 6.2
in pg/L. Sputum zinc concentration was at least 4 fold higher in CF and non-CF
bronchiectasis than controls (p<0.001). Concentrations in CF and non-CF
bronchiectasis were also higher than in asthma and COPD (p<0.05) (Figure 6.1).
Sputum iron was at least 2 fold higher in CF and non-CF bronchiectasis than controls
(p<0.01), and COPD (p<0.05). Levels were higher in the COPD and asthma groups
vs. controls but did not reach statistical significance (Figure 6.2). There was no
difference in sputum iron levels between current and ex-smokers with COPD.
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Disease Zinc Iron Manganese Copper
Control 15.35 (10.4-25.6) 13.5 (8.6-21.5) 0 (0-0.25) 8.6 (3-16.4)
Asthma 12.7 (7.2-41.4) 30.0 (6.9-35.3) 0.8 (0.2-1.7)" 15.2 (8.6-29.5)
COPD 25.4 (9.8-50.7) 21.3 (3.1-35.6) 0 (0-0.7) 15.2 (12.2-22)
CF 135.3 (54.2-209.6)+ 56.9 (24.3-115.3) 11 0.3 (0.1-0.8) 19.5 (14.5-30.1)*
Bronchiectasis 1 11.3 (46.1-150.7)f 54.2 (22.7-91.6) 11 0.6 (0.2-1.3) * 15.7 (10.9-33.3)
Table 6.2. Levels of Metal Elements in Sputum Supernatant
Data are displayed as: median (IQR). P values are displayed for disease group vs.




Note: Zinc was below the limit of detection of the assay in 4 control and 1 COPD.
Iron was below the limit of detection in 4 control, 1 asthma and 1 COPD. Maganese




Figure 6.1 Sputum Zinc Levels Are Increased in CF and Non-CF Bronchiectasis
Sputum zinc differentiates CF and bronchiectasis from other disease groups and
control (p<0.001 vs. control, p<0.05 vs. other diseases). Sputum zinc is also




Figure 6.2 Sputum Iron Levels are Increased in CF and Non-CF Bronchiectasis
Sputum iron is raised in CF and bronchiectasis compared to other groups, (p < 0.001
vs. control, p < 0.05 vs. COPD). Horizontal bars represent medians.
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6.3.5 Sputum Manganese and Copper in Cross Sectional Data
Sputum manganese differentiated bronchiectasis but not CF from control (p<0.05,
figure 6.3). Sputum manganese also differentiated asthma from control subjects
(p<0.01). Sputum copper was higher in all disease groups vs. control but only
reached statistical significance for CF (p<0.01) and showed no difference in
expression between disease groups. In view of the potential copper contamination of






























Figure 6.3 Sputum Manganese Levels differentiate asthma and non-cf bronchiectasis
from controls.
Sputum manganese level differentiated asthma and non-CF bronchiectasis from














































Figure 6.4 Sputum Copper Levels are Higher in all Disease Groups Compared to
Control.
Sputum copper level is raised in all disease groups compared to control but only
reached statistical significance in CF subjects (p<0.01). Bars represent median.
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6.3.6 Correlation of Sputum Zinc and Iron Levels with Lung Function
As the most statistically significant changes were seen in the CF group further
comparisons were made with clinical data and other inflammatory markers for this
group. There was a negative correlation of zinc and FEVi% predicted in the CF
group (Spearman r=-0.47, p<0.05. Figure 6.5), suggesting that higher concentrations
of zinc are associated with poorer lung function. Sputum iron was also negatively
correlated with FEVi% (Spearman r = -0.43, p<0.05).
6.3.7 Correlation of Sputum Zinc with Protein Biomarkers of Inflammation in CF
Subjects
Zinc levels in CF sputum correlated with other measurements of airways
inflammation in sputum; myeloperoxidase (Spearman r=0.67, p<0.001), interleukin-
8 (Spearman r=0.81, p<0.001), figure 6.5. Sputum zinc levels correlated most
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Figure 6.5 Correlation of Sputum Zinc with Lung Function and Sputum Biomarkers
A. Sputum zinc levels demonstrate a significant negative correlation to FEVj%
predicted suggesting that sputum zinc levels may reflect the severity of underlying
lung disease (Spearman r =-0.47, p<0.05). B. Correlation between sputum
interleukin 8 (IL8) and zinc (Spearman r =0.67, p<0.001). C. Correlation between
sputum myeloperoxidase (MPO) and zinc (Spearman r = 0.81, p<0.001). D.




The results from this chapter demonstrate that levels of elemental zinc and iron in
sputum from CF and bronchiectasis subjects are elevated compared to levels seen in
healthy controls and subjects with other inflammatory airways diseases. This study
also demonstrates correlations between levels of zinc, calprotectin, IL-8 and MPO.
6.4.2 Trace Elements Compared to Protein Biomarkers
I have demonstrated the presence of protein biomarkers and cytokines in previous
chapters. However, protease activity in expectorated sputum may affect the
robustness of cytokine assays(305). The association between trace element levels and
suppurative lung disease demonstrated by the data in this chapter as well the
correlation with FEVi commends sputum zinc as a robust biomarker. It may also be
suggested that trace element measurement would also be less susceptible to serine
proteases present in the lung than more established markers such as IL-8 and
myeloperoxidase, although this remains speculative and will require further
investigation.
6.4.3 Sputum Zinc as a Biomarker and Possible Pro-inflammatory Mediator
Previous studies have investigated the potential use of serum zinc as a marker of lung
disease (306, 307), this is however the first study to describe an association between
(sputum) zinc levels and inflammation in the sputum of individuals with CF lung
disease and the phenotypically similar condition bronchiectasis. Whether elevated
zinc has a role in maintaining (or modulating) inflammation or is a by-product of the
inflammatory process is less clear. The presence of increased levels of zinc at areas
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of inflammation has been described historically(287) and the dietary supplementation
of zinc has long been suggested as an adjunct to the treatment of inflammatory skin
conditions(308, 309). Zinc may play an important role in modulating the immune
response to inflammation, with high concentrations of zinc inducing peripheral blood
monocyte apoptosis(310). Zinc may also induce cytokine production such as IL-1,
IL-6 and TNF-alpha in monocytes, suggesting a role for zinc in TH1 type
inflammatory responses(311). Moreover, zinc has been demonstrated to enhance the
stimulatory effects of bacterial lipopolysaccharide on monocyte cytokine
expression^ 12), suggesting an important role in stimulating and modulating
inflammation. Conversely low concentrations of zinc may suppress monocyte
function and decrease neutrophil phagocytosis(313).
As well as having an effect on circulating immune effector cells, zinc may also
interact with the epithelium in airways inflammation(289, 293). Zinc deprivation of
bronchial epithelial cells in culture induces apoptosis, which is reversed by zinc
supplementation(301, 314), and anti-oxidants(301). In this study I measured the total
zinc content of sputum (i.e. bound and unbound) rather than the unbound (labile)
content. Labile zinc can be measured in airway epithelial cells and is found in
association copper/zinc dismutase and pro-caspase-3 and as such may be important
in inflammation and apoptosis regulation(299). Zinc deficiency in a murine model of
asthma leads to increased levels of epithelial cell apoptosis and increased levels of
airways inflammation on challenge with ovalbumin and is associated with a loss of
labile zinc from the epithelium(295). It is unclear how the increased level of zinc in
the CF airway lumen demonstrated by the present data relates to the levels of labile
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intracellular zinc in the bronchial epithelial cells. This merits further investigation as
it may represent an excess of zinc in the airway lumen at the expense of levels
elsewhere. These findings could in part explain the low serum zinc in CF subjects
compared healthy controls(283). Zinc application to epithelial cells in an animal
model can restore chloride transport (the primary defect in CF)(315), and therefore
the interaction of the high concentration of airway zinc with epithelial cells may be
fundamentally important but ultimately depend on whether the zinc is bound or
labile. The measurement of labile zinc in sputum and saliva has recently been
described(316) and a comparison of total zinc measured by the method used in this
chapter and labile zinc levels may be appropriate.
6.4.4 Sputum Iron as A Biomarker and Pro-Inflammatory Mediator
Increased concentrations of sputum iron have previously been described in CF(227-
230). Iron is a pre-requisite for microbial growth, and elevated levels in the CF
airway fluid are proposed to be of pathophysiological significance, contributing (for
example) to the proliferation of bacteria such as Pseudomonas aeruginosa and to
systemic iron deficiency through diversion of iron from the circulation(229). Our
results are in agreement with a previous study that demonstrated elevated sputum
iron levels in CF exceeding those seen in COPD(230). The difference between
sputum iron levels in CF and bronchiectasis compared to healthy controls is unlikely
to be solely attributable to leak of iron into the lung from the circulation although
further work is required to elucidate the mechanism of increased airways iron.
Cigarette smoke has also been suggested as a potential source of airways iron(317),
but there was no difference sputum iron between current and ex-smokers with COPD
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in this study. Thus the source of increased airways iron in inflammatory disease
requires further investigation.
6.4.5 Sputum Manganese and Copper
Associations between the levels of sputum manganese and copper with disease type
are less obvious, manganese for example was only significantly elevated in the
asthma and bronchiectasis groups and copper only in CF. Both metals (like zinc) are
co-factors for SODs, which have leading roles in alleviating oxidative stress in the
lung(288). In contrast to zinc and iron, they were not as abundant in sputum in our
study. Ultimately it is difficult to reconcile the data from these metals with what is
known about SOD regulation in airway disease, and in particular with the
observation that copper-zinc and manganese SODs may be down regulated in
asthmatic airways suggesting sputum copper and manganese are not merely tracking
SOD levels. A measurement of SOD level or activity would help to elucidate these
complicated relationships but was not perfonned in this study and thus would form
the basis of further work.
6.4.6 Correlation of Zinc Levels with Calprotectin May Be Biologically Significant
Sputum zinc levels correlated with protein biomarkers of airways inflammation
namely calprotectin, MPO and IL-8 suggesting its usefulness as a biomarker.
Calprotectin is a highly abundant neutrophil protein proposed to have anti- and pro¬
inflammatory functions, and the ability to chelate zinc and other cations(264, 286,
304, 318). Furthermore calprotectin has been demonstrated promote apoptosis in cell
lines via the exclusion of zinc(319, 320). The observation of highly correlated
sputum zinc and calprotectin levels may therefore be of importance in the
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pathophysiology of CF lung disease. Zinc and calprotectin have been demonstrated
to co-localise in Staphylococcal abscess in a murine model(286), and calprotectin
knock-out mice infected with S. aureus, have more marked abscess formation. This
work suggested that the majority of calprotectin function was due to the chelation of
zinc and to a lesser extent manganese. As such the interaction of zinc and
calprotectin in the CF airway may be ofmechanistic importance.
Elevated levels of zinc and calprotectin may reflect passive release of the neutrophil
contents in view of the large number of nectrotic neutrophils in the CF airway(91), or
may represent active sectretion in response to the inflammation in CF and
bronchiectatic airways as is observed with lactoferrin release from neutrophils in
response to interleukin-l(302). This would certainly be supported by the correlation
of zinc with myeloperoxidase, an actively released neutrophil granule protein.
Nevertheless, the correlation of zinc and calprotectin might simply reflect an overall
abundance of neutrophils, which are rich in both of these substances(321, 322), and
may also sugget that the zinc and calprotectin are complexed in the airway. The
extent to which the airway neutrophilia characteristic of CF contributes to the excess
zinc in the lung is difficult to judge, but it could account for a significant proportion,
as neutrophils contain 5-10 ng zinc per 106 cells(321). It is also possible that excess
sputum zinc may arise due to leakage of zinc-albumin complexes from plasma into
the airway as a result of structural lung damage, however this would be difficult to




Sputum levels of the trace elements zinc and iron differentiate CF and bronchiectasis
from control. Furthermore the trace element copper differentiates CF from controls
and manganese levels differentiate asthma and bronchiectasis from the control
population in this study. Thus high levels of sputum zinc and iron may be used to
differentiate suppurative diseases i.e. CF and bronchiectasis from control
populations. Sputum zinc levels are highly correlated with other sputum
measurements of inflammation such as IL8 and MPO. The most striking correlation
was that of zinc and calprotectin and this may ultimately be of biological
significance.
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CF lung disease is characterised by chronic bacterial infection, beginning in
childhood and persisting throughout life. As has been previously discussed, CFTR
dysfunction dehydrates the airways lining fluid and decreases mucociliary clearance
allowing colonisation with bacteria that rapidly evolve to evade the host defence
system(l). CF patients also experience recurrent episodes of increasing pulmonary
symptoms termed exacerbations which are often accompanied by a decrease in lung
function(98). This may be due to new pathogenic organisms(99) or an increasing
burden of already colonising organisms(lOO). Treatment of chronic of bacterial
colonisation with nebulised anti-pseudomonal treatment(104) decreases the need for
exacerbation treatment as well as improving lung function. Treatment with antibiotic
therapy can decrease the bacterial load in exacerbation, as well as decreasing levels
of pro-inflammatory mediators(102, 103). As well as bacterial infection other
pathogens such as respiratory viruses may be implicated in the initiation of
exacerbation, particularly in children(lOl). The pathophysiology of pulmonary
exacerbation in CF is yet to be fully elucidated but it likely combines the host
inflammatory response to chronic and acute infection in the already damaged lung,
with a number of as yet unidentified triggers.
A major problem in studying the aetiology and pathophysiology of CF exacerbations
is the lack of objective diagnostic criteria; indeed no consensus criteria exist in spite
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of a definite clinical need(323). Exacerbation has been defined in major CF
therapeutic trials from empirical data(104, 105) but these lacked specific objective
outcome measurements. In routine practice, clinical judgement and changes in lung
function are most commonly used to dictate the need for therapy. In a retrospective
study investigating treatment of CF exacerbation, patients were more likely to be
treated if symptoms of exacerbation were associated with a loss in lung function and
the presence of new pulmonary symptoms and signs(279).
Nevertheless, CF exacerbation provides a model of changing inflammation in CF
lung disease. Sputum obtained from CF subjects contains a mixture of proteins
which may serve as objective measures of lung inflammation such as interleukin 8
(IL8) (197, 199, 255, 259, 279, 280), myeloperoxidase (MPO) (189, 194, 208, 277),
matrix metaloproteinase 9 (MMP 9) (198) and neutrophil elastase (NE) (91, 198,
258). Furthermore NE and IL8 can be inversely correlated to lung function
suggesting a relationship of sputum markers to disease severity(193). I have
demonstrated similar findings in the previous chapters but have also shown the
presence of other biomarkers in CF such as sputum and serum calprotectin and
sputum zinc.
Sputum protein profiles(208) and cytokine levels have been demonstrated to change
following treatment of CF exacerbations with antibiotic therapy(102, 103). In those
studies it is suggested that altering the level of bacterial burden in the lung with
antibiotic therapy alters the host inflammatory response. This suggests that
exacerbation may be used as an in vivo model to study the clinical significance of
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new markers of CF lung disease. Other groups have also used exacerbation in CF to
demonstrate the presence of novel biomarkers, for example prostaglandin FT and cys-
leukotrienes, mediators of oxidative stress, were elevated in CF exacerbation
compared to stable CF(256). Furthermore serum vascular endothelial growth factor
has been reported as a marker of inflammatory change following treatment of CF
exacerbation with antibiotic therapy(278). Therefore as well as allowing the
assessment of known biomarkers, exacerbation may also be utilised for biomarker
discovery experiments similar to those in chapter 4.
7.1.2 Aims of Chapter
The primary aim of this study was to demonstrate whether biomarkers described in
previous chapters changed following antibiotic therapy for a CF exacerbation. I
therefore investigated changes in sputum and serum calprotectin as well as sputum
zinc, iron and copper (I was unable to assess the role of CCSP in exacerbation
monitoring due to problems in obtaining the commercial assay). A secondary aim
was to compare changes in these biomarkers with changes in lung function and
biomarkers suggested previously demonstrated to change with therapy. Additionally
I wished to assess the utility of mass spectrometry to discover new markers of CF
exacerbation in sputum. This chapter employs CF exacerbation as an in vivo model
of changing lung inflammation in CF to assess non-invasive biomarkers in sputum
and serum samples.
200
7.2 Materials and Methods
7.2.1 Subjects
Ethical approval for this study was granted by the South East Scotland Research
Ethics Service. All patients gave formal written consent. Patients were recruited at
the time of a pulmonary exacerbation requiring antibiotics as determined by the
clinical team in charge of the individual patient based on the patient having increased
respiratory symptoms and an associated decrease in lung function from baseline (for
further description please see methods chapter).
7.2.2 Sample Collection
Spontaneous sputum was collected for the assessment of biomarkers at the beginning
and end of an exacerbation treatment period, usually within the first 24 hrs of
commencing treatment and within 72hrs of treatment cessation. Venous blood was
collected by venepuncture and serum separated as in methods section.
7.2.3 Sputum Processing
Spontaneously expectorated sputum was collected from patients and processed
within 2 hours of collection as described in previous chapters. Supernatant was
stored at -80 C until further analysis.
7.2.4 Measurement of Specific Protein Biomarkers by ELISA
Calprotectin in sputum was assayed by an in-house double antibody sandwich
ELISA, using monoclonal and polyclonal antibodies against human Calprotectin
(antibodies and calprotectin standard were gifts of Erling Sundrehagen, Norway).
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Interleukin-8, myeloperoxidase and VEGF were measured using commercially
available kits as described in previous chapters.
7.2.5 Trace Element Assay
Trace elements (zinc, iron, copper and manganese) were measured by inductively
coupled plasma optical emission spectrometry (Vesta AX, Varian, Yarnton, Oxford,
UK) with yttrium as internal standard as described in previous chapters.
7.2.6 SELDI TOF Mass Spectrometry
A weak cation exchange at pH4 (CM 10) was utilised in view of this surface yielding
multiple significant biomarkers in cross sectional studies. Sputum samples were
adjusted to contain lmg/ml protein at a concentration of 0.05% DTT. 10 pL of
sample were added to CM10 in a bioprocessor unit (Ciphergen, Freemont, USA).
Chips were treated with sinapinnic acid matrix (2x0.8 pF/spot) and allowed to air
dry. Samples were analysed on the Protein Biology System 2 SEFDI-TOF mass
spectrometer (Ciphergen, Freemont, USA). Chips were read with a laser intensity of
210 with deflector set at 4000 Da and a focus mass of 7500 Da following
optimisation.
7.2.7 Data Analysis
Paired data analysis of specific biomarkers was carried out using GraphPad Prism
software (GraphPad, Ca, USA). For normally distributed data a paired t test was
performed. If data was not normally distributed a Wilcoxon sign rank test was used.
Data analysis ofmass spectral data was performed using Ciphergen Express platform
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specific software and then exported to GraphPad Prism for analysis as above. Prior
to analysis mass spectral data were pre-processed and normalised to total ion current
as described in chapter 2. Mass spectral data analysis was subject to a post hoc
bonferoni correction to account for multiple comparisons.
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7.3 Results
7.3.1 Patient Demographics and Spirometry
27 individual patients completed the study. Their demographic details are given in
table 7.1. FEVi was normally distributed pre- and post-exacerbation. There was a
significant improvement in FEVi%(SEM) from 41%(3.3) to 49%(3.6) following
treatment as demonstrated in figure 7.1
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1 f AF508/3659AC 20 67 66 BC, SM, HI, SA TO, CFZ
2 f AF508/AF508 30 42 49 PA, SA TO, CFZ
3 f AF508/AF508 20 13 13 PA CO, MER
4 f AF508/AF508 18 55 60 PA TO, CFZ
5 f AF508/G551D 18 23 39 BC UK
6 m AF508/UK 46 36 38 PA, SM TO, CFZ
7 f AF508/AF508 21 56 59 PA, SA TO, MER
8 m AF508/AF508 18 58 59 MRSA, SA TO, CFZ
9 f AF508/G551D 31 31 49 PA CFZ, CIP
10 m AF508/AF508 18 33 43 SA, SM TAZ, MIN
11 f AF508/AF508 20 60 73 PA, Asp TO, MER
12 m AF508/UK 32 75 88 PA CIP, AZI
13 f AF508/P67L 27 45 49 SA, BMV TO, CFZ
14 f AF508/G542X 23 50 82 SA, HI TO, CFZ
15 f AF508/AF508 22 66 75 PA, SA CO, CFZ
16 f AF508/UK 17 38 44 SA FL, COAMOX
17 m AF508/G542X 22 56 52 PA TO, MER, AZ
18 m AF508/G551D 41 24 31 SM, PA, SA. Asp TO, MER
19 m AF508/AF508 24 41 49 SA, PA, SM TO, CFZ
20 m AF508/AF508 37 21 27 BC, PA TO, MER
21 f AF508/AF508 22 45 52 PA TO, MER
22 f AF508/AF508 18 15 15 PA, SA AZ, MER
23 m AF508/G551D 20 28 28 PA TO, CFZ
24 f AF508/AF508 26 61 64 PA, SM, Asp TO, CFZ
25 m AF508/AF508 17 23 28 PA CO, MER
26 m AF508/AF508 17 33 45 PA, SA TO, CFZ
27 m AF508/3849+10
kb C->T
22 34 49 PA TO, CFZ
Table 7.1 Patient Demographics
Patient demographics and lung function from study population. Colonising
organisms reflect most recent sputum culture prior to exacerbation.
PA=Pseudomonas Aeruginosa, BC=Burkholderia Cenocepacia, SA=Staph Aureus,
SM=Stenotrophomonas Maltophillia, H\=Haemophilus Influenzae, Asp=Aspergillus
Fumigatus, MRSA=Methicillin Resistant Staph Aureus, BMV=Burholderia
multIvorans. Treatment for exacerbation was with intravenous antibiotics apart from
subject 12 who received oral treatment. AZ=aztreonam, AZI=azithromycin.








Figure 7.1 Change in spirometry following treatment of CF exacerbation
Mean FEVi%(SEM) improved following treatment of CF exacerbation from
41%(3.3) to 49%(3.6) and was statistically significant (p<0.001). FEV] increased in
22 from 27 patients following treatment.
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7.3.2 Changes in Specific Sputum Protein Biomarkers
Due to limitations in sputum sample size not all patients could be assessed for all
biomarkers (priority was given to sputum calprotectin which was measured in all 27
paired samples). There was a significant reduction in the level of Calprotectin from
median 619.4 (IQ range; 484.1- 971.9) pg/ml to 274.4 (184.0-570.9) pg/ml (p=0.013
figure 7.2). Sputum IL8 and MPO were measured in 26 paired samples (figure 7.2).
Sputum IL8 showed a trend to decrease following treatment, from median 30.8
(18.8-53.5) ng/ml to 20.6 (10.3-60.6) ng/ml (p=0.11). Sputum MPO showed a trend
to decrease following treatment, from median 41.3 (18.6-49.8) pg/ml to 24.4 (8.8-
45.5) pg/ml (p=0.07). Sputum VEGF was measured in 22 paired samples and
demonstrated no significant differences before and after treatment 119 (90.5-207) vs.
130.2 (58.5-265.1) ng/ml (p=0.78).
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Figure 7.2 Changes in Sputum Biomarkers Following Exacerbation Treatment
Sputum biokmarkers were measured by ELISA in spontaneous sputum samples.
Samples were collected before and after antibiotic treatment for exacerbation. A.
Only sputum calprotectin demonstrated a statistically significant change following
treatment of an exacerbation (p=0.013). B. Sputum IL-8, C. Sputum MPO, and D.
Sputum VEGF did not demonstrate any statistically significant changes following
exacerbation treatment. Bars represent median.
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7.3.3 Sputum Analysis by SELDI TOF MS
Sputum analysis with SELDI TOF demonstrated significant changes in 6 protein
peaks following correction for multiple comparisons. These data relate to 26 paired
samples. Four of these peaks represented calgranulin A and B, and 3 are yet
unidentified markers at 11061, 9837 and 5295 kDa. The previously identified
sputum proteins of calgranulin C and lysosyme C also demonstrated changes
between pre- and post- treatment measurements but did not reach statistical
significance. These results are displayed in table 7.2 and figure 7.3.
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Table 7.2 Most Discriminating Proteins in Paired Analysis Pre- and Post Treatment of
Exacerbation.
Spontaneous sputum samples were subjected to SELDI TOF MS on pH4 CM10
surface. Initial data analysis revealed 39 clusters of proteins for comparison before
and after treatment. 17 of 39 protein peaks were statistically significant on paired
analysis. 6 protein peaks were considered statistically significant following
Bonferoni correction for multiple comparisons including calgranulin A and B
(calprotectin). Calgranulins A and B were observed at two separate molecular










Figure 7.3 SELD1TOF MS Markers During Exacerbation
Spontaneous sputum was subjected to SELDI-TOF MS analysis. Sputum was
collected before and after treament of and exacerbation. A. Unidentified biomarker,
molecular weight 9837 Da decreases significantly with treatment (p<0.01). B.
Unidentified biomarker at 11061 Da decreases significantly with treatment (p<0.01).
C. Calgranulin A 10596 Da decreases with treatment (p<0.05). Calgranulin A 10853
Da decreases with treatment (p<0.01). Bars represent median.
Post Treatment
211
7.3.4 Changes in Sputum Trace Metal Levels
Both sputum zinc and iron measurements decreased following treatment of an
exacerbation with antibiotic therapy. These results relate to 25 paired samples in
view of sample limitations. Sputum zinc decreased significantly following antibiotic
therapy from 230.9 (101.4-310) pg/1 to 141.4 (53.2-228.6) [p=0.0002]. Sputum iron
decreased from 54 (41.05-70.70) pg/1 to 49.6 (20.10-76.10), but not significantly [p=
0.1305], There was no significant change in sputum copper levels from 23.10 (7.3-








Figure 7.4 Sputum Trace Elements Following Treatment of Exacerbation.
Sputum trace element levels were measured in sputum using optically coupled
plasma optical emission spectroscopy in samples collected before and after treatment
of a CF exacerbation. A. Sputum zinc decreased with treatment p<0.001. Sputum
iron (B) and sputum copper (C) did not change significantly. Bars represent median.
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7.3.5 Change in Specific Blood Biomarkers
Serum was available in 25 patients from 27 recruited as 2 declined blood sampling.
Serum CRP a marker of systemic inflammation decreased from 30.4 (7.6-62.5) mg/1
to 6.5 (2.3-20.6) at p=0.002 (measurement relates to 22 paired samples as 3
individual samples were above the limit of detection of the assay: 300mg/l).
Peripheral white blood cell count similarly decreased from 11.2 (8.5-16.0) xlO3 cells
to 8.5(5.2-9.6), this was measured in only 20 patients due to samples not reaching the
local haematology lab in time for analysis. CRP and white blood cell count are
demonstrated in figure 7.5. Serum calprotectin also decreased significantly over the
course of exacerbation from 21.5 (13.3-55.5) fig/ml to 9.3 (6.5-18.2) at p=0.002
(measurement in 25 paired samples), figure 7.6. Serum VEGF, previously suggested
as a biomarker of CF lung disease that changes with treatment of an exacerbation,
decreased from 385.0 (226.2- 581.5) pg/ml to 236.1 (142.6- 411.9) at p=0.013
(measurement in 25 patients).
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Exacerbation Post Treament Exacerbation Post Treatment
Exacerbation Post Treatment Exacerbation Post Treatment
Figure 7.5 Changes in Serum Biomarkers Following Treatment of Exacerbation
Blood samples were taken into clot activation tubes and the serum separated.
Separate samples were taken for full blood count assessment. Specific ELISAs were
used to measure Calprotectin, VEGF and CRP (High sensitivity CRP was utilised
with lower limit of detection of 0.1mg/l). A. Serum calprotectin decreases following
treatment of an exacerbation at p<0.01 (n=25). B. Serum VEGF decreases following
treatment of an exacerbation at p<0.05. (n=25). C. CRP (n=22) and D. WBC (n=20)
decrease following treatment of a CF Exacerbation with statistical significance
(p<0.01). The high outlier in each group represents a different patient. Bars
represent median.
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7.3.6 Correlation of BiomarkersWith Lung Function
Serum and sputum biomarkers were subjected to correlation with lung function.
Table 7.3 demonstartes the correlation of all biomarkers that demonstrated a
significant change with exacerbation treatment. Serum calprotectin and sputum zinc
demonstrated the most significant negative correlations with FEVi (Spearman r=-
0.4795, p<0.001 and Spearman r= -0.4507, p<0.001 respectively).
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Biomarker Spearman r Exacerbation Spearman r Post-Treatment Spearman r Overall
Sputum Calprotectin -0.1933 -0.0775 -0.1718
Sputum Neutrophils -0.2064 0.1337 -0.09082
Sputum Zinc -0.5634** -0.2543 -0.4507***
Sputum 9837 Da Marker -0.009 0.03569 -0.1218
Sputum 11061 Da Marker 0.2969 0.01373 -0.00714
Serum Calprotectin -0.4942* -0.3863 -0.4795***
Serum CRP -0.3274 -0.2634 -0.3666*
Serum VEGF 0.01393 0.2915 0.08998
White Blood Cell Count -0.2064 0.1337 -0.09082
Table 7.3. Correlation of Biomarkers Pre- and Post-Exacerbation with Lung Function
Selected biomarkers were correlated with lung function measured by FEVi both
before and after exacerbation treatment by Spearman rank testing (*p<0.05,
***p<0.001). Serum Calprotectin (p<0.001), sputum zinc (p<0.001) and CRP
(p<0.05), demonstrated a significant correlation with lung function overall. No




































































Figure 7.6 Significant Correlations with FEN/-,
A. Serum calprotectin was negatively correlated with FEV1 at exacerbation but not
post-treatment B. Sputum zinc was negatively correlated with FEV1 at exacerbation
but not post treatment. For Spearman r values please consult table 7.3.
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7.3.7 Relationship of Serum Calprotectin to Time of Next Exacerbation
In order to investigate whether the level of inflammation measured by serum
calprotectin at the end of exacerbation would give any useful predictive information
patient case notes were reviewed at 1 year following completion of the study and the
time to next exacerbation calculated in days from the end of antibiotic therapy. A cut
off figure was chosen with reference to serum calprotectin measurements in Chapter
5 where the median value in stable patients was 9.1pg/ml. This divided the group in
equal proportions and the median time to exacerbation was significantly shorter in
the group with higher serum calprotectin at 70 days compared to 112 days (p=0.032).
Furthermore 3 patients in the higher serum calprotectin group had died within 18
months of their final study visit. A similar analysis was performed for CRP, using
a clinically relevant cut-off of 10 mg/ml but failed to show a difference in the median






Figure 7.7 Serum Calprotectin but not CRP Predicts Time to next Exacerbation.
Time to next exacerbation from the completion of therapy was calculated for all
subjects in the study. A. Subjects with serum calprotectin of <9. lpg/ml at the end of
exacerbation treatment have longer time to next exacerbation with median time to
exacerbation 128 days vs. 70 days (p<0.05). B. Serum CRP of <10 mg/ml did not





In this chapter I have demonstrated that treatment of an exacerbation with antibiotic
therapy results in improvements in FEVi (as may be expected) and significant
changes in several biomarkers in sputum and serum such as calprotectin, whilst
failing to demonstrate significant changes in more established markers such as IL-8.
7.4.2 Changes in Pulmonary Function
Several published studies have investigated the effects of antibiotic therapy on
pulmonary function, showing that intravenous antibiotics improve FEV](99, 102,
103, 324, 325), and suggest that exacerbation may cause reversible changes in the
large airways as measured by FEVi. Furthermore, studies of nebulised antibiotic
therapy demonstrate improvements in lung function that result in fewer
exacerbations(104). The data presented in this chapter is consistent with the
published literature in terms of lung function response, however the patient group
utilised in this chapter was older than in previously published articles investigating
CF exacerbation (102, 103), which have mainly studied children and younger adults.
Therefore the almost uniform improvement in lung function in our patient group may
not have been expected, considering that the average % predicted FEVi in these
patients at the time of exacerbation was 42% predicted compared to 71% predicted in
the largest study of exacerbating patients to date(102). The data in this chapter
therefore demonstrate that even in a patient population with low baseline lung
function FEVi is a useful clinical test in assessing the response to therapy and
underlines the importance and clinical usefulness of simple procedures such as
spirometry in the day-to-day clinical management of patients.
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7.4.3 Sputum Calprotecitin
There was a statistically significant decrease in sputum calprotectin following
treatment of a CF exacerbation. High levels of calgranulin A and B (the constituent
polypeptides of calprotectin) were shown by mass spectrometry and calprotectin by
ELISA in CF sputum when compared to control populations in the previous chapters.
This chapter firstly demonstrates that calprotectin levels change with antibiotic
therapy and secondly that calprotectin in measurable in large amounts in sputum.
Calprotectin may be secreted from stimulated neutrophils(326), or released by cell
death(322) and as such is an appropriate marker for inflammation in the CF airway,
which is predominantly neutrophil mediated. Calprotectin may play an important
mechanistic role in the CF airway and has been previously implicated in early lung
disease in animal models (75). Furthermore functional knock out of calprotectin in a
murine model of pneumonia leads to decreases in inflammatory cell recruitment
suggesting an integral role in inflammatory cell recruitment (268). Thus the change
in sputum calprotectin following antibiotic therapy implies a direct association of
calprotectin with a changing state of airways inflammation. Therefore the data from
this chapter demonstrates significant changes in a neutrophil protein in the CF airway
following treatment of a CF exacerbation and as such suggests a potential role for
this marker as biomarker of response to therapy as well as suggesting a potential role
for calprotectin in the pathophysiology of CF lung disease. It should be noted that
sputum calprotectin does not change in all subjects and indeed in some subjects it did
increase following exacerbation treatment reflecting the complicated biological
situation in CF exacerbation.
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7.4.4 Sputum IL-8 and MPO
In this study there was no statistically significant change in sputum interleukin-8 (IL-
8) and myeloperoxidase (MPO) following antibiotic therapy. Ordonez et al and
Colombo et al previously demonstrated a decrease in sputum IL-8 following IV
antibiotic treatment(102, 103) and similar findings have been reported following
nebulised antibiotic therapy(327). It seems unlikely that this study was
underpowered to demonstrate a change in sputum IL-8 (a secondary outcome), as
other groups have demonstrated changes in sputum IL-8 with similar sized patient
cohorts (103, 327). The largest study demonstrating changes in sputum IL-8
following antibiotic therapy was performed by Ordonez et al, utilising 42 paired
samples and demonstrating a modest decrease in sputum IL-8 (0.5 +/- 1.3 loglO
pg/ml)(102). Therefore, even if this study was underpowered to detect changes in
IL-8 (which seems unlikely), it demonstrates the superiority of sputum calprotectin
measurement in this population. One possible explanation for the failure to
demonstrate a decrease in IL-8 is that this study utilised an adult population with
more severe disease compared to Ordonez et al who excluded patients with an FEV]
of less than 40%(102). Indeed Downey et al demonstrated no serial change in
sputum IL-8 in CF adults following exacerbation treatment, further underlining the
possibility that sputum IL-8 is not as powerful a marker in the older patient
group(328). This suggests that IL-8 is a less reliable marker in patients with more
advanced lung disease and is consistent with the finding that sputum IL-8 is less well
correlated to lung function that other sputum markers such as free elastase (193). A
further explanation for the differences between this chapter and the study of Ordonez
and co-workers was that I utilised spontaneously expectorated sputum and not
induced sputum. However, both Colombo(103) and Husson(327) employed
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protocols using spontaneously expectorated sputum, and demonstrated similar
findings to induced sputum in terms of changes in cytokine profiles.
Although MPO was not investigated in previous studies of CF exacerbation, as a
protein released from neutrophils it would be expected to demonstrate a temporal
change following treatment of an exacerbation as it has been previously described at
high levels in CF sputum compared to control populations(189, 194, 208, 277). The
failure to demonstrate a change in this marker may be due to the same reasons that
there was no statistical difference with IL-8. The findings of the present chapter are
also consistent with a pilot study of oral macrolide antibiotics in CF patients infected
with the antibiotic azithromycin which demonstrated no change in sputum MPO
following treatment(195), albeit that this study was performed in stable non-
exacerbating patients. Furthermore MPO is a primary granule protein in the
neutrophil and as such one could postulate its release from neutrophils may be more
tightly controlled than that of calprotectin, a cytoplasmic protein.
7.4.5 Changes In Sputum Trace Elements
Sputum Iron has been previously demonstrated to change with antibiotic therapy in a
modest number of patients(230). In chapter 6 of this thesis high levels of iron, zinc
and copper were observed in CF sputum. Sputum zinc levels changed (decreased)
significantly following exacerbation treatment but iron and copper did not. The
changes in zinc levels were highly statistically significant, indeed more so than any
of the protein biomarkers measured in sputum in this study, and this may reflect the
greater stability of zinc in sputum samples and a resistance to protease activity. The
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failure to demonstrate a change in sputum iron levels compared to previous
work(230) is less easy to explain although could be related to the larger sample size
used in this study excluding a previous finding in a small study. As in the previous
chapter the similarities in zinc and calprotectin measurement are noted and suggest a
possible relationship between these biomarkers and the complicated pathophysiology
of CF lung disease.
7.4.6 Changes In Sputum Protein Markers Measured by SELDI TOF MS
SELDI TOF MS demonstrated changes in 6 protein peaks between pre- and post-
treatment of an exacerbation. SELDI TOF MS was utilised in earlier chapters to
discover biomarkers in CF sputum in cross sectional samples. From this previous
work I was able to classify 4 of the significantly different peaks as calgranulin A and
B (calprotectin). Interestingly there was no significant representation of a protein
peak representative of CCSP, one of the key biomarkers discovered in previous
chapters, this may be due to the very low levels of this protein at the time of
exacerbation as in the stable CF patient it is already markedly lower than healthy
controls. The two remaining peaks were at 9837 and 11601 Da and further
identification and characterisation is required to ascertain the significance of these
peaks. A greater number of peaks were statistically significant prior to correction for
multiple comparisons, including lysosyme c and as such applying the Bonferoni
correction to our MS data may have increased type 2 error leading to rejection of
actual biomarkers of exacerbation(329). Only 1 ProteinChip surface was selected for
the comparisons in this study as the CM10 cation exchange selectively binds
biomarkers that have been previously identified in sputum and can be performed
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reproducibly. Therefore SELDI TOF MS confirmed the findings of temporal
changes in calgranulin A and B (calprotectin) as well as suggesting some future
target proteins for identification as biomarkers.
7.4.7 Changes in Serum Calprotectin and VEGF
Serum calprotectin decreased following exacerbation treatment. This finding was of
higher statistical significance than calprotectin in sputum suggesting that the
measurement of calprotectin in serum is less variable than in serum. Calgranulin A
(sub-unit of calprotectin) has previously been described in the serum of homo- and
heterozygotes with CF mutations(282) and was previously known as CF antigen. In
this study the changing serum levels of calprotectin, suggest a potentially important
role for calprotectin in the complicated biology of CF exacerbation. The serum levels
of calprotectin are approximately 4 fold less than those observed in sputum
suggesting that the high concentrations of calprotectin observed in sputum are likely
to arise from local excretion into the airways as an active process from neutrophils,
macrophages and epithelial cells or possibly by release from necrotic neutrophils
which are more prevelant in the sputum of CF patients with gram negative infection
(91). Furthermore the levels of calprotectin in serum could reflect increased
neutrophil recruitment and activity from the bone marrow or backwash of
calprotectin from the lungs into the systemic circulation due to a breakdown in
epithelial barrier intergrety, although this would require further study.
I have also demonstrated that serum calprotectin concentrations of less that 9.1 pg/ml
following exacerbation treatment are a good prognostic indicator for patients in terms
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of time to next exacerbation, and furthermore that this is superior to measuring CRP
in these patients. The cut-off value was representative of the median calprotectin
level in the serum of CF patients from chapter 5, and as such represents a clinically
relevant endpoint.
Serum VEGF has previously been demonstrated to decrease with treatment of a CF
exacerbation with the suggestion being that VEGF is produced by hypoxic lung
tissue(278). Increased levels of serum VEGF have also been reported in other lung
diseases such as tuberculosis and severe obstructive sleep apnoea(330, 331). The
present data demonstrates a decrease in serum VEGF following treatment of an
exacerbation but no corresponding change was observed in sputum VEGF,
suggesting that the high levels of serum VEGF that change with exacerbation
treatment are not derived directly from the central airways. VEGF production has
been demonstrated in vitro in hypoxic alveolar cells(281), and therefore the
measurement in sputum may be underestimate the level of VEGF being produced in
the peripheral airways and alveoli. Nevertheless this study confirms that serum
VEGF may be used as a surrogate marker of response to exacerbation. Further
investigation would be required to assess any potential mechanistic role in CF lung
disease.
7.4.8 Changes in CRP and WCC
This study demonstrates changes in standard clinical measurements of systemic
inflammation, namely C reactive protein (CRP) and white blood cell count (WCC).
These measurements may be expected to change with therapy of an exacerbation
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with antibiotics as decreasing the bacterial load in the lung may decrease the amount
of inflammation measurable systemically. These findings are in agreement with
those of Colombo et al who demonstrated a decrease in both CRP and WCC
following intravenous antibiotic therapy(103). Unfortunately only limited
conclusions can be drawn from the data relating to white blood cell counts as these
were measured in the local haematology laboratory and only 20 subjects had paired
measurement due to some samples being discarded prior to analysis following delays
in reaching the laboratory.
7.4.9 Limitations of Present Study
Although presenting a number of interesting clinical observations this study also
presents some caveats. Firstly no measure of quantitative microbiology was taken
pre- and post- antibiotic therapy as in other studies of exacerbation(102, 103).
Therefore the effectiveness of antibiotic therapy at reducing bacterial burden is
assumed by the clinical response of patients to therapy. Moreover the usefulness of
quantitative bacterial culture as an outcome may be questionable due to difficulties in
its interpretation in this more complicated adult population. Furthermore this study
was designed to assess the usefulness of biomarkers in monitoring serial changes in
subjects rather than to assess the efficacy of antibiotic therapy.
This study was performed on spontaneous samples of sputum. This sampling
modality was employed to reduce the sampling burden on participating subjects, as
the majority of adults with CF lung disease will spontaneously expectorate sputum.
Data from chapter 3 demonstratesthe similarities in sputum profiles between
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spontaneous and induced sputum on mass spectrometry and as such suggests
equivalence. Furthermore Colombo et al employed a protocol of using spontaneous
sampling giving similar findings to those from an induced sputum study of
exacerbations(102, 103). Ultimately by employing spontaneously expectorated
sputum as a sampling modality in adult CF patients, this allows clinical tests to be
performed without the need for more invasive and time consuming procedures that
may impact on patient care. It is worth noting however that the sampling of induced
sputum may be required in children with CF lung disease or adults with mild disease
to perform this sort of study.
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7.5 Conclusions
This study demonstrates a number of important clinical observations. A number of
sputum and serum markers change significantly during the treatment of infective
exacerbations, and therefore could be used to monitor such events. Sputum and
serum calprotectin were the most informative protein biomarkers and appeared
superior to sputum IL8 and serum CRP, both of which have been favoured hitherto.
The level of serum calprotectin following treatment of an exacerbation may also
predict the time to next exacerbation. Sputum levels of zinc change informatively
following treatment of an exacerbation with high statistical significance. I would
suggest that calprotectin and zinc may interact in vivo as they do in vitro, and as such
the role of calprotectin and zinc in CF lung disease merits further investigation.
Finally this study demonstrates two, as yet unidentified sputum protein markers, that
when measured with mass spectrometry, change significantly following exacerbation
treatment.
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8.0 Conclusions and Suggested Further Investigations
8.1 Biomarker Discovery and Validation in CF
In this thesis I have described the application of mass spectrometry to the discovery
of protein biomarkers in CF lung disease, as well as utilising techniques to discover
non-protein biomarkers in CF. This will allow the development of clinically relevant
biomarkers, in particular calprotectin, for further validation in CF populations and
ultimately into clinically relevant assays.
8.1.1 The Use of SELDI TOF MS in Biomarker Discovery
Chapter 3 on this thesis describes early experiments employed to validate and assess
the reproducibility of SELDI TOF MS to investigate biomarkers in CF sputum.
SELDI TOF MS is reproducible in both patient and control samples and large
amounts of information regarding protein profiles may be gained from using
relatively few chip surfaces. Furthermore, spontaneously expectorated sputum and
induced sputum result in statistically similar protein profiles on mass spectrometry.
In Chapter 4 SELDI TOF MS is utilised as a high throughput screening tool to
differentiate patients with CF lung disease from control subjects and patients with
other lung diseases. Protein profiles were similar in CF and non-CF bronchiectasis
but were markedly different from controls, asthmatic patients and COPD patients.
The most discriminatory biomarker between CF and other groups (bronchiectasis
excluded) was calgranulin A (part of the calprotectin heterodimer). Further
proteomics and western blotting confirmed this identity. Furthermore a lower
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molecular weight version of calgranulin A was characterised from the sputum of CF
subjects, a finding that has since been described in a study using CF BALF(175), and
may have mechanistic implications.
8.1.2 The Measurement of Calprotectin and Other Biomarkers by Immunoassay
Chapter 5 demonstrates that sputum calprotectin is readily measurable by ELISA and
that it can differentiate CF from control subjects with a similar statistical significance
and sensitivity/specificity to more established biomarkers such as IL-8 and MPO.
These findings suggest that calprotectin is readily measurable in sputum by a
clinically relevant technique as compared to the highly sophisticated technique of
mass spectrometry employed in the preceding chapters. Furthermore calprotectin is
readily measurable in the serum of CF patients and differentiates them from control
subjects in a similar manner to sputum calprotectin, thus providing an alternative
means of measuring calprotectin in CF patients, which does not necessitate the
sampling of sputum. Chapter 5 also demonstrate that sputum VEGF is lower in CF
patients than control, an unexpected finding when one considers the previous
findings of elevated levels ofVEGF in CF serum(278).
8.1.3 The Measurement of Non-Protein Biomarkers in Sputum
Chapter 6 describes the measurement of metal ions in sputum. Previous studies have
demonstrated raised iron levels in the sputum of CF patients(229, 230). Calprotectin
may exert extracellular effects by chelation of zinc and thus the measurement of zinc
levels in sputum seemed appropriate. Sputum zinc levels were indeed raised in
sputum from patients with CF and bronchiectasis, and zinc and calprotectin were
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highly correlated in the CF group. Sputum iron and copper are raised in CF,
bronchiectasis and COPD sputum compared to control. The potential mechanistic
interactions of calprotectin and zinc in the lung are of interest and merit further
investigation.
8.1.4 Longitudinal Measurement of Biomarkers In Sputum and Serum in CF
Patients
Chapter 7 assesses the usefulness, among other markers, of sputum and serum
calprotectin in the monitoring of CF patients during an exacerbation of lung disease.
Sputum and serum calprotectin decrease following treatment of an exacerbation,
which is in keeping with changes in lung function in these patients, but not tracked
by changes in IL-8 or MPO as might have been expected. Furthermore serum
calprotectin levels may predict future outcome following an exacerbation in terms of
time to next exacerbation. A change is also noted in sputum levels of zinc, a finding
that matches that of sputum calprotectin, further underlining the potential use of zinc
as a biomarker in CF and its possible mechanistic interaction with calprotectin.
8.2 Possible Insights Into The Pathophysiology of CF
The work in this thesis describes a number of biomarkers that are relevant to CF and
possibly some other respiratory diseases. As well as serving as biomarkers they may
also offer some insight into the disease process of CF, which is characterized by
chronic lung infection and inflammation. Calprotectin has been previously described
in CF but its role in the pathophysiology of the disease is poorly understood. There
is now a growing interest in the potential pro- and anti-inflammatory effects of
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calprotectin leading to some recent high profile research publications(268, 269). The
data presented in this thesis demonstrates that it is not only present in CF but also
that calgranulin A (a subunit of calprotectin) is present as a truncated peptide in CF
and bronchiectatic sputum. This suggests a possible post-translational modification
of calgranulin A or possibly degradation in situ in the chronically inflamed lung.
This is of novel interest and should certainly form the basis of further work.
In this thesis I have also observed increased levels of zinc in CF sputum. As such
this is the first described observation of this phenomenon. Calprotectin is a molecule
with proposed zinc chelating properties and therefore the observation of calprotectin
and zinc levels in sputum being closely correlated is of interest and may also be of
mechanistic importance, which is further highlighted by recent findings in the
literature(286).
8.3 Proposed Further Work
8.3.1 Calprotectin as Clinical Biomarker
Calprotectin is of potential use as a biomarker in CF. Further work is clearly
indicated to validate the findings in both sputum and serum in CF patients. The
measurement of calprotectin may also be relevant to other predominantly neutrophil
mediated pathologies such as community acquired pneumonia. Of particular interest
is the ability of serum calprotectin to predict outcome in CF. From the data presented
in this thesis it is evident that patients with a lower serum calprotectin at the end of
exacerbation fare better. I would propose a longitudinal study of stable CF patients
to observe whether an increased calprotectin level at baseline predicts outcome over
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a 1 year follow up period in terms of mortality and morbidity. Further to this,
clinical studies to assess the effects of standard interventions in CF on serum and
sputum calprotectin levels, such as macrolide anti-biotic therapy and nebulised
DNAse may allow one insight into how interventions may effect the underlying
pathophysiology of disease.
8.3.2 Calprotectin as a Biomarker in Gene Therapy Trials
The ultimate aim of this thesis was to discover new biomarkers for use in gene
therapy trials as part of the UK CF Gene Therapy consortium (UKCFGTC). The
evidence that I present to date demonstrates the worth of calprotectin and zinc
measurements on outcomes in CF in cross sectional studies and longitudinally in
exacerbation treated by antibiotic therapy. Sputum and serum calprotectin and
sputum zinc certainly merit further investigation in CF and will be assessed in future
gene therapy studies for CF by the UKCFGTC.
8.3.3 Calprotectin as a Key Mediator in CF Lung Inflammation
The link between the genetic mutation in CF and the onset of lung inflammation is
poorly understood. Calprotectin is present in high concentrations in CF sputum and
serum and may offer a unique insight into CF inflammation. Recent evidence has
demonstrated calprotectin to be beneficial(286) and detrimental(268) in murine
models of inflammation. Furthermore calprotectin has been demonstrated to have
major effects via the activation of toll like receptor 4 (TLR-4)(269), a major pro¬
inflammatory pathway which is also stimulated by bacterial LPS, e.g. produced by
Pseudomonas aeruginosa (PA) a major bacterial pathogen in CF. Therefore one
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could propose that in the CF lung not only bacteria, but endogenous proteins may be
stimulating major inflammatory pathways.
It has recently been proposed that PA infection in CF may stimulate a TH-17
response (a recently described form of inflammation in which Interleukin-17 is
released as a key mediator) via interactions with TLR-4 on dendritic cells(332). This
mechanism is proposed as a possible driver for inflammation in the CF lung,
however not all patients with CF are chronically infected with PA, particularly not
during childhood and therefore endogenous stimulation of this system by calprotectin
as a TLR-4 ligand may be implicated. I would therefore propose investigation of the
activation TH-17 responses via TLR-4 by calprotectin as an early driver of
inflammation in CF lung disease. Studies will be required to focus on confirming
activation of dendritic cells via TLR-4 in vitro by calprotectin and also measuring the
response to calprotectin in in-vivo models.
The release of calprotectin from neutrophils is also of interest. Recently published
data suggests that calprotectin is released by netrophils during death by
NETosis(265), a recently described form of neutrophil cell death by which DNA and
proteins are released into the surrounding area in web-like structures(333, 334). This
would suggest that calprotectin may be present in the CF airway complexed to DNA
and thus be a central component of the highly viscous mucous characteristic of the
CF airway. Further work concerning the release of calprotectin and its potential role




This thesis has demonstrated the discovery and characterisation of biomarkers of CF
lung disease in sputum. The most significant biomarker discovered by this process
in sputum was calprotectin and the measurement of this molecule with immunoassay
in sputum and serum is demonstrated, further underlining its potential as a
biomarker. A relationship with the trace element zinc, in sputum, is also suggested.
The usefulness of calprotectin measurement as a biomarker in CF was confirmed by
its measurement in exacerbating CF patients before and after therapy, demonstrating
significant changes in both sputum and serum measurements. Furthermore potential
prognostic information was derived from the serum calprotectin levels following
exacerbation. In conclusion the data in this thesis strongly endorses the use of
sputum and serum calprotectin (among others) as non-invasive biomarkers of
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Sputum Proteomics in Inflammatory and Suppurative
Respiratory Diseases
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Rationale: Markers of inflammatory activity are important for assess¬
ment and management ofmany respiratory diseases. Markers that are
currently unrecognized may be more valuable than those presently
believed to be useful.
Objectives: To identify potential biomarkers of suppurative and in¬
flammatory lung disease in induced sputum samples.
Methods: Induced sputum was collected from 20 healthy control
subjects, 24 patientswith asthma, 24with chronic obstructive pulmo¬
nary disease, 28 with cystic fibrosis (CF), and 19 with bronchiectasis.
Twelve patients with CF had sputum sampled before and after
antibiotic therapy for an infective exacerbation. The fluid phase of
induced sputum was analyzed by surface-enhanced laser desorption/
ionization time-of-flight (SELDI-TOF) mass spectroscopy on three
protein array surfaces. Some protein markers were selected for
identification, and relevant ELISA assays sought. For 12 patients with
CF, both SELDI-TOF and ELISA monitored changes in inflammatory
responses during infective exacerbations.
Measurements and Main Results: SELDI-TOF identified potential bio¬
markers that differentiated each of the disease groups from healthy
control subjects: at a significance of P < 0.01, there were 105 for
asthma, 113 for chronic obstructive pulmonary disease, 381 for CF,
and 377 for bronchiectasis. Peaks selected for protein identification
yielded calgranulin A, calgranulin B, calgranulin C, Clara cell secretory
protein, lysosyme c, proline rich salivary peptide, cystatin s, and
hemoglobin a. On treatment of an infective CF exacerbation, SELDI-
TOF determined falls in levels of calgranulin A and caigranuiin B that
weremirrored by ELISA-measured falls in calprotectin (heterodimerof
calgranulins A and B).
Conclusions. Proteomic screening of sputum yields potential bio¬
markers of inflammation. The early development of a clinically rele¬
vant assay from such data is demonstrated.
Keywords: biomarkers; calprotectin; cystic fibrosis
Although there is considerable clinical and research need for
good assessment of inflammation in airway diseases, the re¬
quirement of relatively invasive procedures, such as bronchos¬
copy and bronchoalveolar lavage (BAL), precludes sampling
from a wide range of patients and on repeated occasions. This
has encouraged investigators to use techniques of exhaled gases
and exhaled breath condensate (EBC) analysis, although there
may be limitations of value (1-10). The cellular phase of
induced sputum is helpful in evaluating and monitoring asthma
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AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Induced sputum cytology has been used to investigate
a number of respiratory diseases, including asthma. The
fluid phase is less well characterized and likely to contain
undiscovered biomarkers that may be used to monitor
disease.
What This Study Adds to the Field
High-throughput mass spectrometry identifies key bio¬
markers in sputum, allowing quantitative measurement
with immunoassay, and potential development of new
clinically applicable tests of inflammation in lung disease.
(11), but its use in suppurative lung diseases such as cystic
fibrosis (CF) is less clear, although in children induced sputum
measurements have been shown to correlate with lung function
(12). The fluid phase of sputum has been rather underutilized;
however, potential problems of variability in noncellular mate¬
rial may be encountered and as yet there is no agreed-upon
correction factor as in BAL sampling.
Surface-enhanced laser desorption/ionization time-of-flight
(SELDI-TOF) technology has been used to discover bio¬
markers of disease groups in direct comparison to control
groups. The primary focus of much of this research has been
to determine diagnostic biomarkers in a wide range of diseases,
such as rheumatoid arthritis, HIV infection (13), prostate cancer
(14), ovarian cancer (15, 16), motor neurone disease (17),
ischemic heart disease (18), and infectious diseases (19, 20),
using a diverse range of body fluids, such as serum, urine,
cerebrospinal fluid, and joint fluid. The generated protein
profiles demonstrate differences between disease groups and
individual proteins may be identified to act as biomarkers either
alone or in tandem with others. SELDI-TOF data may be used
to generate serum "protein fingerprints" using bioinformatics to
provide a potential diagnostic test in cancer and infectious
diseases (15, 19, 20). This approach relies on interpretation of
mass spectral patterns rather than identifying individual pro¬
teins and has been widely criticized in the literature and, in
some cases, such as the work of Petricoin and colleagues (15),
analysis of data sets independently have led to completely
different conclusions (21). Baggerly and coworkers (2l) dem¬
onstrated that inconsistent data processing can alter the ulti¬
mate outcome of these sorts of experiments. A different, and
more direct, approach is to identify the actual proteins re¬
sponsible for the mass spectral peaks provided by mass spec¬
trometry (MS) data. Indeed, the identification of key bio¬
markers after initial proteomic studies may provide a more
viable route to clinical application (22) and furthermore may
allow the functional importance of such markers to be in¬
vestigated. Therefore, using SELDI-TOF as a screening tool
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to identify individual potential biomarkers for further charac¬
terization may be a more valid and robust approach. SELDI-
TOF has been applied to a small number of patients with
chronic obstructive pulmonary disease (COPD) demonstrating
a protein profile in BAL (23), and in pulmonary sarcoidosis
(24). SELDI-TOF has been used to demonstrate protein
expression in BAL in CF (25, 26). There is as yet a lack of
published data using SELDI-TOF to profile sputum, although
complementary proteomic approaches of two-dimensional elec¬
trophoresis (27), shotgun protein sequencing (28), and affinity
immunoproteomics (29) have been applied to sputum in an
effort to discover new biomarkers.
We applied SELDI-TOF to induced sputum from patients
with inflammatory (asthma, COPD) and suppurative (CF,
bronchiectasis) airway diseases to determine whether a high-
throughput proteomics screening method can reveal differential
protein expression between disease groups and therefore can¬
didate biomarkers, which may then be developed into point
assays of inflammation with potential application in the clinic.
This work was driven by the need to develop biomarkers to
monitor suppurative lung disease, in particular CF.
METHODS
Subjects and Selection
The Lothian Ethics Committee (Edinburgh, UK) granted ethical
approval and all participants gave written consent. Sputum was
obtained from 28 patients with CF, 19 with bronchiectasis, 24 with
asthma, 24 with COPD, and 20 healthy control subjects. All patients
were clinically stable and recruited from the outpatient clinic of
a respiratory medicine unit. All subjects were recruited from specialist
respiratory clinics at a major teaching hospital where they were
attending with a diagnosis of their respective illness. In the absence
of preexisting data on intersubject variability, formal statistical power¬
ing was not possible, but we approached this problem by recruiting
similar numbers of subjects to previous biomarker studies. The patient
groups represented respiratory diseases with clinical features that both
complement and contrast with each other.
Longitudinal Data
To determine the usefulness of discovered markers in the assessment of
lung disease during a changing level of inflammation, longitudinal
samples were collected from 12 patients with CF during an infective
exacerbation. Samples were collected at onset and completion of
intravenous antibiotic therapy (duration, 14-21 d). The biomarkers
were assessed both by SELDI-TOF and by ELISA.
Induced Sputum
Sputum induction was performed as previously described (30). Subjects
inhaled nebulized hypertonic saline at concentrations of 3, 4, and 5%.
Sputum was processed within 2 hours of collection (31). Sputum plugs
were selected and processed with 4 X weight/volume of 0.1%
dithiothreitol after which 4 X weight/volume of phosphate-buffered
saline was added. Samples were filtered through 48-p.m mesh and
centrifuged to remove the cells. Supernatants were stored at -80°C
until further analysis. Cytospins were stained with May-Grunwald-
Giemsa for differential cell counting.
SELDI-TOF MS
Three different chromatographic chip surfaces were used to cover
a wide range of protein characteristics: a weak cation exchange at pH 4
(CM10), an anion exchange at pH 10 (Q10), and an immobilized metal
affinity surface activated with nickel (IMAC nickel [IMACNi]). In¬
duced sputum samples were adjusted to contain 1 mg/ml protein at
a concentration of 0.1% dithiothreitol. Ten microliters of sample were
added to CM10 and Q10 surfaces in a bioprocessor unit (Ciphergen,
Freemont, CA) and 1 |xl of sample was added to the prcactivated
IMACNi surface for on-spot incubation (more reproducible for IMACNi
surfaces). All chips were treated with sinapinic acid (SPA) matrix (2 x
0.8 p.l/spot) and allowed to air dry. Samples were analyzed on the
Protein Biology System 2 SELDI-TOF mass spectrometer (Cipher¬
gen). Chips were read with a laser intensity of 205 with the deflector set
at 4,000 D and a focus mass of 7,500 D. Profiles were then exported to
Ciphergen Express (Ciphergen) for clustering and data analysis. Intra-
and interassay coefficients of variation were assessed with the CM10
surface as outlined in the online supplement.
Data Analysis
Data were normalized to total ion current to take into account any spot
to spot variability in chip surface binding. Data with high normalization
coefficients were identified and individual spectra examined. Poor-
quality spectra or absent signal were excluded from further analysis.
Protein peaks were automatically clustered to identify biomarkers of
similar molecular weight. Mann-Whitney rank testing was performed
to demonstrate statistical differences in clusters between disease
groups. Values of P < 0.01 were taken to be significant. For longitu¬
dinal data, paired t test analysis was performed using Prism 4 software
(GraphPad, San Diego, CA). For a further description of methods,
please refer to the online supplement.
Protein Identification
Highly significant peaks (P < 0.0001), assessed on relative abundance
and quality of original spectral data, were selected for protein iden¬
tification. Pooled sputum was used. Samples were applied to 18%
trisene/glycine acrylimide gel for electrophoresis. Bands of appropriate
molecular weight were excised and destained and the protein eluted.
The eluate was digested with proteomics grade trypsin (Sigma,
Gillingham, UK), applied to a normal-phase chromatography chip
surface and analyzed with SELDI-TOF MS or MALDI (matrix-
assisted laser desorption/ionization)-TOF MS using a Voyager DE
STR mass spectrometer (Applied Biosystcms, Foster City, CA). The
resultant mass fingerprint was used to identify the parent protein
through reference to protein identification databases (MS-Fit; Univer¬
sity of California, San Francisco, San Francisco, CA). Proteins were
identified based on molecular weight search (MOWSE) score and
cross-checkcd with online MASCOT (http://www.matrixscience.com),
which allows a probability-based MOWSE score. Protein identification
was only accepted when P values were less than 0.05. Tandem MS/MS
analysis was performed to confirm identification of proteins using a
Q-star tandem MS instrument (Applied Biosystems) with SELDI
chip interface (Ciphergen). This approach provided additional pro¬
tein identification based on amino acid sequence from the MS/MS
analysis.
Commercial antibodies, when available, were used for protein con¬
firmation by Western blotting. For calgranulins A and B, we were also
able to use an in-house quantitative immunoassay measuring calprotectin
(calgranulin A/B complex). An in-housc double antibody sandwich ELISA
(antibodies and calprotectin standard courtesy of E. Sundrehagen,
M.D.) was developed for use in the 12 patients with CF monitored
longitudinally, and results compared with data from SELDI-TOF.
RESULTS
Demographics
Patient demographics are given in Table 1. Of the patients with
CF, 18 were chronically infected with Pseudomonas aeruginosa.
Reproducibility of SELDI-TOF Assay in Sputum
This was assessed as described in the online supplement. The
intraassay coefficient of variation ranged from 11.5 to 44% with
an average coefficient of variation (CV) of 22.4%. Interassay
variation demonstrated a CV ranging from 6 to 43%, with an
average CV of 16.2%.
Protein Profiles Generated by SELDI-TOF
An example of generated data is demonstrated in Figures 1 and 2.
Cluster analyses determined a large number of peaks present in
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TABLE 1. DEMOGRAPHIC, LUNG FUNCTION, AND SPUTUM
NEUTROPHIL DATA OF THE PATIENTS STUDIED
Group Age (yr) Sex FEV, (% pred) Sputum Neutrophil (%)
Asthma 47.8 (2.9) 15 F/8 M 82.3 (4.4) 50.6 (5.0)
COPD 65.2 (1.2) 10 F/14 M 57.7 (4.1) 79.1 (2.7)
Bronchiectasis 61.8 (3.5) 15 F/3 M 71.7 (11.6) 83.2 (5.6)
CF 28.8 (1.7) 8 F/19 M 59.2 (3.9) 91.6 (2.0)
Control 36.4 (2.1) 11 F/9 M 101.4 (3.1) 54.2 (5.3)
Definition of abbreviations: CF = cystic fibrosis; COPD = chronic obstructive
pulmonary disease; F = females; M = males.
Values are mean (SEM).
relative proportions that differentiated between disease groups
and healthy controls (Table 2). Three chip surfaces yielded
a total of 621 clustered protein peaks, 105 of those significantly
different at P < 0.01 and 56 at P < 0.001 for asthma versus
healthy controls. For COPD compared with healthy controls,
the respective figures were 625 protein peaks, with 113 signif¬
icant at P < 0.01 and 50 at P < 0.001 for three surfaces. For
bronchiectasis versus healthy controls, the respective figures
were 671 protein peaks, with 377 significant at P < 0.01 and 314
at P < 0.001 for three surfaces. For the CF group, the respective
figures were 660 protein peaks, with 381 significant at P < 0.01
and 315 at P < 0.001 for three surfaces (Table 2; for full
summary, see Table El in the online supplement).
Although all four groups of patients yielded a substantial
number of differential proteins compared with healthy control
subjects, there were much closer similarities between the two
obstructive airway diseases and between the two suppurative
airway diseases. For asthma and COPD, only 16 proteins, on the
three chip surfaces, were different at P < 0.01, and one protein
was different at P < 0.001 (Table 2; Table El). This latter
protein, molecular weight (MW) 29 kD, was seen on the
IMACNi surface (Figure 3A) but had low signal intensity. This
marker has not yet been identified. CF and bronchiectasis
demonstrated relatively similar biomarker profiles compared
with each other, albeit the abundance of protein in the CF
group was greater. Fifty-eight proteins differentiated the groups
at P < 0.01 and 9 proteins differentiated the groups at P < 0.001
(Table 2; Table El) over the three surfaces. Five of these nine
proteins were observed on the IMACNi surface, two on CM10
and two on Q10. The marker that showed the greatest separa¬
tion between the disease groups and had the highest signal
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Figure 7. This figure demonstrates spectra from individual subjects on the immobilized metal affinity chromatography (IMAC) nickel surface in the
mass range of 5 to 15 kD. Even in this mass range, there is an abundance of peptide peaks, and noticeable differences are observed between groups.
B'iectasis = bronchiectasis; CF = cystic fibrosis; COPD = chronic obstructive pulmonary disease.
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Figure 2. This figure demonstrates spectra
from an individual with cystic fibrosis (CF)
on the CM 10 (cationic exchange) surface
shown at different magnifications demon¬
strating the abundance of peaks in an
individual sample. (4) demonstrates the
entire spectrum (3,000-50,000 D); each
label (most of which cannot be discerned
individually at this magnification) repre¬
sents a peak with signal-to-noise ratio of
more than 3. (8) demonstrates some mag¬
nification to cover the spectrum from
5,000 to 20,000 D; again, most of the
individual labels cannot be seen clearly at
this magnification. (C) demonstrates mag¬
nified spectrum from 6,500 to 7,000 D,
and at this level the individual peaks can be
easily discerned.
The top 20 protein peaks that showed the most statistically
significant differences between individual disease groups and
healthy controls are shown in Table E2, indicating their mo¬
lecular weight and the chip surface on which they were iden¬
tified. There are common peaks found in asthma and COPD,
and CF and bronchiectasis.
Biomarker Identification
The proteins we have formally identified from the induced
sputum samples are calgranulin A, calgranulin B, calgranulin C,
Clara cell secretory protein (CCSP, CC16, CCSP10, uteroglo¬
bin), lysosyme c, proline rich salivary peptide, cystatin s, and
hemoglobin a (Table 3).
Calgranulins A, B, and C were highly abundant in CF and
bronchiectasis, but were also seen in the other disease groups.
These proteins are represented by mass spectral peaks at 10.831
kD, 12.700 kD, and 10.100 kD, respectively. These peaks were
preferentially expressed on the IMACNi surface but were also
bound to the weak cation exchange surface. Some binding of
calgranulin A was also demonstrated on the anion exchange
surface. A separate form of calgranulin A with a lower molec¬
ular weight (10.574 kD) was seen in the CF and bronchiectasis
groups. This was identified by mass fingerprinting of both
molecular weights after purification on sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (data not shown). The relative
expression of calgranulin A across all groups is shown in Figure
4A and the relative expression of the smaller form of calgra¬
nulin A in Figure 4B. The presence of calgranulin A was
confirmed with Western blotting in pooled sputum samples
from all disease and control groups (Figure 4C).
In contrast to the calgranulins, CCSP was in lower abun¬
dance in all disease groups compared with controls, but to the
greatest extent in CF and bronchiectasis. This had a mass
spectral peak of 7.900 kD on the CM10 surface. The relative
expression of CCSP across all groups is shown on Figure 5.
CCSP was confirmed on Western blot (data not shown).
Correlation of Biomarkers with FEV, and Sputum Cytology
In the CF group, the most abundant biomarker, calgranulin A,
showed a weak inverse correlation with FEV]% predicted,
which failed to reach statistical significance (Spearman r =
0.63, P = 0.08). There was no correlation of calgranulin A with
the percentage of sputum neutrophils (data not shown).
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TABLE 2. THE TOTAL NUMBER OF PEAKS DETECTED BY SELDI-TOF
IMAC Nickel Weak Cation Exchange (CM10) Anion Exchange (Q10)
Asthma vs. control 4 (n = 22 vs. 20) 16 (n = 20 vs. 19) 36 (n = 16 vs. 1 8)
COPD vs. control 11 (n = 23 vs. 20) 13 (n = 22 vs. 19) 26 (n = 21 vs. 1 8)
CF vs. control 108 (n = 28 vs. 19) 111 (n = 22 vs. 19) 96 (n = 22 vs. 1 9)
Bronchiectasis vs. control 112 (n = 19 vs. 20) 103 (n = 1 7 vs. 19) 99 (n = 18 vs. 1 9)
CF vs. bronchiectasis 19 (n = 28 vs. 19) 18 (n = 28 vs. 1 7) 21 (n = 22 vs. 1 9)
Asthma vs. COPD 10 (n = 23 vs. 22) 5 (n = 21 vs. 20) 1 (n = 21 vs. 25)
Definition of abbreviations-. CF = cystic fibrosis; COPD = chronic obstructive pulmonary disease; SELDI-TOF = surface-enhanced
laser desorption/ionization time-of-flight.
Significantly different (P < 0.001) for disease versus control are shown. The two suppurative airway diseases, CF and
bronchiectasis, and the two inflammatory airway diseases, asthma and COPD, were also compared in terms of numbers of
differentiating proteins (P < 0.01). Proteins could be increased or decreased in their abundance. Spectra that failed normalization
were excluded from analysis (see text), n = number of normalized spectra used in each analysis, as per order in table legend. The
spectra failing to normalize were not the same for each analysis. The data are displayed for each of the three chip surfaces that
were used in the study.
Longitudinal Assessment of Identified Biomarker and
Application of Specific ELISA
There were decreases in the levels of both calgranulin A and B,
as assessed by SELDI-TOF, during treatment of an exacerba¬
tion of CF (Figures 6A and 6B; P < 0.01). Calprotectin
(heterodimer of calgranulins A and B), measured by ELISA,
similarly showed significant reduction (Figure 6C).
DISCUSSION
The use of SELDI-TOF MS has allowed us to generate sputum
protein profiles of several diseases. We have shown there are
substantial numbers of potential protein biomarkers that dif¬
ferentiate patients with inflammatory airway diseases from
healthy subjects. We have proceeded to identify several of
these candidate biomarkers and, using the example of calgra¬
nulins A and B, have demonstrated clinical relevance with
longitudinal evaluation during altered disease activity. We have
demonstrated that, having identified a biomarker by primary
screening rather than empirical preselection, a standard assay,
ELISA, can then be applied to the same clinical samples and
deliver quantitative measures of the biomarker. Thus, screening
with high-technology SELDI-TOF proteomics can be converted
into clinically applicable measures.
Because this is the first study of its kind to investigate the
proteomics of induced sputum using SELDI-TOF, we sought to
determine the reproducibility of this assay. The average intra-
assay CV was 22.41% and average interassay CV was 16.25%.
This compares well to published data for serum (intraassay CV
of 15.6%, interassay variation of 24.4% [19], urine (intraassay
CV, 8-30%) (32), and saliva (intraassay CV, 18%, and inter¬
assay CV, 31%) (33).
Previous studies have demonstrated the utility of SELDI-TOF
in the diagnosis of illnesses in a range of body fluids. We used the
fluid phase of sputum as a noninvasive means of assessing the
airways. Although previous work has suggested a correlation of
induced sputum with bronchial washings but not BAL (34), and
therefore suggests that it reflects the pathophysiology of more
central airways, induced sputum has been demonstrated useful in
inflammatory respiratory diseases (11, 12, 35—46). Therefore, we
would conclude that the proteomic assessment of induced sputum
is a valid means of assessing airway disease.
As described previously, SELDI-TOF technology has been
used as a technique in a number of inflammatory and neoplastic
diseases, mainly using serum as a sampling medium. It was
suggested as a diagnostic platform using bioinformatic algo¬
rithms to separate subjects with ovarian cancer from healthy
control subjects (15). This initial approach, however, was widely
criticized in the literature because the results were not re¬
producible when the same data sets were examined by in¬
dependent investigators (21). Baggerly and colleagues (21) drew
particular notice to the impact of different modes of data
preparation after acquisition, such as baseline subtraction in
some groups of data and not in others. They also suggested that
inaccuracies in sample collection protocol and mass calibration
could lead to misinformed results in these sorts of experiments.
To ensure uniformity in this study, all data in our analysis
underwent the same steps of preparation before analysis. We
also ensured that all sample preparation was uniform as out¬
lined in Methods and below. Mass calibration was performed
before each experiment using protein and peptide standards
(Ciphergen All in One protein and peptide standards; Cipher-
gen). Furthermore, the widely criticized Petricoin study also
used mass spectral data at less than 1,000 D, a mass range at
TABLE 3. PROTEIN IDENTIFICATIONS CONFIRMED FROM PRESENT STUDY
Molecular Accession Corresponding Confirmed Confirmed Confirmed Direction of
Protein Weight (D) Number SELDI Peak (D) by PMF by MS/MS By Antibody Change in Suppuration
Calgranulin A 10,834 P05109 10,834, 10,596 Yes Yes Yes Increased
Calgranulin B 12,960 P06702 12,960, 13,200 Yes Yes Yes Increased
Calgranulin C 10,100 P80511 10,100 Yes Yes No Increased
Clara cell secretory protein 7,900 P11684 7,900 Yes Yes Yes Decreased
Proline rich salivary peptide 8,188 P02814 8,119 No Yes No Decreased
Lysosyme C precursor 16,537 P61626 14,600 Yes Yes No No Change
Cystatin s 16,204 P01036 16,079 No Yes No No Change
hemoglobin alpha 15,117 P69905 15,080 No Yes No No Change
Definition of abbreviations-. PMF = peptide mass fingerprinting; SELDI = surface-enhanced laser desorption/ionization.
Proteins were identified by trypsin digest and PMF and well as tandem MS/MS. When available, antibodies were used to confirm protein identification by Western blot.
Molecular weight refers to the theoretical molecular weight of each protein as derived from sequence. Corresponding SELDI peak refers to the protein peak seen on
SELDI analysis of sputum fluid phase (differences in molecular weight may represent post-translational modifications).
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Disease
Figure 3. (A) The protein that gave the statistically greatest differen¬
tiation between asthma and chronic obstructive pulmonary disease
(COPD) (P < 0.001) had a MW of 29 kD, and was detected on the
IMAC nickel (IMACNi) surface. The individual data and the median bars
are shown. The data are for 22 patients with asthma and 23 patients
with COPD (see explanation in footnote to Table 2). Other disease
groups are demonstrated for comparison. (B) The protein that gave the
statistically greatest differentiation between cystic fibrosis (CF) and
bronchiectasis (B'iectasis) (P < 0.001) had an MW of 12.246 kD, and
was detected on the IMACNi surface. The individual data and the
median bars are shown. The data are for 28 patients with CF and 19
patients with bronchiectasis (see explanation in footnote to Table 2).
Other disease groups are demonstrated for comparison.
which the discrimination of genuine protein peaks from back¬
ground noise may be difficult. Our approach of excluding data
from below 4,000 D from analysis further strengthens the
findings of this study. Other studies using SELDI-TOF as
a diagnostic platform in infectious diseases using more robust
sample collection and data preparation algorithms have proved
more promising (19, 20). However, in this study, we used
SELDI-TOF as a high-throughput screening platform for bio-
marker discovery rather than as a primary diagnostic assay.
Although, on initial observation, our data demonstrate a large
number of differentiating peaks when we look at the combined
data set, the actual clinical significance of this observation is less
clear and should be interpreted with caution.
Previous work by our group suggested an optimum mass
range for respiratory biomarker discovery with this platform to
be 3 to 20 kD (25). This may lead to biomarkers of a higher
mass being ignored. Other proteomics methods, such as two-
dimensional gel electrophoresis and immunocapture, may be
better in assessing larger molecular weight proteins, and has
been applied to CF (27, 29).
The largest numbers of differentiating proteins between
disease and control were found in CF and bronchiectasis. This
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Figure 4. Calgranulin A in all disease groups: (A) shows the relative
expression, on surface-enhanced laser desorption/ionization time-of-
flight (SELDI-TOF), of the 10,831-D protein, which was elevated (P <
0.001) in all disease groups versus control; (B) shows the expression of
the 10,576-D form of calgranulin A, which was specifically elevated in
patients with cystic fibrosis (CF) and bronchiectasis (B'iectasis) (P <
0.001 vs. all other groups) (the data in A and B were obtained using the
IMAC Nickel surface); (C) is a Western blot of calgranulin A. The blot
represents the overall abundance of calgranulin A from both 10,834-
and 10,576-D forms in the sample groups (/ones are labeled as Bl =
blank, A = asthma; Br = bronchiectasis; CF = cystic fibrosis; Con =
control; CO = COPD). Note the strong staining for CF and bronchi¬
ectasis groups and very weak staining in asthma. (D) demonstrates the
effect of bacterial colonization on the signal intensity of the 10,576-D
form of calgranulin A; the majority of patients were colonized with
Pseudomonas aeruginosa (shown in the first column labeled "Pseudo¬
monas"); other organisms included Staphylococcus aureus, Haemophi¬
lus, Stenotrophomonas, and Burkholderia (labeled "Other").
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Disease
Figure 5. Clara cell secretory protein, molecular weight (MW) 7.9 kD,
was in lower abundance for all disease groups compared with controls,
but to the greatest extent in cystic fibrosis (CF) and bronchiectasis
(B'ectasis). These data were obtained using the cation exchange
(CM10) surface. The individual data and the median bars are shown.
The data are for 20 patients with asthma, 17 with bronchiectasis, 22
with CF, 22 patients with chronic obstructive pulmonary disease
(COPD), and 19 control subjects (see explanation in footnote to Table 2).
related proteins in these groups or, alternatively, samples obtained
from these groups had greater abundance of protein overall.
Sputum samples obtained from subjects with CF and bronchiec-
tatic subjects were of greater volume and better quality sub¬
jectively. However, selected mucus plugs were used for analysis
and processed with equal ratios of buffer as previously described
(46). Moreover, to ensure samples were comparable, superna-
tants were adjusted to a total protein concentration of 1 mg/ml
before applying to chip surfaces. Also, mass spectral data were
normalized to total ion current before data analysis, thus
minimizing effects of possible variation in protein binding to
chip surfaces. After normalization, samples were excluded be¬
cause they had absent or very poor signals. We would therefore
suggest that the differences expressed between groups represent
real differences in protein expression rather than confounding
due to issues of sample quality and abundance.
Our data revealed large numbers of potential biomarkers. The
preset parameters we created may have limited the possible
number. A lower limit cutoff of 4 kD may have been too harsh.
Indeed, our spectra showed the human a defensins in all groups,
but these were excluded from analysis because their average mass
was less than 4 kD. Alternatively, we may have overestimated
true numbers of differentiating markers because some proteins
were detected on more than one chip surface. Also, a proportion
of some proteins may be doubly protonated. Because the "time
of flight" is related to both MW and charge, such proteins will
appear "twice," once with half the MW of the original protein.
Furthermore, different peaks may represent cleavage products of
the same (higher molecular weight) proteins and this may in part
explain the high numbers of potential differentiating peaks we
recorded, particularly when comparing our CF and bronchiectasis
groups with control subjects.
Despite finding a large number of peaks differentiating CF
and bronchiectasis from controls, we were surprised not to have
identified any of these as known biomarkers of inflammation,
such as IL-8 or neutrophil elastase. In our study, SELDI-TOF
was most efficient at demonstrating peaks in the 5-20-kD range
and this may in part explain these findings as the predicted
molecular weights of neutrophil elastase is 29.5 kD (47).
Furthermore, the chip surface chemistry and binding conditions
may simply not have favored preferential selection of IL-8.
Despite the limitations in this technique, we found large
numbers of potential biomarkers from which we have so far













Figure 6. The results for calgranulins A and B/calprotectin for 12
patients with cystic fibrosis are shown at the onset of an infective
exacerbation and at the completion of antibiotic therapy, when there
was a decrease (P < 0.01) of the proteins measured. (A) shows data for
calgranulin A; (6) shows data for calgranulin B; (Q shows data for
calprotectin measured by ELISA.
other peaks is ongoing. We used one of these biomarkers,
calprotectin (calgranulin A and B), to show that it was possible
to monitor disease activity and to apply an ELISA to the same
clinical samples, obtaining the same results as with MS.
In all disease groups, we identified calgranulin A at higher
levels than in control subjects. This SI00 protein is produced by
neutrophils, macrophages, and epithelial cells. In the CF and
bronchiectasis groups, a protein at 10.574 kD was also identified
as calgranulin A. Theoretical removal of glutamic acid and
lysine from the N terminus of calgranulin A would result in
an identical mass shift from 10.831 to 10.574 kD. Calgranulin
10.574 may therefore be the product of specific cleavage or post-
translational modification in CF and bronchiectasis. Whether
this finding may be of functional significance is as yet unclear.
Calgranulins A and B have also been described recently in
BAL fluid from subjects with CF (25, 26); a similar finding of
a separate peak representing calgranulin A at a lower molecu¬
lar weight was also described in BAL fluid by McMorran and
colleagues (26).
Calgranulin has previously been described in the sera of
subjects who were homo- and heterozygous for CF mutations
and was referred to as CF antigen (48). Calgranulin A may
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provide a robust and sensitive marker of airway inflammation in
CF. The likely source of calgranulin A is from neutrophils in the
airway, although in this study we failed to demonstrate any
significant correlation between neutrophil % in sputum and
calgranulin A as measured by SELDI-TOF. This may in part be
explained by the finding that the majority of the patients with
CF had a profound neutrophilia in sputum in excess of 95%,
regardless of other clinical details. Furthermore, there was
a weak relationship between decreasing FEVj and higher levels
of calgranulin A, implying that calgranulin A may be a marker
of disease severity in CF. We replicated our SELDI-TOF results
using an ELISA to calprotectin, the heterodimer of calgranulins
A and B. Thus, a more practical assay can be applied to induced
sputum and yield the same clinical information. Calprotectin
has previously been recognized as a marker in other inflamma¬
tory disorders, including inflammatory bowel disease and ar¬
thritis (49-51). Calgranulin C, another S100 protein, was also
identified in our samples. This is in keeping with previous work
demonstrating its presence in sputum and its potential useful¬
ness as a biomarker in serum for CF (52).
A second abundant protein identified showed opposite
effects to calgranulin A. CCSP was reduced in all disease
groups compared with controls. CCSP is an antiinflammatory
protein mainly expressed in the epithelial cells of the airways.
Low serum levels have been reported in patients with asthma
(53), and low nasal lavage levels in patients with allergic rhinitis
(54). CCSP has a number of possible activities, including
inhibition of phospholipase A2, chelation of calcium, and
down-regulation of IFN--y, IL-1, and tumor necrosis factor-a.
Our findings are consistent with these previous studies, and
raise the possibility that resolution of inflammatory processes
might be monitored by rising levels of CCSP.
In conclusion, we have demonstrated the utility of SELDI-
TOF MS as a tool for biomarker discovery in induced sputum.
We have positively identified proteins of biological significance
in the fluid phase of sputum. These proteins may form the basis
of clinical point assays to assess the presence and activity of
inflammation in a variety of lung diseases, with a particular
emphasis being placed on disease monitoring.
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Sputum Trace Metals Are Biomarkers
of Inflammatory and Suppurative
Lung Disease
Robert D. Gray, MB ChB; Andrew Duncan, PhD; Donald, Noble, MD; Margaret Imrie, BSc;
Dennis St. J. O'Reilly, MD; J. Alastair Innes, PhD; David J. Porteous, PhD;
Andrew P. Greening, MD; and A. Christojdier Boyd, PhD
Background: Induced sputum cytology and protein biomarkers can be used to assess airways
inflammation. Increases in sputum iron have been described in inflammatory lung disease. We
hypothesized that other sputum metals may be affected by airways inflammation and investigated
their potential value as biomarkers.
Methods: Sputum was obtained from 20 healthy control subjects and from patients with inflam¬
matory pulmonary diseases (23 with cystic fibrosis [CF], 16 with bronchiectasis, 17 with asthma,
and 23 with COPD), and iron, zinc, manganese, and copper were measured. Fourteen patients
with CF were also studied through an exacerbation cycle.
Results: Sputum zinc and iron were elevated in CF and non-CF bronchiectasis vs controls (P < .001,
zinc; P<.01 iron). Manganese was elevated in asthma (P<.01) and bronchiectasis (P<.05) vs
controls. Copper was elevated in CF vs controls (P < .05). Zinc decreased (P < .01) following treat¬
ment of CF exacerbation. In subjects with CF zinc levels correlated with other biomarkers.
Conclusions: These results suggest a relationship of high concentrations of total zinc and iron
with airways inflammation in CF and non-CF bronchiectasis, with longitudinal changes being
observed in CF. Further work is required to elucidate potential inflammatory mechanisms
related to these observations. CHEST 2010; 137(3):635-641
Abbreviations: CF = cystic fibrosis; IL = interleukin; MPO = myeloperoxidase; PBS = phosphate-buffered saline;
SOD = superoxide dismutase
The presence of a proinflammatory milieu in theairway is important for the development of a range
of inflammatory lung diseases. Adequate assessment
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of inflammatory cells, cytokines, ehemokines, and
antiinflammatory molecules is essential for under¬
standing, monitoring, and treating these disorders.
Induced sputum provides a noninvasive means of
investigating airways inflammation.1 Induced sputum
has a fluid phase containing a heterogeneous mix
of proteins and nonorganic substances. A number of
cytokines, including interleukin (IL)-8, have been
measured,2 albeit with significant interstudy variation
in reported levels.3 The nonorganic component, how¬
ever, has been largely neglected.
Previous work performed by this group has demon¬
strated high levels of the neutrophil protein calprotectin
in the sputum4 and lavage fluid5 of patients with CF
and non-CF bronchiectasis. Calprotectin possesses anti¬
microbial properties mediated by the chelation of zinc.6-7
It has been demonstrated recently that calprotectin is
recruited to staphylococcal abscesses in a neutrophil-
dependent manner and inhibits Staphylococcus
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aureus growth through the chelation of zinc and
manganese.8
Increased levels of total iron and iron-binding pro¬
teins have been reported in the sputum of patients
with cystic fibrosis (CF) and COPD.9-12 Scavenging of
free iron is an important component of antimicrobial
defense mechanisms against organisms such as
Pseudomonas aeruginosa,13 an important pathogen in
chronic lung disease. Although iron is clearly an impor¬
tant inorganic substance in the airway, other metals,
such as zinc, may also be important; for example,
increased zinc levels alter the sensitivity ofPseudomonas,
an organism particularly relevant to CF lung disease,
to antibiotics.14 Therefore the measurement of trace
elements in sputum may allow mechanistic insight
into diseases such as CF. Furthermore, trace elements,
likely to be less susceptible to protease activity, may
allow more reliable measurement of inflammation
in the airway. Thus we feel that measurement of trace
elements may allow a more robust sputum measure¬
ment of airways disease as well as giving further insight
into lung inflammation in diseases such as CF.
Based on our previous findings of increased levels of
calproteetin, a known chelator of zinc, in the airway
and previous observations related to iron in the CF
airway we hypothesized that trace metal concentra¬
tions, in particular zinc and iron, would be elevated in
CF and non-CF bronchiectasis compared with control
populations. We also hypothesized that levels of trace
element would change following disease intervention
in CF. Total concentrations of zinc, iron, copper, and
manganese were measured in subjects with CF, bron¬
chiectasis, COPD, and asthma, and in normal controls.
Furthermore, concentrations of trace elements were
compared with previously described markers of
inflammation in CF, including calprotectin.
Materials and Methods
Subjects
Induced sputum was obtained from patients attending the
Respirator)' Unit at the Western General Hospital, Edinburgh.
Approval was obtained from the local regional ethics committee.
Twenty-three patients with CF. 16 with non-CF bronchiectasis. 17
with asthma, 23 with COPD, and 20 healthy controls were studied.
In order to monitor the effects of a changing state of inflammation,
sputum samples were obtained from 14 additional patients with CF
during CF exacerbation. Exacerbation samples were taken within
24 hours of starting antibiotic therapy and at the end of treatment.
Reagents Used
All reagents were purchased from Sigma (Sigma; Gillingham,
UK) unless otherwise stated. Ultrapure. high-performance liquid
chromatography-grade water was used for all experiments and




Sputum induction was performed by a standard method as pre¬
viously described.15"17 In brief, patients inhaled nebulized hyper¬
tonic saline at concentrations of 3%, 4%, and 5% and were asked
to expectorate after each inhalation until a sample was obtained.
Patients with CF underwent induction unless freely expectorating
in keeping with previous CF sputum studies.1519 Nine of 23 subjects
with CF spontaneously produced sputum without induction.
Sputum Processing
Sputum was processed within 2 hours of collection as described
previously.15 In brief, sputum plugs were harvested and processed
with 4 XweightAolume of 0.1% didiiodrreitol in phosphate-buffered
saline (PBS), after which 4 Xweight/volume of PBS was added.
Samples were filtered through 48-p.m mesh and centrifuged at
1,200 rpm to remove die cells. Supernatant was stored at -80°C
until further analysis widiout protease inhibitor. The cell pellet was
resuspended in PBS and used for cytospin preparation. Cytospins
were stainedwith May-Grunwald-Giemsa for differential cell count¬
ing. All cell counts were expressed as percentage of the population
counted. Total cell count was not performed prior to cytospin. All
samples used in diis study contained < 40% squamous cells.
Trace Element Assay
Trace element assaywas performed in the Scottish National Trace
Element Reference Laboratory, Glasgow, Scodand. A four-point
calibration was used (0,100,5CK), 1,000 p.g/L copper, iron, zinc, man¬
ganese in 1 % nitric acid). Sputum samples were centrifuged at 800 g
for 5 min and 200 p.L of sample was dien diluted vvidi 2 raL internal
standard solution (100 p/L yttrium in 1% nitric acid) and mixed by
inversion. Internal accuracywas assessed by use of two aqueous certi¬
fied reference materials, TMDA62 and TMDA64 (Procheni; Chess-
ington, England). Trace clement levels were measured by inductively
coupled plasma optical emission spectrometry using a VISTA AX
(Varian; Oxford, England).
Measurement ofSputum IL-8, Myeloperoxidase,
and Calprotectin
To compare the results of metals in sputum with biochemical
markers of inflammation, comparisons with IL-8, myeloperoxidase
(MPO), and calprotectin were made in die CF group. Immunoas¬
says used commercially available sandwich enzyme-linked immu¬
nosorbent assay kits, following the manufacturer's instructions. The
kits used were IL-S (Biosource Europe SA; Nivelles, Belgium),
MPO (Assay Designs Inc; Ann Arbor, MI), and Calprotectin
(Buhlmann Laboratories, AG: Schonenbuch. Switzerland).
Data Analysis
Data analysis was carried out on GraphPad Prism software
(GraphPad; La folia, CA) for Windows. Cross-sectional data were
nonnormally distributed and were analyzed by Kruskal-Wallis
analysis of variance and Dunn multiple comparison test. P < .05
was considered significant. For longitudinal analysis of zinc and
iron data a paired Student t test was performed. For correlation,
data were subjected to Spearman rank analysis.
Results
Subject Demographics
The demographic profiles and sputum cytology ol
each group are shown in Table 1. The CF group was
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Table 1—Demographics and Sputum Cytology for Subjects in Cross-Sectional and Longitudinal Studies
Disease No. Male, No. Age, y FEV, % Predicted Neutrophil, % Eosinophil, %
Controls 20 6 36.9 (2.5) 105.8 (2.6) 55 (4.3) 2.9 (0.5)
Asthma 17 5 51.9 (3.3) 80 (5.6) 60(6.1) 16.2 (5.2)
COPD 23 16 66.0 (1.4) 55.0 (4.0) 81 (2.6) 4.4(1.6)
CF 23 14 26.3 (2.0) 59.1 (4.4) 92 (2.0) 2.4 (0.5)
Bronchiectasis 16 1 62.3 (2.1) 70.4 (8.5) 84 (4.0) 2.1 (1.3)
CF exacerbation 14 8 25.6 (2.4) 41.0 (4.4) 98.3(0.6) n/d
CF recover)' 14 8 25.6 (2.4) 46.3 (4.5) 96.4 (0.9) n/d
Data are displayed as mean (SEM). CF = cystic fibrosis; n/d = not done.
younger than the control and other disease groups
(P< .01). Ofthe COPD group 10were current smokers,
nine ex-smokers, and four gave no information on
current smoking status. Of the patients with CF, 14
were colonized with P aeruginosa, the other patients
being colonized by a variety' of organisms, including
Stenotrophomonas maltophilia and Burkholcleria
cenocepacia species.
Assay Reproducibility
Pooled samples of five subjects in each group of
control, CF, and non-CF bronchiectasis were assayed
in two separate runs for zinc levels with coefficients
of variance of 14.7%, 2.7%, and 5.4%, respectively,
giving an average coefficient of variation of 7.6%.
Sputum Trace Element Levels in
Cross-Sectional Data
The absolute concentrations ofzinc, iron, and man¬
ganese are displayed in Table 2 in p-g/L. Sputum zinc
concentration was at least fourfold higher in CF and
non-CF bronchiectasis than controls (P < .001). Con¬
centrations in CF and non-CF bronchiectasis were
also higher than in asthma and COPD (P < .05).
Sputum iron was at least twofold higher in CF and
non-CF bronchiectasis than controls (P<.01) and
COPD (P<.05). Levels were higher in the COPD
and asthma groups vs controls but did not reach sta¬
tistical significance. Current smoking status had no
significant effect on the zinc or iron levels in the
COPD group (Fig 1).
Sputum manganese differentiated non-CF bron¬
chiectasis but not CF from control (P < .05). Sputum
manganese also differentiated subjects with asthma
from control subjects (P< .01). Sputum copper was
higher in all disease groups vs control but only
reached statistical significance for CF (P< .01).
In some subjects trace element levels were below
the limit of detection of the assay, in particular for
manganese. Interestingly, zinc and iron were detect¬
able in all subjects with CF. Please refer to Table 2
for further information.
Correlation ofSputum Zinc and Iron Levels
With Lung Function, Sputum Cytology, and
Sputum Biomarkers in Patients With CF
As the most statistically significant changes were
seen in the CF group, further comparisons were
made with clinical data and other inflammatory mark¬
ers for this group. Sputum zinc and iron levels were
correlated in patients with CF (Spearman r = 0.75,
P< .05, data not shown). There was a negative cor¬
relation of zinc and FEVj% predicted in the CF
group (Spearman r= —0.469, P<.05, Fig 2A). Spu¬
tum iron was also negatively correlated with FEVj%
(Spearman r = —0.43, P< .05, data not shown). Spu¬
tum neutrophil % and zinc levels were correlated
(Spearman r= 0.67, PC.05, data not shown). Zinc
Table 2—Levels ofMetal Elements (pg/L) ofProcessed Sputum Supernatant for Zinc, Iron, Manganese, and Copper
Disease Zinc Iron Manganese Copper
Control 15.35(10.4-25.6) 13.5 (8.6-21.5) 0 (0-0.25) 8.6 (3-16.4)
Asthma 12.7(7.2-41.4) 30.0 (6.9-35.3) 0.8 (0.2-1.7)" 15.2 (8.6-29.5)
COPD 25.4 (9.8-50.7) 21.3 (3.1-35.6) 0 (0-0.7) 15.2 (12.2-22)
CF 135.3 (54.2-209.6)b 56.9 (24.3-115.3)" 0.3(0.1-0.8) 19.5 (14.5-30.1)°
Bronchiectasis 111.3 (46.1-150.7)b 54.2 (22.7-91.6)" 0.6(0.2-1.3)" 15.7(10.9-33.3)
Data are displayed as: median (interquartile range). P values are displayed for disease group vs control; for P values between groups please consult
text. Zinc was below the limit of detection of the assay in four control and one COPD. Iron was below the limit of detection in four control, one
asthma, and one COPD. Manganese was below the limit of detection in 14 control, three asthma, 13 COPD, six CF, and one bronchiectasis. See
Table 1 for expansion of abbreviation.
"P < .01 vs control.
bP < .001 vs control.
CP < .05 vs control.
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Figure 1. Smoking status and sputum trace element level in
COPD. Data for zinc (A). Data for iron (B).
levels were unrelated to the underlying colonizing
organism (data not shown).
Sputum zinc and calprotectin levels correlated
with high statistical significance (Spearman r = 0.S6,
P< .001, Fig 2B). Sputum zinc significandy correlated
with MPO and IL-8 (Spearman r=0.81, PC.001,
Spearman r=0.67, PC.001, respectively, Figures 2C
and 2D). Sputum iron demonstrated similar but less
significant correlations to calprotectin, MPO, and
IL-8 (data not shown).
Serial Measurement ofMetals in CF Exacerbation
Sputum zinc levels decreased significantly follow¬
ing antibiotic therapy for an exacerbation (PC.01;
Fig 3). There were no significant serial changes in
iron, manganese or copper.
Discussion
Total elemental zinc and iron concentrations are
elevated in sputum from subjects with CF and non-
CF bronchiectasis compared with healthy control
subjects. There is a small degree of overlap between
die CF and control groups, but this maybe explained
by the finding that patients with CF in this small sub¬
group had better lung function and thus less severe
lung disease (data not shown). Sputum zinc levels
were also significantly higher in CF and non-CF
bronchiectasis compared with COPD. Sputum zinc
levels decrease significantly over the course of a CF
exacerbation. Zinc is strongly correlated with calpro¬
tectin in CF sputum as well as witii other inflamma¬
tory markers, such as IL-8 and MPO.
Protein biomarkers, such as cytokines, have been
used in previous studies to assess levels of airways
inflammation.20-22 However, protease activity in expec¬
torated sputum may affect the robustness of cytokine
assays.23 The potential association we have shown
between trace element levels and inflammation in
sputum samples combined with their likely resistance
to degradation commends diem as potentially robust
markers of lung pathophysiology.
Serum zinc has previously been suggested as a
marker of lung disease,24-25 but we believe tins to be
the first study to describe an association between
sputum zinc and inflammation in individuals with CF
lung disease and non-CF bronchiectasis. Further¬
more, we demonstrate its potential use as a serial
marker during treatment of an exacerbation, although
this must be interpreted with caution as in two sub¬
jects zinc levels actually increased, whereas in four
others there was only a modest decrease of levels.
Nevertheless, the majority of subjects demonstrated
a decrease with treatment and as such further inves¬
tigation is clearly merited.
We thus suggest that sputum zinc may be used as a
biomarker in suppurative diseases, such as CF. We
do realize, however, that as we have used a relatively
small sample size, albeit similar to those use in previ¬
ous biomarker studies, these data represent a novel
observation and further validation in larger studies is
required. Furthermore, a parallel measure of zinc in
serum may have added further insight into the func¬
tional significance of these findings, as would knowl¬
edge of individual subject dietary zinc intake.
Zinc homeostasis may play an important role in
modulating the immune response to inflammation,
with high concentrations of zinc inducing peripheral
blood monocyte apoptosis26 and promoting cytokine
production.27 Conversely, low concentrations of zinc
may suppress monocyte function and decrease neu¬
trophil phagocytosis.28 Zinc may also interact with the
airway epithelium.29-30 For example, zinc deprivation
of bronchial epithelial cells in culture induces
apoptosis,31-32 and zinc deficiency in a murine model
of asthma induces epithelial cell apoptosis and air¬
ways inflammation.33 We have measured total zinc
content of sputum (ie, bound and unbound), whereas
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Figure 2. Correlation of sputum zinc with biomarkers of lung inflammation and physiology. Correlation
between FEV1% predicted and sputum zinc (Spearman r= —0.47, P<.05) (A). Correlation between
sputum calprotectin and zinc. (Spearman r= 0.86, P < .001) (B). Correlation between sputum MPO and
zinc (Spearman r= 0.81, P< .001) (C). Correlation between sputum IL-S and zinc (Spearman r = 0.67,
P < .001) (D). IL = interleukin: MPO = myeloperoxidase.
the amount of freely available unbound zinc might be
equally important. The excess of zinc in sputum is,
however, a possible explanation for the low serum
zinc levels in subjects with CF compared with healthy
controls.34
Increases in sputum iron have been described in CPM2












Time Point of Exacerbation
Figure 3. Sputum zinc levels in CF exacerbation (n = 14). Spu¬
tum zinc decreases over the course of an exacerbation with antibi¬
otic treatment (PC.01). Horizontal lines represent means.
CF = cystic fibrosis.
www.chestpubs.org
prerequisite for microbial growth, with increased levels
in CF sputum possibly contributing to tire proliferation
of bacteria such as P aeruginosa.11 The source of this
iron is unclear, with leak from the circulation being
suggested, although further work is required to investi¬
gate this. Cigarette smoke has also been suggested as a
potential source of airways iron,35 but we have demon¬
strated no difference in sputum iron between current
smokers and ex-smokers with COPD in this study.
Associations between the levels of sputum manga¬
nese and copper with disease type are less obvious.
Manganese was only significantly elevated in the
asthma and non-CF bronchiectasis groups and copper
only in CF. Both metals (like zinc) are eofactors for
superoxide dismutases (SODs), which have leading
roles in alleviating oxidative stress in the lung.36 Fur¬
thermore, the demonstration that manganese differ¬
entiated subjects with asthma from control subjects
but not subjects with CF from control subjects sug¬
gests a possible role for this element in nonsuppurative
lung disease. SODs are downregulated in asthmatic
airways,36 suggesting sputum copper and manganese
are not merely tracking levels of these mediators.
A measurement of SOD level or activitywould help to
elucidate this complicated relationship but was not
performed in this study and thus forms the basis of
future work by this group.
Sputum zinc levels correlated with biomarkers
of airways inflammation, namely calprotectin, MPO,
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and IL-8. Sputum zinc adds to the growing number
of potential biomarkers in sputum and may be seen
to compliment these as well as offering new insight
into pulmonary inflammation. Calprotectin is a highly
abundant neutrophil protein found in the CF airway15
with antiinflammatory and proinflammatory func¬
tions, and the ability to chelate zinc and other' J
cations.7'8'37'3S Calprotectin promotes apoptosis in cell
lines via the exclusion of zinc,39 40 and zinc and calpro¬
tectin have been demonstrated to colocalize in staph¬
ylococcal abscess in a murine model.8 As such, we
would suggest that die interaction of zinc and calpro¬
tectin in the CF airway is ofmechanistic importance,
particularly when we consider diat S aureus is a major
pathogen in early disease.
Elevated levels of calprotectin and zinc may reflect
passive release of the neutrophil contents in view of
the large number of necrotic neutrophils in the CF
airway,41 or may represent active secretion as is
observed with lactoferrin release from neutrophils.42
A passive release of zinc, on cell necrosis, would be sup¬
ported by the correlation of zinc with both neutrophil
percentage in samples and calprotectin, a cytoplas¬
mic protein in neutrophils. A more controlled active
release of zinc may be suggested, however, by die
correlation of zinc witii MPO, a neutrophil granule
protein released from activated neutrophils. Neverthe¬
less, the higher correlation is of zinc, and calprotectin
might simply reflect an overall abundance of neutro¬
phils, which are rich in both of these substances,43-44
as neutrophils contain 5 to 10 ng zinc per 10s cells.43
It is also important to consider that the zinc we have
measured in the airway could also be complexed
to calprotectin (or other proteins) or could be due
to leakage from the pulmonary circulation during
inflammation.
In conclusion, we have demonstrated elevated levels
of trace metals (zinc in particular) in the fluid phase
of sputum from patients with CF and non-CF bron¬
chiectasis compared with patients with asthma or
COPD and healthy adult controls. We also demon¬
strate that the level of zinc in CF sputum decreases
over the course of an infective exacerbation and the
use of chemically stable markers in noninvasive
assays to monitor the course and severity of lung dis¬
eases such as CF would clearly be advantageous. Of
course a valid biomarker must be highly reproducible
and repeatable and, as such, longitudinal studies to
evaluate the robustness of sputum trace metal assays
of inflammation are required.
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Abstract
Background: Adequate monitoring of cystic fibrosis lung disease is difficult. CF exacerbation offers a unique setting to test the utility of
biomarkers in the assessment of changing airways inflammation. We hypothesised that levels of calprotectin in sputum (and serum) would change
informatively following treatment of an exacerbation.
Methods: 27 patients with CF were recruited at onset of pulmonary exacerbation. Sputum and serum were collected at the start and end of anti¬
biotic therapy. Sputum calprotectin, interleukin-8 (IL8), and myeloperoxidase (MPO) were measured, as were serum calprotectin, CRP and
vascular endothelial growth factor (VEGF).
Results: Sputum calprotectin decreased following treatment of an exacerbation (p<0.05), and was superior to other sputum markers. Serum
calprotectin, CRP, and VEGF also decreased significantly (p=0.002, p = 0.002, p = 0.013 respectively). Serum calprotectin level following
treatment had predictive value for time to next exacerbation (p = 0.032).
Conclusions: This study demonstrates the superiority of calprotectin (in sputum and semm) as a biomarker of CF exacerbation over better-
established markers.
©2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
1. Introduction
Cystic fibrosis (CF) lung disease is characterised by chronic
bacterial infection which begins in early childhood, is persistent
throughout life and rapidly evolves to evade host defence
systems [1]. Patients with CF experience recurrent episodes of
increasing pulmonary symptoms, termed exacerbations, which
are accompanied by a decrease in lung function [2]. Viral
infections, including respiratory syncitial virus, may initiate
pulmonary exacerbation [3] but an increase in the density of
colonising organisms [4] or the acquisition of new pathogenic
organisms [5] are also important and as such antibiotic therapy
decreases the bacterial density of respiratory secretions [6,7].
A major difficulty in studying the aetiology and pathophys¬
iology of CF exacerbations is the lack of consensus for
diagnostic criteria despite a definite clinical need [8]. Exacer¬
bation has been defined in major CF therapeutic trials from
* Corresponding author.
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empirical data [9-11]. Nevertheless in routine practice clinical
judgement and changes in lung function are most commonly
used to dictate the need for therapy [11]. Irrespective of
definition, CF exacerbation represents an in vivo state of
increasing inflammation in CF lung disease.
Sputum obtained from CF subjects contains a mixture of
proteins which may serve as objective measures of lung
inflammation. Interleukin 8 [IL-8] [11-16], myeloperoxidase
[MPO] [17-20], matrix metaloproteinase 9 [MMP-9] [21] and
neutrophil elastase [NE] [13,16,22] have all been advocated and
studied. NE and IL-8 correlate inversely to lung function,
suggesting a relationship of sputum markers to disease severity
[23]. We have recently described calprotectin (also known as
calgranulin A/B, S100A8/A9, MRP8/14, CF antigen) in BALF
[24] and sputum [25] as a biomarker of CF lung disease.
Calprotectin was first described in the serum of CF patients in
1975[26], and later became known as CF antigen[27]. In spite
of being present in CF lung secretions in high concentrations,
the function of calprotectin in the CF lung and its mechanism of
action have yet to be explored. Calprotectin is highly abundant
in neutrophils, has pro-inflammatory properties via activation of
1569-1993/$ - see front matter © 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved,
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TLR-4[28], and has been demonstrated as central to lung
inflammation in non-CF models of lung infection[29].
Sputum protein profiles [17] and cytokine levels such as
IL-8 have been demonstrated to change following treatment of
CF exacerbations with antibiotic therapy [6,7], although this is
not a consistent finding in all studies[30]. Altering the level of
bacterial burden in the lung with antibiotic therapy may alter
the inflammatory milieu. Thus we may use this model to study
the clinical significance of new markers of CF lung disease.
Other groups have used exacerbation in CF to demonstrate the
presence of novel biomarkers, for example prostaglandin E2
and cys-leukotrienes, mediators of oxidative stress, were
elevated in CF exacerbation compared to stable CF [31] as
was HMGB1[32], although these studies did not utilise serial
samples in the same patients. Serial monitoring has been used
for serum vascular endothelial growth factor, which appears to
be a marker of inflammatory change following treatment of
CF exacerbation with antibiotic therapy [33].
On the basis of our previous work with calprotectin [24,25]
we hypothesised that calprotectin (sputum and serum) would
change informatively following treatment of CF exacerbation.
We wished to compare its utility to previously assessed
biomarkers, sputum IL-8 and serum CRP and VEGF.
2. Methods
The Lothian Hospitals Ethics Committee granted approval
for this study. Patients were recruited at the time of a pulmonary
exacerbation requiring antibiotics, as determined by the
patient's physician on the basis of increased breathlessness,
increased sputum production and a decrease from baseline
FEV|. Sputum and serum were collected for the assessment of
biomarkers within 24 hrs of commencing treatment with
antibiotics and again at cessation. This ranged from one to
three weeks of therapy. FEV i was recorded at these time points.
Sputum was processed within 2 hours of collection as
described previously [34], In brief, sputum plugs were
harvested and processed with 4x weight/volume 0.1% dithio-
threitol (DTT) after which 4x weight/volume PBS was added.
Samples were filtered through 48 jam mesh and centrifuged at
1200 rpm to remove the cells. Supernatant was stored at -80 °C
until further analysis. The cell pellet was re-suspended in PBS,
cytospins prepared and stained with May-Gmnwald-Giemsa for
differential cell counting. All counts were expressed as
percentage of the population counted. All samples utilised in
the study contained <40% squamous cells ensuring samples
were from the lower airway.
Table 1
Patient Demographics, colonising organism and antibiotic treatment.
Patient M/F Genotype Age FEV1% Pred Start FEV1% Pred End Colonising Organism Treatment For Exacerbation
1 f AF508/3659AC 20 67 66 BC, SM, HI, SA TO, CFZ
2 f AF508/AF508 30 42 49 PA, SA TO, CFZ
3 f AF508/AF508 20 13 13 PA CO, MER
4 f AF508/AF508 18 55 60 PA TO, CFZ
5 f AF508/G551D 18 23 39 BC UnK.
6 m AF508/Unk 46 36 38 PA, SM TO, CFZ
7 f AF508/AF508 21 56 59 PA, SA TO, MER
8 m AF508/AF508 18 58 59 MRSA, SA TO, CFZ
9 f AF508/G551D 31 31 49 PA CFZ, CIP
10 m AF508/AF508 18 33 43 SA, SM TAZ, MIN
11 f AF508/AF508 20 60 73 PA, Asp TO, MER
12 m AF508/Unk 32 75 88 PA CIP, AZI
13 f AF508/P67L 27 45 49 SA, BMV TO, CFZ
14 f AF508/G542X 23 50 82 SA, HI TO, CFZ
15 f AF508/AF508 22 66 75 PA, SA CO, CFZ
16 f AF508/Unk 17 38 44 SA FL, COAMOX
17 m AF508/G542X 22 56 52 PA TO, MER, AZ
18 m AF508/G551D 41 24 31 SM, PA, SA. Asp TO, MER
19 m AF508/AF508 24 41 49 SA, PA, SM TO, CFZ
20 m AF508/AF508 37 21 27 BC, PA TO, MER
21 f AF508/AF508 22 45 52 PA TO. MER
22 f AF508/AF508 18 15 15 PA, SA AZ, MER
23 m AF508/G551D 20 28 28 PA TO, CFZ
24 f AF508/AF508 26 61 64 PA, SM, Asp TO. CFZ
25 m AF508/AF508 17 23 28 PA CO. MER
26 m AF508/AF508 17 33 45 PA, SA TO, CFZ
27 m AF508/3849+10 kb C—>T 22 34 49 PA TO, CFZ
Unk = unknown.
Colonising organisms relate to most recent sputum culture prior to exacerbation recorded for each patient. PA=Pseudomonas aeruginosa, BC=Burkholderia
cenocepacia, BMV=Burkholderia multivorans, SA=Staph aureus, SM=Stenotrophomonas maltophillia, H\=Haemophilus influenzae, Asp=Aspergillus fumigatus.
Treatment for exacerbation was with intravenous antibiotics apart from subject 12 who received oral treatment. AZ=aztreonam, AZl=azithromycin,
CIP=ciprofloxacin, CFZ=ceftazidime, CO=colomycin, COAMOX=coamoxiclav, FL=flucloxacillin, MER=meropenem, MIN=minocycline, TAZ=tazobactam/
pipericillin, TO=Tobramycin.
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Blood was collected into serum tubes with pre-added clotting
activator (Monovette serum collection tubes, Sarstedt AG and
Co, Germany). The tube was then mixed by inverting 5 times.
Blood was left to clot at room temperature for 45 minutes.
Tubes were centrifiiged at 1800 *g for 15 minutes at room
temperature. Separated serum was removed into cryovials
(Nunc, Thermo Fisher Scientific, Denmark) as above and stored
at -80 °C until further analysis. A separate EDTA blood sample
was taken for routine haematology (white cell count).
Calprotectin was measured in sputum and serum by a double
antibody sandwich ELISA, using monoclonal and polyclonal
antibodies against human calprotectin complex (gift of Erling
Sundrehagen, Norway). Interleukin 8 (Biosource, UK); myeloper¬
oxidase (Assay Designs, Michigan, USA); CRP; and VEGF
(Quantikine, R and D Systems, Oxford, UK); were measured using
commercial kits according to the manufacturers' instructions. All
standard curves and dilutions for sputum ELISAs were performed
in the presence of 0.05% DTT to ensure accurate measurement of
mediators in sputum as samples had been processed with DTT.
2.1. Prediction offuture exacerbations
Table 2
Measurements taken at the start and end of exacerbation treatment.
Measurement Start of Exacerbation End of Treatment
FEV i % predicted 41.8(3.2) 49.1(3.6)**
Sputum Calprotectin pg/ml 619.4 (484.1- 971.9) 274.4 (184.0-570.9)*
Sputum IL8 ng/ml 30.8(18.8-53.4) 20.6(10.3-60.5)
Sputum MPO pg/ml 41.3(18.6-49.8) 24.4(8.8-45.5)
Sputum Neutrophil % 98.8(97.2-99.6) 97.5(95.6-98.7)*
WCC 109 11.8 (0.9) 9.0(1.5)**
CRP mg/ml 35.6(8.6-75.2) 9.9(3.0-23.5)**
Serum Calprotectin pg/ml 21.5 (13.3-55.5) 9.3 (6.5-18.2)**
Serum VEGF 385 (226- 582) 236 (143-412)*
Data are displayed as median (IQR) or mean (SEM) depending on normality of
distribution. Paired analysis was performed to investigate which markers
changed most significantly with treatment, for exact p values please see text.
* p<0.05.
** p<0.01.
trend to decrease following treatment, from median 30.8 (18.8-
53.5)ng/ml to 20.6 (10.3-60.6)ng/ml (p=0.11). Sputum MPO
showed a trend to decrease following treatment, from median 41.3
(18.6-49.8)pg/ml to 24.4 (8.8-45.5)pg/ml (p=0.07).
To investigate whether serum calprotectin at the end of
exacerbation could predict patient outcome the clinical case notes
were reviewed 1 year following completion of the study and the
time to next exacerbation calculated in days. A cut off 9.1 pg/ml
(median value in stable non-exacerbating CF subjects) was
employed and this divided the group into 13 (<9.1 pg/ml) and 12
(>9.1 pg/ml) patients. The same analysis was performed for CRP
using a cut off level of 10 mg/ml (upper limit of normal ).
2.2. Statistical analyses
Data analyses were performed with GraphPad Prism
software (GraphPad, La Jolla, Ca, USA). Normally distributed
data were analysed by paired t test and non-normally distributed
data by Wilcoxon sign rank test. Kaplan Meier curves were
compared by log rank (Mantel Cox) testing.
3. Results
Twenty-seven patients completed the study (demographics
in Table 1). FEV] improved over the course of an exacerbation,
increasing from 41.8 (SEM 3.2) to 49.1 (3.6)% predicted
(p = 0.001). Whole blood white cell count decreased from 11.8
(SEM 0.9) to 9.0 (1.5) (p = 0.004) and sputum neutrophils from
98.8% to 97.5% (p = 0.04), see Table 2.
3.1. Sputum results
Due to limitations in sputum sample size not all patients could
be assessed for all biomarkers (priority was given to sputum
calprotectin which was measured in all 27 paired samples). There
was a significant reduction in the level of calprotectin from
median 619.4 (IQ range; 484.1- 971.9)pg/ml to 274.4 (184.0-
570.9)pg/ml (p=0.013; Fig. 1). Sputum IL8 and MPO were



































Fig. 1. Panel A. Sputum calprotectin decreases over the course of an
exacerbation following treatment with antibiotics; p=0.013. Individual data
are shown for 27 subjects. Panel B. Serum calprotectin decreases over the course
of an exacerbation following treatment with antibiotics; p = 0.002. Individual
data are shown for 25 subjects.
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3.2. Serum results
Serum was available in 25 patients from 27 recruited as two
declined venepuncture. Serum calprotectin decreased from
median 21.5 (13.3-55.5)pg/ml to 9.3 (6.5-18.2) (p=0.002; Fig. 1).
Serum CRP decreased from median 35.6 (8.7-92.0)mg/ml. to 9.9
(3.0-23.5) (n=22 paired samples [3 single samples were above the
limit of detection of the assay: 300 mg/ml]; p=0.002; Table 2).
Serum VEGF decreased from median 385 (226- 582)pg/ml to 236
(143- 412) (p=0.013; Fig. 2).
3.3. Significant correlations
Serum calprotectin was negatively correlated with FEV|
(Spearman r -0.49 [p<0.012] pre-treatment vs. -0.38 [p=0.056]
post-treatment), giving an overall Spearman r of -0.48
(p = 0.0004) for calprotectin and FEV] before and after
exacerbation treatment. Serum CRP correlated less well with
lung function (Spearman r -0.32 [p=0.12] pre-treatment vs. -0.26
[p=0.21] post-treatment), giving an overall Spearman r of -0.36
(p=0.011) for CRP and FEV) before and after exacerbation
treatment. Sputum calprotectin did not significantly correlate with
lung function.
calprotectin at the end of exacerbation treatment for time to
next exacerbation.
Sputum calprotectin decreased following treatment of a CF
exacerbation. We have previously demonstrated high levels of
calgranulins A and B (the constituent subunits of calprotectin),
by mass spectrometry, in CF sputum and BALF[24,25].
Calprotectin may be secreted from stimulated neutrophils
[35], or released at cell death [36] and as such is an appropriate
marker for inflammation in the CF airway. Faecal calprotectin
has been recognised as a marker of organic bowel disease [37]
and can differentiate inflammatory bowel disease, which is
neutrophil predominant, from irritable bowel syndrome [38].
Calprotectin may play an important mechanistic role in the CF
airway and has been previously implicated in early lung disease
in animal models [39]. Furthermore functional knock out of
calprotectin in a murine model of pneumonia leads to decreases
in inflammatory cell recruitment suggesting an integral role in
inflammatory cell recruitment [29], Thus the change in sputum
calprotectin following antibiotic therapy implies a direct
association of calprotectin with a changing state of airways
inflammation. The exploration of a possible role of calprotectin
as a pro-inflammatory molecule in the lung requires further
work.
3.4. Predictive values ofseium markers
The median time to exacerbation in patients with calprotectin
>9.1 pg/ml was 70 days compared to 112 days in the <9.1 pg/ml
group (p = 0.032; Fig. 4). Three patients in the >9.1 pg/ml group
died within 18 months of their final study visit. CRP failed to
show a difference in the median time to next exacerbation 81
(<10 mg/ml) vs. 84 (> 10 mg/ml) days (p = 0.12; Fig. 3).
4. Discussion
We have demonstrated that treatment of an exacerbation with
antibiotic therapy in CF results in decreasing levels of sputum
and serum calprotectin. Serum CRP and VEGF also decreased.
We have also demonstrated a predictive value of serum
Exacerbation Recovery
Time Point
Fig. 2. Serum VEGF decreases over the course of an exacerbation following
treatment with antibiotics; p=0.013. Individual data are shown for 23 subjects.
Fig. 3. Panel A. Subjects with serum calprotectin of 9.1 mg/ml at the end of
exacerbation treatment have longer time to next exacerbation with median time
to exacerbation 112 days vs. 70 days (p=0.032). Panel B. Serum CRP of
<10 mg/ml did not differentiate time to next exacerbation with median time to
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In this study we failed to demonstrate a significant change in
sputum IL-8 or MPO following antibiotic therapy, although
there were trends to reduction. Decreases in sputum IL-
8 following IV antibiotic treatment have been described [6,7],
with similar findings reported following nebulised antibiotic
therapy [40], Our study was performed using spontaneously
expectorated sputum in line with both Colombo et al [7] and
Husson et al [40], but in contrast to Ordonez et al [6], who
induced sputum. We do not believe our study was underpow¬
ered to demonstrate a change in sputum IL-8 (a secondary
outcome), as other groups have demonstrated changes in
sputum IL-8 with similar sized patient cohorts [7,40], The
largest study demonstrating changes in sputum IL-8 following
antibiotic therapy was performed by Ordonez et al, utilising 42
paired samples and demonstrating a modest decrease in sputum
IL-8 (0.5+/- 1.3 loglO pg/ml) [6], Therefore even if our study
was underpowered to detect changes in IL-8 (which we feel
unlikely) we have clearly demonstrated the superiority of
sputum calprotectin measurement in this population. One
possible explanation for our failure to demonstrate a decrease
in IL-8, is that our study utilised an adult population with more
severe disease compared to Ordonez et al who excluded patients
with an FEV, of less than 40% [6], Indeed Downey et al
demonstrated no serial change in sputum IL-8 in CF adults
following exacerbation treatment, further underlining the
possibility that sputum IL-8 is not as powerful a marker in the
older patient group[30]. This suggests that IL-8 is a less reliable
marker in patients with more advanced lung disease and is
consistent with the finding that sputum IL-8 is less well
correlated to lung function that other sputum markers such as
free elastase [23],
Sputum MPO has been less well studied. As a neutrophil
protein we might have expected a change in sputum concentra¬
tions following treatment of an exacerbation, and it has been
described at high levels in CF sputum compared to control
populations [17-20], The failure to demonstrate a significant
change in MPO may be explained by many of the points
pertinent to IL-8. And our findings are consistent with a study of
oral macrolide antibiotics in CF patients infected with P.
aei-uginosa, which demonstrated no change in sputum MPO
following treatment [41]. Also, MPO is a primary granule
protein in the neutrophil and as such we could postulate its
release from neutrophils may be more tightly controlled than
that of calprotectin, a cytoplasmic protein.
Serum calprotectin decreased over the course of an
exacerbation. This finding was of higher statistical significance
than calprotectin in sputum suggesting less variability in serum
sampling than sputum. Calgranulin A (sub-unit of calprotectin)
has previously been described in the serum ofhomozygotes and
heterozygotes with CF mutations as CF antigen [26], The serum
levels of calprotectin are approximately 4 fold less than those
observed in sputum, suggesting that the high concentrations of
calprotectin observed in sputum are likely to arise locally in the
airways from neutrophils, in particular from necrotic neutro¬
phils, which are more prevalent in the sputum of CF patients
with gram negative infection [42], Changing levels of
calprotectin in serum may reflect increased neutrophil recruit¬
ment from the bone marrow or leak of calprotectin from the
lungs into the systemic circulation due to a breakdown in
epithelial barrier integrity although further work is required to
investigate this.
Serum CRP and VEGF also decreased significantly. This
may have been anticipated as CRP is an acute phase protein
previously recognised to change in CF exacerbations [7]. Serum
VEGF has also been demonstrated to decrease with treatment of
a CF exacerbation, with the main source being postulated as
hypoxic lung tissue [33], In our study both serum CRP and
VEGF fell, consistent with previous studies. Serum CRP was
demonstrated to show a similar serial change to serum
calprotectin following exacerbation treatment but was less
well correlated to lung function suggesting a more significant
relationship of serum calprotectin to the airway than CRP.
However this study does suggest a role for the measurement of
CRP in the clinical management of CF exacerbations.
Serum calprotectin concentrations of <9.1 pg/ml at the end
of an exacerbation predicted a delayed time to next exacerba¬
tion, with the median time being 112 days vs. 70 days for
patients with calprotectin >9.1 pg/ml. Indeed three patients in
low serum calprotectin group had not exacerbated by 1 year,
whereas 3 patients in the high group had died by the time of
follow up. CRP was less good in this regard, with no difference
in median time to next exacerbation between those patients with
normal and those with raised CRP values at the end of
exacerbation. Further studies are now required to assess and
validate serum calprotectin as a predictor of outcome in CF, but
the current data raise the possibility that calprotectin levels may
inform whether treatment needs to be prolonged.
We conclude that sputum and serum calprotectin decrease
significantly with treatment of an exacerbation and are superior
to sputum IL8 and serum CRP and VEGF, all of which have
been advocated hitherto, as indicators of response. The
additional value of a serum biomarker is recognised because
of the greater ease of sample acquisition and processing. Further
investigation is required to assess the potential clinical impact of
these novel observations.
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